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Protein synthesis is an essential process that allows the nucleic acid code to be translated in 
the cell. For protein translation to occur, the ribosome must be supplied with tRNA 
molecules charged with amino acids. The enzymes responsible for ligating tRNA and amino 
acids are the aminoacyl-tRNA synthetases (ARS), encoded by a family of 37 genes. Variants 
in all 37 ARS genes can cause dominant and/or recessive human genetic diseases. The 
recessive diseases are severe, multi-system disorders that primarily affect the central nervous 
system, as well as the muscles, lung, and liver. The dominant diseases are axonal peripheral 
neuropathies commonly classified as Charcot-Marie-Tooth disease. The full clinical and 
genetic spectrum for both dominant and recessive ARS-related disease has yet to be 
determined. Additionally, the mechanism of these diseases is poorly understood. This 
dissertation seeks to expand the locus, allelic, and phenotypic heterogeneity of ARS-
mediated diseases, and to define the mechanism of ARS-mediated disease, through 1) 
characterizing newly identified patient alleles; 2) developing a pipeline of model organisms 
to predict novel ARS disease candidates and define their associated dominant and recessive 
phenotypes, and 3) testing pathogenic alanyl-tRNA synthetase (AARS1) alleles for a 
dominant-negative effect in a yeast model. 
 
Here, we characterized 15 variants across glycyl-(GARS1), histidyl-(HARS1), methionyl-
(MARS1), asparginyl-(NARS1), and threonyl-tRNA synthetase (TARS1) identified in patients 
with dominant peripheral neuropathy or multisystem recessive diseases. Through 
synthesizing genetic and functional evidence, we expanded the allelic spectrum of GARS1- 
and HARS1- mediated dominant neuropathy, and the allelic and phenotypic spectrum of 
MARS1- and TARS1-mediated recessive disease. We also identified NARS1 as a candidate 
gene for dominant peripheral neuropathy. To complement these efforts, we developed a 
predictive pipeline using the defined phenotypes of pathogenic ARS alleles in yeast, C. 
elegans, and mouse. We used this pipeline to design deleterious mutations in TARS1 and 
 xvi 
assess them for a dominant peripheral neuropathy or multi-system recessive phenotypes. 
Through studies in yeast and worm, we identified a hypomorphic TARS1 allele, R433H. 
When tested in mouse, in trans with a null TARS1 allele, R433H causes a recessive 
phenotype of lung failure, growth restriction, and hair defects. This model will be an asset to 
determine how reduced TARS1 function differentially impacts mammalian tissues, and can 
inform clinical efforts to identify and treat patients with bi-allelic TARS1 mutations. 
 
Finally, we directly tested the hypothesis that dominant ARS variants are dominant-negative 
alleles. We focused on two variants in alanyl-tRNA synthetase (AARS1) with strong genetic 
evidence for pathogenicity, R329H and G102R AARS1. These variants reduce gene function 
in a yeast complementation assay, indicating that they are loss-of-function alleles. However, 
they repress yeast growth when co-expressed with wild-type AARS1, indicating that they are 
also dominantly toxic. To determine if this dominant toxicity was due to dimerization with 
wild-type AARS1, we designed a dimer domain mutation that impaired dimerization, and 
placed it in cis with R329H and G102R. This double-mutant rescued yeast growth, showing 
that dimerization is required for toxicity and that R329H and G102R are dominant-negative 
alleles. We also assessed three additional AARS1 variants, and found that they also are 
dominant-negative alleles in this assay. 
 
In sum, this work significantly contributes to defining the known genetic and phenotypic 
spectrum of ARS-mediated diseases, to expanding the role of model organisms in identifying 
candidate pathogenic ARS variants, and to defining the mechanism of dominant ARS-
mediated peripheral neuropathy. 
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Chapter 1  
Aminoacyl-tRNA Synthetases in Genetic Disease 
 
1.1 Protein Translation and Disease 
 
A cell’s ability to divide, function, and differentiate depends on the flow of information from the 
nucleotide code into proteins that perform tasks required to sustain life and confer cellular 
identity. Gene sequences are transcribed from deoxyribonucleic acid (DNA) into pre-messenger 
ribonucleic acid (pre-mRNA), which is then processed into messenger RNA (mRNA) with a 5’ 
cap and a 3’ polyA tail, and shuttled out of the nucleus to the ribosome.1 When the ribosome has 
assembled on the mRNA, transfer RNAs (tRNAs) charged with amino acids arrive to pair with 
their cognate sequences in the mRNA and donate their amino acid to a growing polypeptide 
chain.1 The peptide chain is then ultimately released from the ribosome and folds to become a 
protein.1 This process depends on the availability of tRNAs that are charged with the appropriate 
amino acid. The ligation of tRNA and amino acid is catalyzed by a family of enzymes, the 
aminoacyl-tRNA synthetases (ARSs). ARS enzymes, and the genetic disorders caused by ARS 
mutations, are the subject of this dissertation. 
 
Rebecca Meyer-Schuman is the sole contributor to this chapter. This chapter is adapted from 
“Emerging mechanisms of aminoacyl-tRNA synthetase mutations in recessive and dominant 
human disease,” published in Human Molecular Genetics (Volume 26, Issue R2, pages R114-
R127, October 1 2017, License number 5114320712101) and “Evidence for a dominant-negative 
mechanism in HARS1-mediated peripheral neuropathy,” published in The FEBS Journal 
(Volume 288, Issue 1, pages 91-94, September 17 2020, License number 5114321014941). Part 
of Figure 1.1 is published in The Journal of Clinical Investigation (Volume 129, Issue 12, pages 
5568-5583, December 2 2019, License number 1135456-2).  
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1.1.1 Key stages in protein translation 
Eukaryotic protein translation is initiated by the GTP-bound form of eukaryotic initiation factor 
2 (eIF2) bringing the methionine-charged initiator tRNAMet to the 40S ribosomal subunit.2 This 
complex then binds the 5’ cap of mRNA and, assisted by helicases that unwind the mRNA’s 
secondary structure, scans in the 3’ direction until it finds an AUG codon.2 When the AUG is 
located, the eIF2-GTP is hydrolyzed to eIF2-GDP and is released for recycling.3 Then, the 60S 
ribosomal subunit joins the initiation complex to form the 80S subunit, with the charged initiator 
tRNAMet already positioned in the peptidyl site (P site) of the ribosome.4 To begin the process of 
elongation, the elongation factor eEF1A, bound to GTP, brings a tRNA molecule charged with 
an amino acid to the acceptor site (A site) of the ribosome.5 The anticodon of the tRNA 
recognizes the corresponding mRNA codon, and eEF1A-GTP hydrolysis enables the tRNA to 
properly fit into the ribosome.5 Then, the ribosome catalyzes the formation of a peptide bond 
between the new amino acid and the methionine in the P site.5 This triggers the transfer of the 
deacylated tRNAMet to the exit site (E site), and the transfer of the new tRNA into the P site. The 
process repeats with a new charged tRNA molecule moving into the A site. As the next tRNA in 
the P site moves into the E site, the tRNAMet in the E site is released.5 This process continues 
until the ribosome reaches one of three termination codons: UAA, UAG, or UGA. Then, 
termination factors bind to the ribosome and promote the hydrolysis of the peptidyl-tRNA. 
Ribosomes are then recycled for future iterations of protein translation.5 
 
1.1.2 Translation regulation 
Protein translation is a dynamic process that is responsive to environmental cues and changes in 
intracellular metabolites.6 For example, the cell can sense limited amino acid availability, which 
triggers a repression of global protein translation and upregulation of amino acid biosynthetic 
pathways to restore cellular homeostasis. This process starts with the kinase GCN2, which has a 
tRNA binding domain derived from histidyl-tRNA synthetase that recognizes accumulating 
uncharged tRNA in the cell.3 When GCN2 binds uncharged tRNA, this triggers the kinase 
domain of GCN2 to phosphorylate the α subunit of eIF2.3 eIF2α phosphorylation prevents eIF2B 
from recycling the GDP bound to eIF2 into GTP.3 This prevents eIF2 delivering charged initiator 
tRNAMet to the ribosome, inhibiting translation initiation. However, although the dearth of GTP-
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bound eIF2 represses translation globally, it increases specific translation of ATF4 by allowing 
the ribosome to bypass an inhibitory upstream open reading frame (ORF) and translate the ATF4 
coding sequence.7 ATF4 then localizes to the nucleus where it increases the transcription of 
genes that help the cell respond to stress,3 including genes involved in amino acid biosynthesis or 
transport.8  
 
1.1.3 Genetic defects in protein translation cause disease 
Mutations in genes that encode components of the translation machinery can cause a variety of 
genetic diseases. Defects in ribosomal proteins cause Diamond Blackfan anemia, which 
manifests as anemia, skeletal abnormalities, short stature, and cardiac and genitourinary 
malformations.9 Mutations can also arise in the factors that process ribosomal RNA, causing 
bone marrow failure, cirrhosis, microcephaly, and leukoencephalopathy.9 Defects in translation 
initiation or elongation factors cause similar central nervous system defects; mutations in the 
eEF1 complex, which delivers charged tRNA to the ribosome, cause microcephaly, epilepsy, 
autism, and intellectual disability.10 Defects in the eIF2B complex (which normally helps recycle 
eIF2 to re-initiate protein translation) causes Vanishing White Matter disease, a 
leukoencephalopathy that can include ovarian failure in women.11 Protein translation diseases 
can also be caused by mutations in tRNAs, or the enzymes that modify them.12 Defects in 
proteins that process cytoplasmic tRNA can cause intellectual disability, developmental delay, 
and microcephaly, while defects in proteins that process mitochondrial tRNA cause anemia, 
encephalopathy, cardiomyopathies, and lactic acidosis.12 Overall, the phenotypes caused by 
mutations in the protein translation machinery indicate that the central nervous system, the liver, 
the heart, and the hematopoietic system are particularly sensitive to disrupted cytoplasmic or 
mitochondrial protein translation. 
 
The subject of this dissertation is another component of the protein translation machinery, the 
aminoacyl-tRNA synthetase (ARS) enzymes. This chapter will discuss the basic biology of ARS 
enzymes, as well as the dominant and recessive diseases caused by defects in ARS genes. It will 
also summarize the outstanding questions in the field pertaining to disease heterogeneity and 
disease mechanism. This thesis aims to address these questions.  
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1.1.4 An introduction to aminoacyl-tRNA synthetases 
In order for the genetic code to be faithfully executed, each tRNA that recognizes a mRNA 
codon must be charged with the appropriate amino acid. The aminoacyl-tRNA synthetase (ARS) 
enzymes are responsible for charging these tRNAs with the required amino acids. They perform 
this pairing in a two-step reaction: first, the ARS enzyme binds the amino acid and ATP, then 
hydrolyzes the ATP to form an aminoacyl-adenylate, releasing a pyrophosphate molecule.13 
Then, the ARS anticodon binding domain recognizes and binds the appropriate tRNA, and the 
amino acid is transferred to the 5’ end of the tRNA, releasing the charged tRNA and AMP.13   
 
ARS enzymes must perform this reaction for each of the 20 amino acids that comprise the 
building blocks of proteins. Additionally, this reaction must occur both in the cytoplasm and the 
mitochondria to meet the needs of protein translation in both compartments. To fulfill these 
requirements, there are 37 members of the ARS family, enough to service each amino acid in 
each cellular compartment. Each ARS can charge one of the twenty amino acids, with two major 
exceptions: 1) there are two ARS proteins, FARSA and FARSB, that come together in a multi-
unit structure to charge tRNA with phenylalanine, and 2) a single cytoplasmic ARS enzyme, 
EPRS1, charges both glutamic acid and proline.13 All ARS genes are encoded in the nuclear 
genome, but upon translation, 17 ARS proteins localize to the mitochondria and 18 localize to 
cytoplasm.  Two ARS can function in both compartments: lysyl-tRNA synthetase (KARS1), 
which undergoes alternative splicing to include or exclude the mitochondrial targeting sequence 
(MTS)14; and glycyl-tRNA synthetase (GARS1), which encodes a single mRNA with an 
upstream translation start site that includes the MTS in the open reading frame, and a 
downstream translation start site that excludes the MTS.15  There is no glutaminyl-tRNA 
synthetase for mitochondria; instead, EARS2 improperly recognizes tRNAGln, charging it with 
glutamic acid.16 Then, the glutamic acid is trans-aminated by glutamyl-tRNA amidotransferase 
into glutamine.16 
 
The nomenclature for the human ARS family dictates that the gene or enzyme name begin with 
the one letter code of the amino acid substrate followed by “ARS”. This is then followed by a 
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“1” if the enzyme functions in the cytoplasm or a “2” if it functions in the mitochondria. For 
example, the gene encoding the cytoplasmic threonyl-tRNA synthetase is TARS1, and the gene 
encoding the mitochondrial threonyl-tRNA synthetase is TARS2. 
 
Each of the 37 ARS enzymes can be grouped into one of two classes, distinguished by their 
approach to binding tRNA (Table 1.1). Class I enzymes utilize a Rossmann nucleotide binding 
fold, which binds the minor groove side of the tRNA acceptor stem and ligates the amino acid to 
the 2’ hydroxyl group on the terminal tRNA adenosine.17,18 Class II enzymes utilize a core of 
anti-parallel β sheets, which binds the major groove side of the tRNA acceptor stem and ligates 
the amino acid to the 3’ hydroxyl group on the terminal adenosine.17,18 Class II enzymes 
primarily function as multimers, whereas Class I enzymes are usually, but not exclusively, 
monomers19 (Table 1.1).  
 
Interestingly, nine of the cytoplasmic ARS are known to congregate in a larger multi-synthetase 
complex (MSC) (Table 1.1), along with three non-ARS scaffolding proteins (AIMPs) that 
stabilize the complex and promote tRNA binding.20 Although the function of the MSC is poorly 
understood, association with the MSC is thought to be required for the tRNA charging function 
of its members.21 One hypothesis proposes that the MSC functions as a docking system for its 
ARS members; while localized to the MSC, they perform canonical tRNA charging, but upon 
dissociation they pursue non-canonical roles in signaling pathways22 (for example, LARS1 can 
act as a leucine sensor in the mTORC1 pathway23). The MSC may also coordinate other aspects 
of protein translation: one of the scaffolding proteins (AIMP3) has been shown to be critical for 
delivery of charged initiator tRNAMet to eIF2 for translation initiation.24  
 
In addition to LARS1, several other cytoplasmic ARS enzymes contribute to cellular pathways 
unrelated to tRNA charging. Some of these non-canonical functions employ the full-length ARS 
protein, but others involve isoforms that arise from alternative splicing or proteolytic 
fragmentation.25,26 There is substantial evidence that ARS proteins and their fragments play a 
role in immune responses. Anti-synthetase Syndrome, an autoimmune disease marked by 
interstitial lung disease, arthritis, myositis, fever, and decreased blood flow to fingers is  
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Table 1.1. ARS localization and structural groups. 





Class28 Monomer or Dimer 
Participant in the 
multisynthetase 
complex (MSC)29 
alanyl-tRNA synthetase 1 AARS1 Cytoplasm II Dimer30 No 
alanyl-tRNA synthetase 2 AARS2 Mitochondria II Dimer31 No 
cysteinyl-tRNA synthetase 1 CARS1 Cytoplasm I Dimer32,33 No 
cysteinyl-tRNA synthetase 2 CARS2 Mitochondria I ND; monomer in E. coli34 No 
aspartyl-tRNA synthetase 1 DARS1 Cytoplasm II Dimer35 Yes 
aspartyl-tRNA synthetase 2 DARS2 Mitochondria II Dimer36 No 
glutamyl-prolyl-tRNA synthetase EPRS Cytoplasm I/II37 Dimer29 Yes 
glutamyl-tRNA synthetase 2 EARS2 Mitochondria I Monomer38 No 
phenylalanyl-tRNA synthetase alpha 
subunit FARSA Cytoplasm II Tetramer
39 No 
phenylalanyl-tRNA synthetase beta 
subunit FARSB Cytoplasm II Tetramer
39 No 
phenylalanyl-tRNA synthetase 2 FARS2 Mitochondria II Monomer38 No 
glycyl-tRNA synthetase 1 GARS1 Cytoplasm and mitochondria II Dimer
40 No 
histidyl-tRNA synthtetase 1 HARS1 Cytoplasm II Dimer41 No 
histidyl-tRNA synthetase 2 HARS2 Mitochondria II Dimer42 No 
isoleucyl-tRNA synthetase 1 IARS1 Cytoplasm I Monomer29 Yes 
isoleucyl-tRNA synthetase 2 IARS2 Mitochondria I ND; monomer in T. thermophiles43 No 
lysyl-tRNA synthetase 1 KARS1 Cytoplasm and mitochondria II
44 Dimer/Tetramer45 Yes 
leucyl-tRNA synthetase 1 LARS1 Cytoplasm I Monomer29 Yes 
leucyl-tRNA synthetase 2 LARS2 Mitochondria I ND; monomer in T. thermophilus46 No 
methionyl-tRNA synthetase 1 MARS1 Cytoplasm I Monomer47 Yes 
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methionyl-tRNA synthetase 2 MARS2 Mitochondria I ND; monomer in E. coli48 No 
asparaginyl-tRNA synthetase 1 NARS1 Cytoplasm II Dimer49 No 
asparaginyl-tRNA synthetase 2 NARS2 Mitochondria II Dimer50 No 
prolyl-tRNA synthetase 2 PARS2 Mitochondria II Dimer51 No 
glutaminyl-tRNA synthetase 1 QARS1 Cytoplasm I Monomer52 Yes 
arginyl-tRNA synthetase 1 RARS1 Cytoplasm I Monomer53 Yes 
arginyl-tRNA synthetase 2 RARS2 Mitochondria I Monomer38 No 
seryl-tRNA synthetase 1 SARS1 Cytoplasm II Dimer54 No 
seryl-tRNA synthetase 2 SARS2 Mitochondria II Dimer55 No 
threonyl-tRNA synthetase 1 TARS1 Cytoplasm II Dimer56 No 
threonyl-tRNA synthetase 2 TARS2 Mitochondria II Dimer57 No 
valyl-tRNA synthetase 1 VARS1 Cytoplasm I Monomer58 No 
valyl-tRNA synthetase 2 VARS2 Mitochondria I ND; monomer in T. Thermophilus59 No 
tryptophanyl-tRNA synthetase 1 WARS1 Cytoplasm I Dimer60 No 
tryptophanyl-tRNA synthetase 2 WARS2 Mitochondria I ND; dimer in B. stearothermophilus61 No 
tyrosyl-tRNA synthetase 1 YARS1 Cytoplasm I Dimer62 No 
tyrosyl-tRNA synthetase 2 YARS2 Mitochondria I Dimer36 No 
 




characterized by the presence of autoantibodies against ARS enzymes.27 These antibodies most 
commonly recognize HARS1, but have also been observed to recognize TARS1, AARS1,  
IARS1, GARS1, NARS1, FARS1, KARS1, QARS1, and YARS1.27 Additionally, multiple ARS 
proteins respond to cytokine signaling. For instance, the cytokine IFNg triggers the alternative  
splicing of WARS1 into a truncated “mini-WARS” protein that is secreted to the extracellular 
space and acts as an anti-angiogenic factor.63,26 IFNg also triggers the secretion of full-length 
WARS1 to the extracellular space, where it binds the macrophage receptor TLR4 and 
participates in innate immunity against infection.64 Similarly, under apoptotic conditions65 or 
upon treatment with the cytokine tumor necrosis factor alpha (TNF-alpha)63 YARS1 is secreted 
into the extracellular space where it is cleaved into two fragments.65 The N-terminal fragment, 
termed “mini-YARS,” can bind to vascular endothelial cells and trigger angiogenic signaling 
pathways.63 The C-terminal fragment has cytokine properties, and triggers the release of TNF-
alpha from macrophages.65,66 Finally, in myeloid cells, IFNg triggers the release of EPRS from 
the multi-synthetase complex.67 EPRS then participates in another multi-protein complex known 
as the GAIT complex, which binds to the 3’ UTR of inflammatory mRNAs and suppresses their 
translation.67 Overall, these studies implicate aminoacyl tRNA synthetase enzymes in a complex 
network of immune system regulation.  
 
1.2 ARS mutations in disease 
 
It is unsurprising that ARS enzymes are ubiquitously expressed and essential to cellular life, 
given the critical role that they perform in protein translation. Although complete loss of any 
ARS enzyme is incompatible with life, bi-allelic variants that severely impair ARS function can 
cause a spectrum of recessive disorders, many of which have phenotypic overlap with other 
translation-related diseases discussed above in Section 1.1.3. Additionally, mono-allelic variants 
in 5 of the 37 ARS genes have been implicated in a tissue-restricted phenotype, dominant axonal 
peripheral neuropathy. This section will provide an overview of both recessive and dominant 
ARS-mediated disease. 
 
1.2.1 Recessive ARS-mediated disease genotypes 
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All recessive ARS-mediated disorders are, by definition, caused by bi-allelic mutations. 
Typically, patients with these diseases are homozygous for missense mutations, compound 
heterozygous for missense mutations, or compound heterozygous for one missense mutation and 
one null allele.68 Homozygosity or compound heterozygosity for ARS null alleles is lethal due to 
the essential nature of ARS enzymes; this has been experimentally demonstrated with a gene trap 
insertion in Gars1 that ablates Gars1 mRNA expression and is homozygous lethal.69 The 
genotypes identified in patients with recessive ARS-related disease strongly suggest a loss-of-
function mechanism for disease pathogenesis.  
 
1.2.2 Clinical heterogeneity in ARS-mediated recessive phenotypes 
Recessive ARS-mediated disease comprises a wide range of clinical manifestations (Table 1.2). 
Pathogenic variants in ARS genes encoding a mitochondrial enzyme tend to cause phenotypes in 
tissues with a high metabolic demand, particularly in the central nervous system. 
Leukoencephalopathies,70-76 myopathies,77-81 and liver disease82,83 are all common features of 
mitochondrial ARS disease phenotypes. Additionally, lactic acidosis,75,77,84-88 
epilepsy,70,71,74,82,86,89,90 developmental delay and intellectual disability,73,89,91-93 ovarian 
failure,42,70,94-96 and sensorineural hearing loss72,91,94,97-101 are frequently observed in patients with 
mitochondrial ARS mutations. Variants in some mitochondrial ARS can cause a range of diverse 
phenotypes, possibly related to the degree of enzyme impairment. For example, variants in 
AARS2 can cause both fatal infantile cardiomyopathy and adult onset leukodystrophy, with or 
without ovarian failure (Table 1.2). Through structural modeling, Euro et al. found that patients 
diagnosed with cardiomyopathy had two alleles that were predicted to severely reduce function, 
whereas leukodystrophy patients had one allele predicted to severely reduce function and one 
predicted to only moderately reduce function.31 Even in cases where individuals have identical 
genotypes, the severity of protein translation defects can determine the severity of the phenotype. 
In the case of siblings with identical pathogenic RARS2 mutations, the sibling with the greater 
reduction in mitochondrial OXPHOS protein complex levels presented with lactic acidosis and 
neurological symptoms, whereas the sibling with a milder OXPHOS reduction had lactic 
acidosis but no neurological symptoms.86  
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Inheritance Disease Phenotype(s) 
AARS1 16q22 Cytoplasm 
Autosomal 
Recessive 
Early-onset epileptic encephalopathy with myelination defect102 
Microcephaly with hypomyelination, epileptic encephalopathy, 
and spasticity103 
Microcephaly, developmental delay, acute liver failure104 




Charcot-Marie-Tooth disease type 2N106-111 
Distal hereditary motor neuropathy112 
AARS2 6p21.1 Mitochondria Autosomal Recessive 
Leukoencephalopathy with or without ovarian failure70,94,95,113-120 
Cardiomyopathy78,121 
Optic atrophy and retinopathy122 
Ataxia, vision loss, and cognitive impairment without 
leukodystropy123 
Ovarian failure with no reported neurological symptoms124 
Primary pulmonary hypoplasia without evidence of 
cardiomyopathy125 
CARS1 11p15.4 Cytoplasm Autosomal Recessive Microcephaly, developmental delay, brittle hair and nails
126 
CARS2 13q34 Mitochondria Autosomal Recessive 
Epileptic encephalopathy71,127 
Progressive myoclonic epilepsy90 
DARS1 2q21.3 Cytoplasm Autosomal Recessive 
Hypomyelination with brain stem and spinal cord involvement 
and leg spasticity128-130 
DARS2 1q25.1 Mitochondria Autosomal Recessive 
Leukoencephalopathy with brain stem and spinal cord 
involvement and lactate elevation75,76,131-137 
EPRS 1q41 Cytoplasm Autosomal Recessive Hypomyelinating leukodystrophy
138 
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EARS2 16p12.2 Mitochondria Autosomal Recessive 
Leukoencephalopathy with thalamus and brainstem involvement 
and high lactate 76,139-141 
Neonatal lactic acidosis, recurrent hypoglycemia, agenesis of 
corpus callosum84 
Multiple respiratory chain complex defects121 
Seizures, liver dysfunction (no thalamus or brain stem 
involvement)142 
Late onset leukoencephalopathy143 
FARSA 19p13.13 Cytoplasm Autosomal Recessive 
Multisystem disease including growth delay, hypotonia, brain 
calcifications, liver dysfunction144 
FARSB 2q36.1 Cytoplasm Autosomal Recessive 
Multisystem disease including growth restriction, failure to thrive, 
developmental delay, interstitial pulmonary disease, cirrhosis and 
portal hypertension, brain calcifications145-147 
FARS2 6p25.1 Mitochondria Autosomal Recessive 
Early onset epileptic encephalopathy with lactic acidosis, liver 
dysfunction, developmental delay, and premature death74,148-150 
Juvenile onset epilepsy83,151,152 
Spastic paraplegia153-155 








Systemic mitochondrial disease157,158 
Cardiomyopathy121 
Severe multisystem disorder159 
Autosomal 
Dominant 
Dominant peripheral neuropathy with or without sensory 
involvement (CMT disease type 2D, dSMA-v, dHMN)160-171 
HARS1 5q31.3 Cytoplasm 
Autosomal 
Recessive 




Dominant peripheral neuropathy with or without sensory 
involvement (CMT, dHMN)174-176 
HARS2 5q31.3 Mitochondria Autosomal Recessive Perrault syndrome
42,177-180 
IARS1 9q22.31 Cytoplasm Autosomal Recessive 
Growth restriction, neonatal cholestasis, muscular hypotonia, 
intellectual disability, infantile hepatopathy181-184 
IARS2 1q41 Mitochondria Autosomal Recessive 
Cataracts, growth hormone deficiency, sensory neuropathy, 









Neurological disorder including leukodystrophy, sensorineural 
hearing loss, microcephaly, cerebral calcifications, epilepsy, 
vision loss nystagmus72,100,186-194 
Recessive intermediate Charcot-Marie-Tooth disease type B, 
dysmorphic features, developmental delay, self-abusive behavior, 
vestibular Schwannoma195 
Hypertrophic cardiomyopathy and combined mitochondrial 
respiratory chain defect81 
LARS1 5q32 Cytoplasm Autosomal Recessive 
Infantile liver failure, intrauterine growth restriction, 
neurodevelopmental delay, microcytic anemia, recurrent 
infections, hypotonia, hypoalbuminemia196–201 
LARS2 3p21.31 Mitochondria Autosomal Recessive 
Perrault syndrome96,202-209 
Hydrops, lactic acidosis, sideroblastic anemia (HLASA)85 
HLASA with sensorineural hearing loss and developmental 
delay101 
Reversible myopathy, lactic acidosis, and developmental delay101 
MARS1 12q13.3 Cytoplasm 
Autosomal 
Recessive 
Multisystem disease including interstitial lung and liver disease, 
pulmonary alveolar proteinosis, anemia, failure to thrive, 
developmental delay 210–215 
Trichothiodystrophy including ataxia, dysmorphic features, 
follicular keratosis, ichthyosis, and intellectual disability (no 
reported lung or liver involvement)105 
Autosomal 
Dominant 
Peripheral neuropathy (Charcot-Marie-Tooth disease type 2U)216–
219 
MARS2 2q33.1 Cytoplasm Autosomal Recessive 
Developmental delay, sensorineural hearing loss91 
Autosomal recessive spastic ataxia with leukoencephalopathy220 
NARS1 18q21.31 Cytoplasm 
Autosomal 
Recessive 
Microcephaly, psychomotor developmental delay, seizures, 
dysmorphisms, ataxia, peripheral neuropathy221,222 
Autosomal 
Dominant 
Severe global developmental delay, intellectual disabilities, 
dysmorphia, seizures, spasticity, peripheral neuropathy, ataxia222 
NARS2 11q14.1 Mitochondria Autosomal Recessive 
Alpers syndrome223,224 
Developmental delay, intellectual disability, epilepsy, 
myopathy89,92 
Nonsyndromic deafness50 
Reversible COX deficiency225 
Lethal epileptic encephalopathy with global brain atrophy226 
Leigh syndrome50,227 
PARS2 3p21.31 Mitochondria Autosomal Recessive 
Alpers syndrome223 
Infantile-onset developmental delay, epilepsy, hypotonia, 
ataxia89,228,229 
Infantile spasms, microcephaly, facial dysmorphy, 








Intractable seizures, progressive microcephaly, cerebral-cerebellar 
atrophy, hypomyelination, developmental delay230–232 
Severe linear growth retardation, poor weight gain, microcephaly, 
cutaneous syndactyly of the toes, intellectual disability, and 
characteristic facial features233 
RARS1 5q34 Cytoplasm Autosomal Recessive 
Hypomyelination, motor delay, ataxia, spasticity, intellectual 
disability with a broad range of severity234–237 
RARS2 6q16.1 Mitochondria Autosomal Recessive 
Pontocerebellar hypoplasia238–244 
Early onset epileptic encephalopathy245,246 
Lactic acidosis with or without neurological symptoms 
(microcephaly, seizures, developmental delay)86  
Dysmorphic features, epileptic spasms, optic atrophy, severe 
hypotonia247 
Intellectual disability93 
SARS1 1p13.3 Cytoplasm Autosomal Recessive 
Intellectual disability, ataxia, microcephaly, speech impairment, 
aggressive behavior248 
SARS2 19q13.2 Mitochondria Autosomal Recessive 
Hyperuricemia, pulmonary hypertension, renal failure, and 
alkalosis249–251 
Spastic paresis252 
TARS1 5p13.3 Cytoplasm Autosomal Recessive 
Trichothiodystrophy including ichthyosis, recurrent respiratory 
infection, developmental delay, and follicular keratosis253 
TARS2 1q21.2 Mitochondria Autosomal Recessive Hypotonia, severe developmental delay, epilepsy
254,255 
VARS1 6p21.33 Cytoplasm Autosomal Recessive 
Severe developmental delay, microcephaly, seizures, cerebellar 
atrophy256–259 
VARS2 6p21.33 Mitochondria Autosomal Recessive 
Multisystem disorder including microcephaly, epilepsy, ataxia, 
lactic acidosis, failure to thrive, with or without cardiomyopathy 
or pulmonary hypertension80,254,260-263 
Multiple respiratory chain complex defects121 
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WARS1 14q32.2 Cytoplasm Autosomal Dominant Distal hereditary motor neuropathy
264,265 
WARS2 1p12 Mitochondria Autosomal Recessive 
Intellectual disability, ataxia, Parkinsonism, microcephaly, lactic 
acidosis, cerebral atrophy, developmental delay, intellectual 
disability, and/or epilepsy73,87,248,266-270 
YARS1 1p35.1 Cytoplasm 
Autosomal 
Recessive 
Severe multisystem disorder including failure to thrive, 
sensorineural hearing loss, brain dysmyelination, nystagmus, liver 
disease, pulmonary disease, anemia, hypotonia, and/or 
developmental delay271–274 
Autosomal 
Dominant Dominant intermediate Charcot-Marie-Tooth disease type C
275,276 
YARS2 12p11.21 Mitochondria Autosomal Recessive 
Myopathy, lactic acidosis, sideroblastic anemia, cardiomyopathy, 
respiratory insufficiency77,79,88,277–281 
Multiple respiratory chain complex defects121 
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A similar dynamic may explain the extreme clinical heterogeneity of SARS2-mediated disease, 
although the relationship between genotype and phenotype is less clear. Homozygosity or 
compound heterozygosity for missense mutations that decrease the levels of aminoacylated 
mitochondrial tRNASerAGY cause hyperuricemia, pulmonary hypertension, infantile renal failure, 
and alkalosis (termed HUPRA syndrome).249,251 However, homozygosity for a splice site 
mutation that significantly reduces SARS2 levels and decreases the levels of aminoacylated 
mitochondrial tRNASerAGY causes childhood-onset spastic paresis, with no apparent kidney 
dysfunction, uricemia, or alkalosis.252 A side-by-side comparison of HUPRA variants with the 
spastic paresis splice variant will be required to understand the relationship between genotype 
and phenotype, and determine whether there is differential SARS2 impairment and/or differential 
defects in mitochondrial protein translation.  
 
Mutations in ARS genes encoding cytoplasmic enzymes also cause a spectrum of recessive 
disorders, which can affect a wider array of tissues but also typically includes a neurological 
component. The recessive neurological phenotypes associated with cytoplasmic ARSs include 
hypomyelination,128,130,138,234 microcephaly,103,126,186,230,231,248,256 seizures,102,103,230,231,256 
sensorineural hearing loss,100,173,194,273 and developmental delay.181,195,210,231,256,271 Mutations in 
cytoplasmic ARS genes also frequently affect the lung or liver (Table 1.2). Interestingly, 
mutations in some ARS cause a uniquely severe phenotype in a commonly affected tissue. For 
example, although mutations in FARSA,144 FARSB,145,147 IARS1,181 MARS1,210 and YARS1272 all 
cause liver dysfunction as one component of a multisystem disease, mutations in LARS1 cause a 
severe, acute form of infantile liver failure.196–199 Similarly, pulmonary disease is particularly 
pronounced in individuals with bi-allelic FARSB145–147 and MARS1 mutations210,213, including a 
MARS1-specific form of pulmonary alveolar proteinosis.211 
 
This relationship between a particular ARS gene and its tissue-predominant pathology is poorly 
understood. It is possible that these tissues produce critical proteins that have a high requirement 
for a specific amino acid; for example, the liver may require certain proteins with a high leucine 
content. Here, if defects in LARS1 reduce the availability of charged tRNALeu, this may 
preferentially affect the synthesis of leucine-abundant proteins that are critical for proper liver 
function, such as proteins in the lipid biosynthesis.196 (Consistent with this hypothesis, liver 
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biopsies from patients with LARS1-mediated liver disease show large fat deposits.196)  In this 
model, the degree to which synthesis of these leucine-rich proteins would be impaired would 
depend on multiple factors: 1) the expression profile of the required tRNALeu, which may vary 
between tissues282 and modify the tRNA charging defect; 2) the availability of leucine based on 
nutrient intake, amino acid transportation, and the requirement for that amino acid in other 
cellular metabolic pathways; and 3) the cumulative need for charged tRNALeu across the other 
polysomes in the cell. Significant work is required to evaluate this hypothesis and determine 
whether it contributes to the phenotypic heterogeneity of ARS-mediated recessive disease. 
 
1.2.3 Dominant ARS-mediated disease genotypes 
Variants in five ARS genes have been confidently implicated in dominant human disease, which 
manifests as dominant axonal peripheral neuropathy (discussed in Section 1.2.4). These are: 
glycyl-(GARS1),160 tyrosyl-(YARS1),275 alanyl-(AARS1),106 histidyl-(HARS1),174 and 
tryptophanyl-tRNA synthetase (WARS1).264 In addition, a small number of variants in methionyl-
tRNA synthetase (MARS1) have been reported in patients with dominant peripheral 
neuropathy.216–219 However, there is currently insufficient genetic evidence to conclude that 
mutations in MARS1 cause dominant peripheral neuropathy, as none of the reported variants 
segregate with disease in a large, multi-generational family. In general, the allelic spectrum of 
dominant pathogenic variants comprises missense mutations, with the exception of two in-frame 
deletions, one in GARS1170 and one in YARS1.275  
 
It is striking that only five ARS genes have been confidently implicated in dominant peripheral 
neuropathy to date, whereas nearly all have been implicated in recessive disorders. This may 
indicate that there is something unique about these five ARS genes that makes neurons 
susceptible to mutations in them. Alternately, if variants in additional ARS genes continue to be 
identified in patients with dominant peripheral neuropathy, this will more convincingly point to a 
generalizable defect in tRNA charging. Identifying patients with dominant peripheral neuropathy 
harboring variants in other ARS genes (and characterizing these variants to define their role in 
disease) will provide additional support for the hypothesis that defects in tRNA charging are a 
common mechanism of disease. These goals are discussed further in Chapter 3.   
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It is worth noting that patients with recessive GARS1-, YARS1-, HARS1-, or AARS1- mediated 
disease are frequently compound heterozygous or homozygous for missense alleles, but no 
parents carrying these missense alleles have been reported to have a peripheral neuropathy. This 
may indicate a separation of function between dominant missense alleles and recessive missense 
alleles, or a differential effect on protein stability. However, this interpretation is complicated by 
the fact that most parents of children with recessive ARS-mediated disease are not carefully 
evaluated by a neurologist. Additionally, dominant ARS-mediated peripheral neuropathy can be 
mild, late-onset, or incompletely penetrant163, which might make it difficult to detect a 
phenotype. The studies presented in Chapter 4 of this dissertation provide a platform to begin 
distinguishing recessive missense alleles from dominant missense alleles. These topics are also 
discussed further in Chapter 5.  
 
1.2.4 Dominant ARS variants cause axonal peripheral neuropathies 
Dominant ARS variants cause dominant axonal peripheral neuropathies, frequently classified as 
Charcot-Marie-Tooth (CMT) disease Type 2. CMT disease is a genetically and clinically diverse 
group of peripheral neuropathies that is estimated to affect between 1 in 1,200 and 1 in 2,500 
individuals.283,284 CMT disease is characterized by decreased sensory and/or motor nerve 
function in the distal extremities.285 This leads to sensory loss and muscle atrophy, which often 
begins in the feet and peroneal musculature. Later, this atrophy may reach the calves and hands, 
and even later, the forearms.285 One unique aspect of GARS1-mediated CMT disease is that it 
presents as an upper-limb predominant phenotype, beginning with weakness and muscle atrophy 
in the hands.286 Only about half of affected individuals develop lower limb symptoms, which can 
vary in severity.286 The reasons for this upper limb predominance are poorly understood. One 
consideration is that GARS1 is the only CMT-associated ARS enzyme that functions in both the 
cytoplasm and mitochondria13; it is possible that its role in mitochondrial protein translation 
contributes to the severity of the upper limb phenotype. 
  
CMT is divided into two groups. CMT Type 1 is a demyelinating form of peripheral neuropathy; 
it is caused by a primary defect in the Schwann cells that form the myelin sheath around 
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peripheral neurons.287 These defects lead to decreased nerve conduction velocities.287 Mutations 
that cause CMT Type 1 are frequently found in genes involved in myelin production, such as 
PMP22 or MPZ.287 CMT Type 2 is caused by a primary defect in the axon, and is identified by 
decreased amplitudes of compound muscle action potentials or sensory nerve action potentials, 
rather than decreased velocities.288 Mutations that cause CMT Type 2 can affect genes 
particularly important for neuronal function, such as ion channels and axonal transport factors, 
but can also affect housekeeping genes, such as MFN2.287,289 MFN2 is a ubiquitously expressed, 
essential gene that encodes a protein with a role in mitochondrial fusion.290 CMT-associated 
alleles in MFN2 have been shown to decrease mitochondrial fusion (classified as loss-of-function 
alleles) or induce mitochondrial aggregation (classified as gain-of-function alleles).290 Although 
MFN2 is ubiquitously expressed, neurons are thought to be particularly sensitive to defects in 
MFN2, as mitochondrial must localize across the axon to provide ATP production to dendrites 
and synapses.290  
 
Similarly, dominant mutations in the ubiquitously expressed RAB7 gene have been implicated in 
CMT Type 2.291 RAB7 is a GTP-ase that regulates the dynamics of late endosomes and 
phagosomes, including their fusion with lysosomes291; CMT-associated mutations are thought to 
partially reduce RAB7 function.292 Although RAB7 is ubiquitously expressed, peripheral neurons 
may be particularly sensitive to partial loss of RAB7 function, since endosomes are required to 
carry neuronal signaling molecules across long axons.293 Interestingly, a recent study by Cioni et 
al. demonstrated that ribosomes, mRNAs, RNA-binding proteins, and mitochondria frequently 
associate with endosomes in the axons of Xenopus retinal ganglia cells.294 The authors also found 
that 35% of RAB7-marked endosomes were adjacent to mitochondria. Of these mitochondria-
adjacent endosomes, 80% were associated with RNA granules, and 76% were associated with de 
novo protein translation, as measured by puromycin incorporation.294 The authors demonstrated 
that two proteins important for mitochondrial function—Lamin B2 (which is required for 
mitochondrial integrity and axonal survival) and VDAC2 (which exchanges solutes across the 
outer mitochondrial membrane)—were translated at these late endosomes, indicating that these 
endosomes serve as a platform for the local translation of mitochondrial proteins.294 Expression 
of CMT-associated RAB7 mutations lead to decreased local translation of both Lamin B2 and 
VDAC, correlating with disrupted mitochondrial morphology and trafficking.294 This study 
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highlights the interrelatedness of axonal trafficking, mitochondrial integrity, and local protein 
translation, as well as their importance for axonal health. 
 
In addition to CMT Type 2, dominant ARS variants cause a closely related form of peripheral 
neuropathy, distal hereditary motor neuropathy (dHMN). dHMN results in a similar lower limb 
weakness and atrophy of the peroneal musculature, but primarily affects the motor neurons, 
compared to both sensory and motor neurons in CMT disease.295 Similar to CMT disease, 
mutations that cause dHMN can affect genes specific to neuronal function, such as ion channels 
and axonal transporters, but also genes involved in basic cellular function such as RNA 
metabolism and DNA integrity.295 In the case of GARS1, this motor neuron-predominant 
neuropathy is termed distal spinal muscular atrophy type V (dSMA-V), and, like GARS1-
mediated CMT, predominantly affects the upper limbs. 
 
Some ARS mutations, such as E71G and D500N GARS1, can cause both dSMA-V and CMT 
within the same family.160,164,296 Considering that all affected family members carry the same 
genetic variant, it is unknown what dictates the degree of sensory neuron involvement that leads 
to the two distinct classifications. De novo GARS1 variants can also cause a severe, infantile-
onset form of dSMA-V. Individuals who are heterozygous for these GARS1 variants have 
delayed or regressing motor milestones, severe muscle wasting, respiratory distress, and poor 
feeding abilities.162,165,170,171 It is unclear what distinguishes these variants from the GARS1 
variants that cause a later onset, milder phenotype. One potential explanation is that these 
variants cause a unique neomorphic interaction that is toxic to motor neurons. These hypotheses 
are considered further in Section 1.4.4.  
 
1.3 The molecular mechanisms of ARS-related genetic disease 
 
1.3.1 Assays to evaluate impaired ARS function 
One approach to defining pathogenic ARS alleles for both dominant and recessive disease is to 
determine if the variant impacts protein function. For variants with strong genetic evidence 
supporting their pathogenicity, these studies provide insight into the mechanism of disease. As 
the mechanism of disease is further defined, these approaches can also be used to build a case for 
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or against the pathogenicity of a newly characterized variant of uncertain significance. There are 
three commonly used assays for determining whether a variant impairs ARS function: 1) in vitro 
aminoacylation assays with recombinant proteins, 2) in vitro aminoacylation assays with patient 
cell lysates, and 3) in vivo yeast complementation assays. 
 
Human ARS proteins can be expressed in bacteria, purified, and tested in an in vitro 
aminoacylation assay that measures its steady-state enzymatic activity.297 Aminoacyl-tRNA 
synthetases charge tRNA with amino acids in a two-step reaction: in the first step, the enzyme 
binds ATP and the amino acid, resulting in the release of pyrophosphate. This step can be 
measured by treating the reaction with a colorimetric reagent that can quantify the amount of free 
phosphates released.298 Then, the enzyme binds to the appropriate tRNA, ligating it to the amino 
acid and releasing AMP. The efficacy of the entire reaction can be assessed by incubating 
purified ARS enzyme with tRNA, ATP, and radiolabeled amino acid.297 Aliquots of the mixture 
are then spotted on filter paper across time points. The tRNA is precipitated from the filter paper 
and washed to remove any unincorporated amino acid. Then, radioactivity of the amino acid that 
remains ligated to the tRNA is measured as the output of the reaction.297   
 
Interpreting data from these kinetic assays can be challenging for partial loss-of-function 
variants. If these assays are performed with an excess of substrate (ATP, tRNA, and/or amino 
acid), this can mask the reduced function of a hypomorphic ARS. For example, the P234KY 
GARS1 protein was initially reported as fully functional allele when tested with saturating 
concentrations of glycine and tRNA.69 When re-analyzed under Michaelis-Menten conditions, 
the mutation was found to significantly decrease enzymatic activity.170 Furthermore, it is difficult 
to know what substrate concentrations best reflect substrate availability in vivo, or what degree 
of impaired function is required to have a downstream effect in the relevant tissue. 
 
One way to assess ARS function in the context of an affected cell is a steady-state 
aminoacylation assay performed with patient cell lysates. In these assays, whole cell lysate is 
incubated in a reaction buffer that contains additional ATP, yeast total tRNA, and stable-isotope 
amino acid. The tRNA is then precipitated and washed before ammonia is added to release the 
stable-isotope amino acids from the tRNAs, which are then quantified with LC-MS/MS. This 
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assay has successfully been used to identify tRNA charging defects in patients cells with bi-
allelic CARS1126, AARS1,105 MARS1,105 VARS1,257 EPRS,138 and NARS1221,222 variants. However, 
because this data reflects the total tRNA charging defect in the cell, it is not informative about 
the degree to which each of the two alleles contribute to the loss-of-function effect. Additionally, 
these reactions are performed with fibroblasts or lymphoblast cells that do not have a detectable 
phenotype, and so may not reflect the defective charging in the affected patient tissues. This 
assay has not been employed for cells from patients with dominant peripheral neuropathy, and is 
less likely to detect a significant defect in these cells, due to the later-onset and tissue-specific 
nature of ARS-mediated dominant neuropathy.  
 
An alternate in vivo approach for assessing the impact of an ARS variant on gene function is a 
yeast complementation assay. This is a relatively straightforward, inexpensive, and quick 
approach that is well-suited to testing patient variants of uncertain significance. The assay relies 
on the fact that yeast need ARS function to survive and grow; as such, yeast growth serves as a 
proxy for ARS gene function. In these assays, the endogenous yeast ARS gene is deleted—
temporary viability is maintained with the yeast ARS gene expressed from its endogenous 
promoter, on a URA3-bearing plasmid. The human ARS ortholog, expressed from a strong 
ubiquitous promoter on a high-copy number plasmid, can be transformed into yeast cells, and 
selected for using the LEU2 auxotrophic marker expressed from the plasmid backbone. Then, 
yeast cells are plated on media containing the drug 5-fluoroorotic acid (5-FOA). Ura3 converts 
5-FOA into a toxic compound, causing cells that express URA3 from the maintenance vector to 
die, and selecting for the cells that have spontaneously lost the maintenance vector during cell 
division.299 The only source of ARS in these surviving yeast is the exogenous human ARS, and 
the function of this gene determines whether the yeast will grow or not. In this assay, the growth 
of yeast expressing patient mutations are compared to the growth of yeast expressing wild-type 
ARS. An empty vector serves as a negative control, ensuring that 5-FOA selection is complete.  
 
Yeast complementation assay are an important in vivo counterpart to in vitro aminoacylation 
assays, as they demonstrate the degree of ARS impairment required to impact a living cell. Yeast 
complementation assays almost always correspond to results from in vitro aminoacylation 
assays; variants that significantly impair in vitro aminoacylation also do not support yeast 
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growth. For example, the re-analyzed P234KY GARS1 variant (discussed above) does not 
support yeast growth, consistent with its loss of function in vitro170 (Figure 1.1). Similarly, 
∆ETAQ GARS1, which is severely enzymatically impaired in vitro170 does not support yeast 
growth (Figure 1.1). Occasionally, yeast complementation data is discordant with enzymatic 
assay, specifically when human variants are modeled in the yeast ortholog. For example, G240R 
GARS1 significantly impairs enzyme function in vitro300, but does not reduce yeast growth when 
modeled in GRS1, the yeast ortholog of GARS1.301 However, when G240R is modeled in the 
human GARS1 open reading frame, it significantly impairs yeast growth compared to wild-type 
GARS1 (Figure 1.1), consistent with the in vitro enzymatic data for the human protein. This 
highlights the discrepancies that can arise between functional assays with the yeast gene and 
functional assays with the human gene, and the importance of testing variants in the human ARS 
gene when possible.  
 
One limitation of the yeast complementation assay is the incongruence between a yeast cell and 
the human tissues affected in ARS-related disease, particularly neurons, which are affected in 
nearly all patients with dominant or recessive ARS-related phenotypes. On one hand, mutations 
that may be deleterious in the relevant human context may not affect yeast growth, particularly 
when over-expressed in rapidly dividing cells growing in nutrient-rich media. This is especially 
relevant to mutations that may only moderately reduce enzymatic function; although this 
reduction may be tolerable to yeast, it might be pathogenic in a human patient if it is in trans 
with a null mutation. On the other hand, reduced function of the human gene in a yeast cell may 
not reflect the effect of pathogenic variants in affected human tissues due to differences in the 
human transcriptome and proteome, and the tissue-specific availabilities of ARS substrates. 
 
1.3.2 Reduced enzymatic function causes recessive ARS diseases 
Bi-allelic variants identified in patients with ARS-mediated disease are typically missense 
mutations, splice site mutations, or insertions or deletions that lead to a frameshift and a 
premature stop codon. Premature stop codons generate null alleles, reducing total ARS protein 
levels.145,159,103 Similarly, splice site mutations cause aberrant inclusion of introns242 or exclusion 




Figure 1.1. Pathogenic GARS1 variants do not support yeast growth. 
 
Representative images of yeast strains lacking endogenous GRS1, transformed with an empty 
vector (“Empty pyy1”), a vector expressing the wild-type human GARS1 open reading frame, or 
vectors expressing the mutant human GARS1 open reading frame. Two independent colonies 
were tested for each GARS1 mutation (from left to right, ∆ETAQ, P234KY, and G240R). Each 
colony was plated undiluted or in 1:10 serial dilutions on media containing 5-FOA. Yeast were 
grown at 30°C.  
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generate null alleles.147 Recessive missense mutations either impair protein stability, decrease 
enzymatic function, or both. In many cases, the primary defect of the missense mutation appears  
to be through decreased protein levels. This is detected through immunostaining for the affected 
ARS protein in patient cell lines, and comparing protein levels to those of heterozygous parents 
or wild-type controls. For example, two patients who are compound heterozygous for different 
AARS1 missense variants have 15% or 30% of wild-type AARS1 levels.105 Similarly, individuals 
who are homozygous for a missense MARS1 variant, or homozygous for a missense TARS1 
variant have 30% of wild-type MARS1 levels and less than 20% of wild-type TARS1 levels, 
respectively.105,253 Perhaps most dramatically, an individual who is compound heterozygous for a 
missense mutation and a frameshift mutation in FARSB showed an approximate 97% reduction 
in FARSB levels145, indicating that the missense allele produced only a small amount of FARSB 
protein.   
 
In these cases, any existing protein must have some enzymatic function, or the genotype would 
be incompatible with life. To discern how much function is retained, it is necessary to test the 
allele in isolation, either using in vitro aminoacylation assays or in vivo yeast complementation 
assays. These studies can be useful for estimating the total decrease in ARS activity in a patient 
cell, which can inform efforts to understand the relationship between genotype and phenotype. 
For example, two individuals could each have an 80% reduction in ARS protein. However, if one 
individual has almost no functional enzyme in that remaining 20%, their phenotype is likely to 
be more severe than an individual with a fully functional 20%.  
 
In some cases, the primary defect does appear to be in protein abundance, not enzymatic 
function. For example, a recent study evaluated patients with a multi-system ataxic syndrome 
and bi-allelic HARS1 variants. One patient was compound heterozygous for D206Y HARS1 and 
V244Cfs*6 HARS1.172 V244Cfs*6 HARS1 was not expressed at the mRNA level, indicating that 
it was unstable or subjected to nonsense-mediated decay.172 This allele would be expected to 
decrease HARS1 levels by 50%. However, total HARS1 protein levels were significantly below 
50% of wild-type levels, indicating that D206Y also impairs protein production or stability. 
When D206Y was tested in a yeast complementation assay, it did not lead to a decrease in yeast 
growth, indicating that it did not significantly impair gene function when over-expressed in 
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yeast.172 This suggests that in human cells, D206Y is deleterious primarily through decreasing 
protein levels, and not through significantly decreasing protein function.  
 
In other cases, a missense allele can decrease both protein levels and protein function. Here, an 
informative case is found in two siblings presenting with microcephaly, hypomyelination, and 
epileptic encephalopathy, both of whom were compound heterozygous for Y690Lfs*3 AARS1 
and G913D AARS1.103 Immunostaining of patient and parent-derived lymphoblastoid cells 
showed that Y690Lfs*3 decreased AARS1 protein levels by ~50% in a heterozygous parent and 
did not result in a truncated AARS1 band (of note, these studies were performed with an 
antibody to the N terminus that would recognize a truncated protein).103 Compared to wild-type 
controls, the compound heterozygous patient had less than 20% of wild-type AARS1 protein 
levels—50% of this decrease was likely due to Y690Lfs*3, and the other 30% or more due to the 
G931D allele.103 To discern how much activity G931D retained, in vitro aminoacylation assays 
were performed. G931D decreased enzymatic activity by ~70% compared to WT AARS1.103 
This indicates that, in addition to G931D decreasing protein abundance, any remaining G931D 
has decreased enzymatic activity.   
 
Lastly, it is possible that the primary defect of a missense variant is in enzymatic activity, rather 
than decreased protein levels. To date, this has only been effectively demonstrated for one 
variant, R310Q GARS1. This variant was identified in trans with a frameshift variant, G831Ifs*6 
GARS1, in a patient with a severe multisystem disorder.159 Careful analysis of protein levels from 
the patient and from unaffected wild-type controls identified a 50% reduction of GARS1 protein, 
consistent with G831Ifs*6 ablating protein expression and the remaining GARS1 protein 
representing the R310Q allele.159 In vitro measurements of initial charging velocity for R310Q 
GARS1 found that it decreases enzymatic activity by greater than 99% compared to wild-type 
GARS1.159 It is likely that R310Q retains more function in patient tissues, as such a significant 
decrease would be incompatible with life. Regardless, this demonstrates that R310Q primarily 
decreases GARS1 function by impairing enzymatic activity, not by decreasing protein levels.  
 
From these studies and others, it is clear that recessive ARS-mediated disease is due to a loss-of-
function mechanism. This is also supported by work on IARS,182 QARS,230 and KARS1,194 in 
 26 
zebrafish, and models of HARS242 and LARS296 in C. elegans demonstrating that knocking down 
the ARS gene recapitulates key elements of the recessive disorder. However, there is still work 
to be done to define the downstream molecular consequences of reduced ARS activity. On this 
front, studies of mutations in mitochondrial ARS genes lead the way.  
 
Investigations of recessive mitochondrial ARS disorders have demonstrated a relationship 
between decreased mitochondrial ARS activity, reduced protein translation, and impaired 
mitochondrial function. Studies of bi-allelic partial-loss-of-function variants in VARS2,254 
TARS2,254 and NARS250 have examined corresponding changes in aminoacylated tRNA levels. 
Total RNA was extracted from patient cells under acidic condition to preserve the ester bond 
between tRNA and amino acid, separated on a urea polyacrylamide gel, transferred to a 
membrane, and hybridized with radiolabeled probes against the respective tRNAs.50,254 Then, the 
amount of high molecular weight aminoacylated tRNA was compared to the amount of low 
molecular weight uncharged tRNA. Defects in VARS2 and TARS2 corresponded to a 50% and 
60% reduction in aminoacylated tRNAVal or tRNAThr, respectively;254 defects in NARS2 
corresponded to a similar depletion of aminoacylated tRNAAsn.50 To investigate how decreased 
abundance of charged tRNA corresponded to the function of the mitochondrial respiratory chain 
(MRC) complexes, each member of the MRC complexes was analyzed using spectrophotometric 
assays that analyze the appearance or disappearance of MRC substrates and products.50,254 
Muscle samples from all patients demonstrated reduced function of at least one Complex, with 
the exception of Complex II, which is the only complex comprising proteins translated in the 
cytoplasm.50,254 All samples also showed a decrease in oxygen consumption, consistent with 
mitochondrial defects.50,254 Similar studies performed for other mitochondrial ARS variants show 
either decreased abundance of MRC complex proteins (for patients with variants in FARS2,82 
LARS2,85 or AARS2302), decreased activity of MRC complexes (for patients with variants in 
EARS2141 or RARS2244), or both (for patients with variants in YARS2303 and MARS291). 
Comprehensively, these studies demonstrate that reduced mitochondrial ARS function leads to 
reduced levels of aminoacylated tRNA, reduced abundance and/or activity of mitochondrial ARS 
proteins, and impaired mitochondrial function.  
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In sum, these studies provide evidence that recessive ARS alleles cause a partial reduction of 
ARS activity. This could ultimately result in impaired protein translation by one of two 
mechanisms (Figure 1.2). First, impaired translation could be a direct result of uncharged tRNA 
binding to GCN2 through its tRNA recognition domain, which subsequently triggers GCN2 to 
phosphorylate eIF2α.3 Phosphorylated eIF2α then blocks the recycling of GDP-eIF2 to GTP-
eIF2, preventing it from delivering initiator tRNAMet to the ribosome and causing global shut-
down in protein synthesis.3 Second, a dearth of charged tRNAs for a given amino acid could 
cause the ribosome to stall at these amino acid codons, reducing protein expression from the 
transcript.304 Interestingly, ribosome stalling has also been shown to activate GCN2;305 this 
suggests that both mechanisms of decreased protein synthesis may co-exist in cells with reduced 
ARS activity.  
 
1.3.3 Proposed mechanisms of dominant ARS disease 
In contrast to the recessive phenotypes, the molecular mechanism of ARS-related dominant 
axonal neuropathy is less clear. The fact that mutations in five genes encoding an aminoacyl-
tRNA synthetases (GARS1, YARS1, AARS1, HARS1, and WARS1) cause a similar dominant 
phenotype points to a common disease mechanism. In support of this, over-expression of 
neuropathy-associated GARS1 and YARS1 mutants in a Drosophila model cause a strikingly 
similar phenotype.306 Although there is a growing body of work defining various non-canonical 
functions for the above five ARS enzymes (Table 1.3), none are common to all five enzymes, 
nor do they relate to neuron (or axon) function. Thus, it is currently challenging to investigate if 
a loss of some non-canonical function is responsible for ARS-related neuropathy. Also, 
considering that most neuropathy-associated ARS mutations impair rather than enhance enzyme 
function,307 it is unlikely that a gain of canonical function is responsible for disease. As a result, 
there are currently two mechanisms being explored: impaired ARS activity and toxic gain-of-
function effects (Figure 1.3). It should be emphasized that these pathogenic mechanisms may not 
be mutually exclusive—for example, impaired tRNA charging may be a prerequisite for a gain-







Figure 1.2. Potential mechanisms of ARS-related recessive disease. 
 
(A) Two wild-type ARS alleles supply cells with the requisite charged tRNA for protein 
translation. (B) Two loss-of-function ARS alleles severely reduce the amount of charged tRNA 
available for translation, which impairs protein production. Uncharged tRNA is either degraded 
or binds to GCN2, which phosphorylates eIF2α and inhibits global translation. In both panels, 
dimeric enzymes functioning in the cytoplasm are shown for simplicity; however, please note 





Table 1.3. Non-canonical functions of dominant disease-associated ARS proteins. 
ARS Species Non-canonical function 
AARS1 Homo sapiens C-terminal splice variant binds DNA30 
GARS1 
Bos taurus Localizes to the nucleus and activates NFκB1 and mTOR gene expression308 
Homo sapiens Secreted in response to damage in mesenchymal stem cells, promotes differentiation and migration309 
Homo sapiens Chaperone in neddylation pathway310 
Homo sapiens Tumorigenesis defense311 
Saccharomyces cerevisiae mRNA 3’ end formation312 
HARS1 
Danio rerio Angiogenesis regulation313 
Saccharomyces cerevisiae Autoregulatory repression of HARS mRNA translation in response to low tRNA levels314 
Homo sapiens Epitope for autoantibodies in inflammatory myositis315–317 
WARS1 
Homo sapiens In response to IFN-g stimulation, is a cellular entry factor for Enterovirus318 
Homo sapiens In response to IFN-g stimulation, increases tryptophan uptake into cells319 
Homo sapiens Upon secretion from cells, participates in the antiviral innate immune response64,320 
Homo sapiens 
 Mini-WARS1 inhibits angiogenesis
65,321–324 
Homo sapiens In response to IFN-g stimulation, facilitates p53 activation325 
YARS1 
Homo sapiens Fragmented YARS1 stimulates megakaryopoiesis and platelet production326 
Homo sapiens Locates to the nucleus and protects against DNA damage327–329 





Figure 1.3. Potential mechanisms of ARS-related dominant axonal neuropathy. 
 
Neurons are illustrated with the cell body on the left and the axon extending to the right. A wild-
type neuron (A) has functional ARS activity (green dimers) facilitating protein translation. There 
is appropriate NRP1 (orange) and Trk signaling (blue). YARS1 translocates to the nucleus upon 
oxidative stress and binds TRIM28 (blue), changing the regulation of DNA damage response 
genes. HDAC6 (yellow) de-acetylates tubulin under homeostatic conditions. Proposed 
mechanisms of ARS-mediated peripheral neuropathy are represented in (B); neuronal function 
may be compromised by impaired protein translation due to an unknown function of mutant ARS 
(red subunits) and/or a depletion in available charged tRNA from a reduction of aminoacylation 
activity. For peripheral neuropathy related to GARS1, mutant GARS1 may interfere with NRP1 
signaling by preventing VEGFA (magenta) from binding to NRP1. In developing sensory 
neurons, mutant GARS1 may also act as a ligand for Trk receptors, aberrantly activating Trk 
signaling. Mutant GARS1 could also bind to HDAC6, increasing its de-acetylation activity and 
leading to hypo-acetylated tubulin. For peripheral neuropathy related to YARS1, increased mutant 
YARS1 binding to TRIM28 (blue) may alter regulation of DNA damage response genes or genes 
important for neuronal function.   
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1.3.4 Impaired ARS function in dominant axonal neuropathy 
Data from in vitro aminoacylation and yeast complementation assays indicate that almost all 
neuropathy-associated ARS mutations cause deficits in tRNA charging.110,170,171,176,307 
Additionally, data from three animal models suggest that the mutant proteins are sub-functional. 
First, in Drosophila projection neurons, the morphological defects caused by neuron-specific 
homozygosity for a null gars1 allele were fully rescued by a wild-type human GARS1 transgene, 
partially rescued by the neuropathy-associated E71G allele, and not rescued by the neuropathy-
associated L129P allele.331 Second, whereas over-expressing wild-type gars1 rescues the 
neuromuscular phenotype of zebrafish homozygous for a loss-of-function allele, over-expressing 
the neuropathy-associated G526R allele showed no rescue.332. Finally, mice heterozygous for 
P234KY or C201R Gars1 display a dominant neuropathy, but homozygosity for these mutations 
is lethal.333 In sum, there is an abundance of data showing that neuropathy- 
associated ARS missense mutations have a deleterious effect on gene function, indicating that 
this is a component of disease pathogenesis. 
 
In contrast, three lines of evidence argue against a simple loss-of-function effect (i.e., 
haploinsufficiency) as the underlying mechanism of ARS-related neuropathy. First, mice 
heterozygous for a Gars1 null allele have a wild-type phenotype.69 Second, none of the 
individuals with ARS-mediated dominant peripheral neuropathy are heterozygous for a null 
allele. However, recessive individuals are frequently compound heterozygous for a missense and 
a null allele. In these cases, parents carrying the null allele are not reported to have peripheral 
neuropathy symptoms, although few have been clinically evaluated. Additionally, data from the 
Genome Aggregation Database (gnomAD) indicate that AARS1, HARS1, GARS1, YARS1, and 
WARS1 are tolerant of protein truncating variants in the heterozygous state.334 In this database, 
the probability that a gene is haploinsufficient is calculated by comparing the number of protein-
truncating variants that would be expected in the gene based on its sequence content, size, and 
methylation to the number of protein-truncating variants seen in the general population 
(excluding individuals with pediatric diseases and their first degree relatives).334,335 This 
probability is communicated as “pLI” scores, or “probability of being loss-of-function 
intolerant,” where the pLI score for a haploinsufficient gene is 1. The pLI scores for the five 
ARS genes implicated in dominant peripheral neuropathy are: 0 (AARS1), 0 (HARS1), 0 
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(YARS1), 0.31 (GARS1), and 0.3 (WARS1).334 Therefore, heterozygosity for a null allele in any of 
these five genes does not cause a phenotype that is subject to purifying selection. Since gnomAD 
only excludes individuals with known pediatric disease, we do not know if these heterozygous 
null individuals in the database have a peripheral neuropathy. However, cumulatively, these data 
strongly argue against haploinsufficiency as the primary mechanism for a penetrant, ARS-related 
neuropathy. 
 
One possible explanation for the role of loss-of-function missense mutations in dominant 
neuropathy is a dominant-negative effect. Dominant-negative mutations, or anti-morphs, are 
loss-of-function mutations that also inhibit the function of the wild-type gene product.336 The 
catalog of Mendelian diseases is replete with pathogenic dominant-negative alleles in genes 
encoding transcription factors such as p53,337 receptors like G-protein subunits338, ion 
channels339,340, and structural proteins like keratins.341 Dominant-negative mutations in enzymes 
are rarer, likely because it takes a large change in enzymatic concentration or function to impact 
metabolic flux.342 As such, most loss-of-function mutations in enzymes are recessive.342 
However, dominant-negative mutations have been described in PLKR 343 (encoding pyruvate 
kinase, a critical metabolic enzyme), PSEN1344 (which encodes a member of the gamma 
secretase complex that cleaves amyloid precursor protein), UBC12345 (a neddylation conjugating 
enzyme), and GALT346 (an enzyme involved in galactose metabolism).  
 
Prerequisites for a dominant-negative effect include: (1) the mutant protein should be stably 
expressed; (2) the mutant protein should have reduced or ablated function; and (3) the affected 
protein should normally dimerize (or oligomerize) and mutant subunits should retain the ability 
to interact with wild-type subunits. Indeed, AARS1, YARS1, GARS1, HARS1, and WARS1 all 
charge tRNA in the cytoplasm as dimers (Table 1.1); if an inactive mutant subunit dimerizes 
with a wild-type subunit, it could result in a significant reduction in tRNA charging compared to 
the haploinsufficient state. This would shift the burden of tRNA charging onto the reduced 
population (i.e., 25%) of wild-type/wild-type dimers. 
 
Multiple lines of evidence support a dominant-negative effect: (1) data from primary patient cell 
lines indicate that pathogenic ARS alleles do not reduce the total amount of protein detectable 
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via Western blots170,301,333,347,348; (2) in vitro and in vivo functional assays demonstrate that the 
vast majority of pathogenic ARS variants impair enzyme function,110,170,171,176,264,307,349 and (3) 
ultracentrifugation experiments or co-immunoprecipitation experiments have shown that mutant 
ARS retain the ability to dimerize.176,264,275,300,350 However, no studies have demonstrated that 
mutant human ARS is dominantly toxic when co-expressed with wild-type human ARS, nor that 
this toxicity is dependent on the hetero-dimerization between wild-type subunits and mutant 
subunits.  
 
Several studies have generated data that is consistent with a dominant-negative effect. The first 
study found that yeast cells expressing one wild-type and one mutant copy of yeast tyrosyl-tRNA 
synthetase showed reduced growth compare to yeast cells expressing only the wild-type 
enzyme.275 The second study identified a loss-of-function zebrafish gars1 mutation, T209K, that 
ablates dimerization.332 Zebrafish that are homozygous for this allele show a severe 
neuromuscular defect, and zebrafish heterozygous for this allele have no phenotype.332 When 
T209K was over-expressed in either gars1T209K/+ or gars1+/+ zebrafish, the fish had no 
phenotype, indicating that a dimer-reducing loss-of-function gars1 mutation is not dominantly 
toxic.332 However, over-expression of G526R gars1, which dimerizes332 but is non-functional301, 
caused neuromuscular junction defects. Notably, over-expression of T209K in cis with G526R 
improved the neuromuscular junction phenotype, suggesting that dimerization is required for the 
toxicity of G526R gars1.332 The third study investigated H257R WARS1, which decreases 
enzyme activity in vitro but does not impact dimerization.264 To measure the potential 
downstream impact on protein synthesis, cultured cells were co-transfected with a construct to 
express wild-type or H257R WARS1 (or an empty vector) and a plasmid expressing b-Gal or 
luciferase. b-Gal or luciferase activity was interpreted as a read-out for translation of the 
respective enzyme, and protein synthesis as a whole. Whereas wild-type WARS1 increased 
reporter activity above that of the empty vector, H257R WARS1 decreased reporter activity 
below that of empty vector.264 There are significant limitations to this approach, including an 
inability to control for a consistent copy number of each vector across a population of transfected 
cells, and the reliance on the enzymatic activity of two reporter proteins as an indication of 
global protein synthesis. However, the authors concluded that these data demonstrated that 
H257R WARS1 exhibited a dominant-negative effect.  
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Lastly, a study of HARS1 variants provides significant circumstantial evidence of a dominant-
negative mechanism of neuronal toxicity. Mullen et al., examine the variant R137Q HARS1175, as 
well as V155G HARS1 and Y330C HARS1, both of which are characterized in Section 2.3.2. The 
authors over-expressed these alleles in PC12 cells, which can be differentiated to generate axon-
like projections. Over-expression of all three HARS1 alleles showed an increase in EIF2α 
phosphorylation, a marker of the integrated stress response and an indication of accumulating 
uncharged tRNA,351 consistent with significantly reduced HARS1 function.350 This was 
accompanied by an approximate 20% reduction in global protein synthesis, as measured by OP-
Puromycin incorporation.350 This also corresponded to a modest decrease in the length of the 
longest neurite in each cell.350 These findings suggest that the ability to form or maintain long 
neuronal processes, such as the long axons of the peripheral nerve, is dependent on protein 
synthesis. Critically, these three phenotypes—increased EIF2α phosphorylation, decreased 
protein synthesis, and shortened length of the longest neurite—were recapitulated when the cells 
were treated with histidinol, a small-molecule inhibitor of HARS1.350 This directly demonstrates 
that pharmacological impairment of HARS1 phenocopies the toxicity of dominant HARS1 
mutations, consistent with a loss-of-function effect achieved through a dominant-negative 
mechanism. 
 
As a complementary approach, Mullen et al. injected wild-type zebrafish embryos with V155G 
or Y330C human HARS1 mRNA. By 48 hours post fertilization, these zebrafish neurons showed 
improper guidance.350 Neuronal processes in fish expressing mutant HARS1 were also shorter 
than those of fish expressing wild-type human HARS1 protein.350 Unsurprisingly for such severe 
morphological defects, the fish also displayed motor deficits in behavioral assays.350 This 
phenotype was replicated by treating the fish with the protein synthesis inhibitor cyclohexamide, 
which also shortened the length of the neuronal processes in the dorsal root ganglia.350 This 
demonstrates that chemically inhibiting protein synthesis will mimic the phenotype 
of HARS1 mutations, supporting the hypothesis that reduced protein synthesis is part of the ARS-
associated neuropathy disease mechanism. 
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It is important to consider how impaired ARS function would specifically affect peripheral nerve 
axons. Of note, Mullen et al. found that over-expressing patient HARS1 mutations in PC12 cells 
did not affect the size of the cell body or the number of neurite projections the cells produced, 
but did decrease the length of the longest neurite; in other words, cells could not grow or sustain 
projections beyond a certain distance from the soma.350 Similarly, expression of these mutations 
in zebrafish caused a decreased axon length in dorsal root ganglia cells.350 It is possible that 
maintaining the health of long axons, such as the long axons of the peripheral nervous system, is 
particularly difficult with defects in housekeeping functions, such as protein translation. Indeed, 
mutations in other ubiquitously expressed genes (e.g., MFN2 and RAB7) have been implicated in 
axonal neuropathy289,352, as discussed in Section 1.2.4.  
 
However, a dominant-negative effect may not apply to all neuropathy-associated ARS mutations. 
One major piece of evidence points away from this as a unifying mechanism; in theory, if ARS 
alleles are dominant-negatives, then loss of ARS function should drive the pathology, which 
should then be rescued by over-expression of wild-type ARS. However, in two mouse models of 
Gars1-mediated peripheral neuropathy, Gars1P234KY/+ and Gars1C201R/+, over-expressing wild-
type human GARS1 was not sufficient to rescue the phenotype333. There are significant caveats 
to these two mouse models; neither represent a human disease allele, and both cause early-onset 
phenotypes that are similar to the mouse model of ∆ETAQ GARS1, a mutation which causes an 
early-onset, severe SMA-like phenotype in humans.170 In particular, Gars1P234KY/+ causes 
premature lethality that is not seen in individuals with dominant peripheral neuropathy.69 As 
such, it remains to be seen whether these findings can be generalized to other ARS alleles that 
cause a later-onset, milder phenotype in human. As future work investigates a dominant-negative 
mechanism, it will be important to determine if it can be alleviated by supplying additional wild-
type enzyme to the cell. To the best of our knowledge, there are only a small number of studies 
showing that over-expression of a wild-type allele rescues a dominant-negative effect; moreover, 
these studies have been performed in vitro, and for dominant-negative alleles in structural 
proteins (Type VII Collagen353) or receptors (Follicle Stimulating Hormone Receptor354). It 
remains to be seen whether a dominant negative mutation in an enzyme can be rescued by over-
expression of the wild-type protein. 
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1.3.5 Proposed gain-of-function mechanisms in dominant axonal neuropathy 
In contrast to a loss-of-function mechanism of disease, a second possibility is that neuropathy-
associated ARS mutations cause the encoded enzymes to gain a novel, dominantly toxic function 
that specifically affects the peripheral nervous system. This may not be mutually exclusive with 
a loss-of-function effect, as a mutation may simultaneously impair enzymatic activity and 
facilitate novel binding partners. There is evidence that YARS1,355 GARS1,356 HARS1,357 and 
AARS1348 mutations change the conformation of the enzyme and expose internal protein 
residues, which are posited to be new binding interfaces for aberrant protein interactions.  
 
One aberrant interaction that has been explored for mutations in both GARS1 and AARS1 is 
neomorphic binding to neuropillin-1 (NRP1). Neuropilin-1 is a transmembrane protein that 
participates in the development of the nervous system and cardiovascular system.358 It acts as a 
receptor for semaphorin axon guidance factors, as well as a receptor for vascular endothelial 
growth factor (VEGF)358, which is critical for both neuron development and angiogenesis.359 A 
2015 study that aimed to identify novel binding partners of mutant GARS1 found that 
immunoprecipitation of NRP1 co-immunoprecipitated a small amount of wild-type GARS1, and 
a significantly increased amount of mutant GARS1 (here, the high-confidence variants L129P, 
G240R, and E71G were tested, along with the mouse spontaneous mutation P234KY).360 By 
systematically deleting different NRP1 domains and assessing whether NRP1 could still co-
immunoprecipitate GARS1, the authors mapped the GARS1 binding location to the b1 domain, 
which is the binding site of VEGF-A165.360 The authors then showed that increasing 
concentrations of VEGF-A165 could decrease the amount of mutant GARS1 bound to NRP1 in 
vitro, and vice versa.360 Additionally, to explain what would be an extracellular interaction for a 
cytoplasmic protein, the authors demonstrated that GARS1 is present in exosomes of NSC34 
motor neuron-like cells by enriching for exosomes in the cell media and immunostaining for 
GARS1.360 This finding was supported by treating cells with an exosome-pathway inhibitor, 
which decreased the amount of extracellular GARS1 detected, and by treating cells with an 
activator of microvesicle release, which increased the amount of GARS1 detected.360 
 
The authors followed this work by investigating the interaction between NRP1 and mutant 
GARS1 in Gars1P234KY/+ mice (as noted above, this mouse does not model a human disease 
 37 
allele, and exhibits a severe early-onset neuromuscular phenotype with pre-mature death between 
5 and 8 weeks of age69, which does not recapitulate patient phenotypes).360 The authors found 
that Gars1P234KY/+ mice had defects in facial neuron migration, similar to those seen in mouse 
models of Nrp1 and Vegf mutants.360 They also found that Gars1P234KY/+ mice who were also 
heterozygous for a Nrp1 null allele had a significantly more severe phenotype, indicating that 
Nrp1 is a genetic modifier of the mouse pathology.360 Finally, the authors showed that treating 
Gars1P234KY/+ with VEGF-A165—but no other trophic factors—improved motor function. From 
these studies, the authors posit that the mechanism of GARS1-mediated peripheral neuropathy is 
due to a gain-of-function interaction with NRP1.  
 
To demonstrate that this interaction is not limited to GARS1, these authors have performed 
similar in vitro studies demonstrating an interaction between mutant AARS1 alleles and 
NRP1.348 Here, both NRP1 and AARS1 were ectopically expressed in NSC34 motor neuron-like 
cells. Immunoprecipitation of NRP1 co-immunoprecipitated three mutant forms of AARS1 
(N71Y, G102R, and R329H).348 However, NRP1 did not co-immunoprecipitate wild-type 
AARS1, or any AARS1 produced from three mutations in the editing domain and C-terminal 
domain.348 The authors also demonstrated that immunoprecipitation of NRP1 in patient 
lymphocyte cells co-immunoprecipitated R329H AARS1, but did not co-immunoprecipitate 
wild-type AARS1 in control lymphocytes.348 Lastly, they pursue a similar domain mapping 
strategy as they performed for GARS1, and determine that mutant AARS1 binds to the same b1 
domain as GARS1.348 Here, to explain the interaction between a cytoplasmic protein and an 
extracellular domain, the authors remove cell culture media from HEK293T cells and 
immunoblot for AARS1. They do not demonstrate that it is present in exosomes, or control for 
the possibility of cell lysis. 
 
There are several major gaps in this model of ARS-mediated peripheral neuropathy. One 
inconsistency is the seemingly neuron-specific interaction between GARS1 and NRP1, despite 
the fact that GARS1 is ubiquitously expressed, and the signaling pathway of NRP1 and VEGF-
A165 is not only critical for neuronal development but for cardiovascular development as well. If 
GARS1 interferes with VEGF-A165 binding to NRP1 in other tissues, this interaction should 
cause cardiovascular defects. However, this is not a known phenotype of any patient with 
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GARS1-mediated peripheral neuropathy. This has also been assessed in another Gars1 mouse 
model, Gars1C201R/+ (this mutation is also not a patient mutation, but arose from ENU 
mutagenesis), where no cardiovascular defects were identified.361 The expression pattern of 
NRP1 is also inconsistent with the human phenotypes, as NRP1 plays a critical role in 
development,362 and the ARS-mediated peripheral neuropathy is a degenerative process that 
usually onsets in adolescence or adulthood. Finally, if impaired NRP1 signaling were to play a 
role in any of the human neuropathies, it would most likely contribute to the severe, childhood-
onset motor neuropathies, like that caused by ∆ETAQ GARS1.170 Indeed, a Gars1∆ETAQ/+ mouse 
model shares a similar phenotypic severity with the Gars1P234KY/+ mouse discussed above.170 
However, overexpression of ∆ETAQ GARS1 in NSC34 cells followed by immunoprecipitation 
of NRP1 did not detect an interaction between ∆ETAQ GARS1 and NRP1.170 Mass spectrometry 
of ∆ETAQ GARS1 binding partners in motor neuron cells also failed to detect an interaction 
with NRP1.170 Based on the inability to replicate this interaction with one of the most toxic 
GARS1 mutations, it is unlikely that neomorphic binding to NRP1 is a common mechanism of 
ARS-mediated dominant peripheral neuropathy. 
 
An alternate gain-of-function mechanism that has been proposed is an aberrant interaction with 
members of the tropomycin receptor kinase (TRK) family—TrkA, TrkB, and TrkC. Trk proteins 
are membrane-bound receptors that bind neurotrophic growth factors in a signaling pathway 
required for the proper development of sensory neurons.363 This proposed mechanism stems 
from the observation that sensory neuron fate is disturbed in Gars1C201R/+ mice, with a prenatal 
imbalance in subtypes of sensory neurons that leads to changes in sensory behavior upon birth.364 
To test a possible interaction between mutant GARS1 and Trk proteins, wild-type, P234KY, or 
C201R GARS1 were transfected into NSC34 cells.364  Then TrkA, TrkB, or TrkC were 
immunoprecipitated, and co-immunoprecipitated proteins were immunostained for GARS1.364  
All three members of the Trk family co-immunoprecipitated P234KY and C201R GARS1, 
although not wild-type.364 To validate this interaction with human GARS1 mutations, 
recombinant wild-type, L129P, or G240R GARS1 was added to the media of N2a neuroblastoma 
cell lines.364 Both mutations (but not wild-type) caused an increase in ERK1/2 phosphorylation, 
an integral component of the Trk signaling cascade.364 These data lead the authors to propose 
that extracellular mutant GARS1 aberrantly binds and activates Trk receptors, changing sensory 
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neuron differentiation and/or survival early in development. Although it is intriguing to consider 
the possibility that developmental defects predispose sensory neurons for later-stage 
degeneration in ARS-mediated CMT, additional in vivo work is required to link these defects to 
impaired Trk signaling. Additional work is also required to test the specificity of this interaction; 
if this interaction can be detected between Trk receptors and a benign GARS1 polymorphism, or 
between Trk receptors and a mutant GARS1 that is strictly linked to motor neuron phenotypes 
such as ∆ETAQ, it would argue against this as a mechanism of sensory neuron impairment in 
GARS1-mediated CMT. 
 
An alternate possibility is that GARS1 mutations cause inappropriate binding of intracellular 
proteins, specifically HDAC6, a histone deacetylase that acts on alpha-tubulin in the 
cytoskeleton.365 One of several post-translational modifications that regulate tubulin function,366 
alpha-tubulin acetylation promotes axonal transport by increasing kinesin binding to 
microtubules.367 In this model, HDAC6 activity decreases alpha-tubulin acetylation, which leads 
to decreased kinesin binding and axonal transport. Defects in axonal transport are linked to a 
number of neurological diseases, including peripheral neuropathies.295  
 
Studies of the Gars1P234KY/+ and the Gars1 C201R/+ mouse models have found reduced tubulin 
acetylation in the dorsal root ganglia and sciatic nerve, accompanied by defects in axonal 
transport.368,369 Inhibiting HDAC6 with the small molecule tubastatin A rescues these defects and 
improves the motor function of both mouse models.368,369 Two studies perform co-
immunoprecipitation experiments in vitro to detect an interaction between GARS1 and HDAC6: 
Benoy et al. identify an interaction between HDAC6 and both wild-type and C102R GARS1, 
whereas Mo et al. shows that only mutant GARS1, not wild-type, can interact with HDAC6. Mo 
et al. also find that the cells expressing the three GARS1 mutants with the strongest HDAC6 
interaction (P234KY, S581L, and G598A) also have the lowest amount of acetylated alpha-
tubulin. This leads them to propose a mechanism in which mutant GARS1 aberrantly binds to 
HDAC6 and increases its de-acetylation activity, decreasing tubulin acetylation and impairing 
axonal transport.370 However, this interaction between GARS1 and HDAC6 does not appear to 
be specific to pathogenic variants. One of the GARS1 variants with the strongest effects on 
HDAC6 binding and alpha-tubulin deacetylation, S581L, has been re-evaluated and found to be 
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non-pathogenic, since it does not segregate with disease in affected families.371 Therefore, it is 
unclear whether this interaction is meaningful for GARS1-mediated peripheral neuropathy. It is 
more likely that the benefits of HDAC6 inhibition are not specific to the genetic or 
environmental insult, but that improving axonal transport ameliorates the overall neuronal 
dysfunction in peripheral neuropathy. For example, HDAC6 inhibitors have been shown to 
improve peripheral neuropathy phenotypes in mice with Mfn2 mutations,372 Hspb1 mutations,373 
and mice with chemotherapy-induced peripheral neuropathy.374  
  
Lastly, there is a body of research investigating non-canonical functions of wild-type YARS1 in 
the nucleus. ARS enzymes can charge tRNA in the nucleus, as a proofreading mechanism to 
ensure that a tRNA molecule is properly spliced and folded before it is exported to the 
cytoplasm.375 However, recent studies focus on a novel role for YARS1 in the nucleus. The 
nuclear localization signal (NLS) of YARS1 is found in the anticodon binding domain, and is 
masked by bound tRNATyr.328 Under oxidative stress conditions, tRNATyr is cleaved and the NLS 
is exposed, increasing YARS1 nuclear localization.329 Through a combination of co-
immunoprecipitation and mass spectrometry experiments, YARS1 was found to bind nuclear 
proteins TRIM28 and HDAC1.329 Both of these proteins are transcriptional co-factors that work 
together to deacetylate the transcription factor E2F1, repressing its activity.329 In this proposed 
model, YARS1 sequesters TRIM28 and HDAC6, preventing them from deacetylating E2F1, and 
increasing the function of E2F1 to upregulate its target genes, which include DNA damage repair 
genes.329 Interestingly, when YARS1 is excluded from the nucleus by mutating the NLS, the 
expression of these DNA damage repairs decreases, supporting the nuclear role of YARS1 in 
driving their expression.329  
 
Small angle X-ray scattering studies and hydrogen-deuterium exchange assays have defined 
protein conformation changes associated with three dominant YARS1 mutations (E196K, G41R, 
and 153-156∆VKQV).355 This corresponds to increased interaction with TRIM28 and HDAC1, 
and subsequent increased E2F1 acetylation and expression of DNA damage response genes.376 In 
this proposed mechanism, YARS1 mutations increase the activity of a non-canonical YARS1 
function (i.e., are hypermorphs). However, it is unclear how increased activity of the E2F1 
transcription factor or increased expression of DNA repair genes relate to peripheral neuropathy 
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phenotypes. Indeed, pharmacologically repressing E2F1 activity does not improve the 
neurotoxicity of E196K YARS1 in a Drosophila model.376  
 
One of the most compelling pieces of evidence from these studies is that inhibiting the 
translocation of E196K YARS1 from the cytoplasm to the nucleus by mutating the NLS does in 
fact appear to rescue numerous neurological phenotypes in Drosophila, including locomotion 
defects and aberrant neuromuscular junction morphology.376 There are a number of possible 
explanations for this observation. The authors, Bervoets et al., propose that this indicates a gain-
of-function mechanism, in which mutant YARS1 aberrantly binds to transcription factors in the 
nucleus and misregulates gene expression. Alternately, it is possible that in this model, YARS1 
is interfering with the nuclear proofreading function of drosophila tyrosyl-tRNA synthetase, and 
that incompletely processed tRNAs are exiting the nucleus and impairing translation in the 
cytoplasm. This hypothesis is supported by transcriptomic data of misregulated genes in the 
brains of Drosophila over-expressing either wild-type YARS1 or E196K YARS1. Here, many of 
the differentially expressed genes play a role in stress response, protein misfolding, and ribosome 
biogenesis, indicating a broader defect in protein translation.376 These defects may not be 
sufficient to cause a detectable neurological phenotype in flies expressing wild-type YARS1, but 
may be exacerbated by E196K YARS1. It is also important to consider that over-expressing 
human YARS1 (wild-type and mutant) in a Drosophila model may produce spurious protein-
protein interactions or cellular pathology that is not representative of YARS1 biology in a human 
peripheral nerve, where it is expressed at endogenous levels.  
 
Although the finding of novel binding interactions with NRP1 receptors, Trk receptors, HDAC6, 
and nuclear transcription co-factors could yield new insights into the pathogenesis of individual 
ARS mutations, it would be surprising if any of these mechanisms were shared across 
neuropathy-associated mutations in different ARS loci. The structures of the five neuropathy-
associated ARS enzymes differ significantly; YARS1 and WARS1 are Class I enzymes, whereas  
GARS1, AARS1, and HARS1 are Class II enzymes (Table 1.1). Furthermore, pathogenic 
mutations do not localize to a specific domain (Figure 1.4), so it is unlikely that they would all 
have the capacity to bind to the same proteins. If different mutant ARS enzymes were to 
aberrantly bind to different proteins that act in a common pathway, it is possible that this may 
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explain the shared pathogenic effect; however, this has not been shown. Such a common 
pathway may be related to neuronal signaling or axonal transport, as discussed above, or may be 
related to protein translation independent of deficits in aminoacylation. Interestingly, the latter 
possibility could provide an explanation for the translation defects observed in Drosophila 
models of GARS1 and YARS1 mutants. When several neuropathy-associated mutations in human 
GARS1 (E71G, G240R, and G526R) or YARS1 (G41R, 153-156delVKQV, and E196K) are over-
expressed in Drosophila motor or sensory neurons, they reduce protein translation rates and 
cause muscle denervation and morphological defects.306 However, this study concluded that 
mutant GARS1 does not impair the endogenous activity of Drosophila gars1, and that the 
reduced translation rate caused by over-expressing G240R human GARS1 cannot be rescued by 
over-expressing wild-type Drosophila gars1. These findings are particularly interesting since, if 
the translation defects in flies over-expressing mutant GARS1 are not a result of mutant GARS1 
suppressing the endogenous protein via a dominant-negative effect, it is possible that they are 
caused by aberrant interactions between GARS1 mutant proteins and other components of the 
translational machinery.  
 
1.3.6 Future directions for defining a mechanism of dominant ARS disease 
There is currently evidence to support multiple proposed mechanisms of ARS-mediated 
peripheral neuropathy; however, additional research is needed to determine if either mechanism 
applies to the majority of neuropathy-associated ARS mutations and loci. For the loss-of-
function model, it will be critical to determine if dimerization is required for pathogenicity. This 
question can be addressed by designing ways to decrease the dimerization of a pathogenic ARS 
protein and testing for phenotypic rescue in a relevant model organism (see Chapter 4), or by 
increasing dimerization and testing for an exacerbation of the phenotype. It will also be 
important to determine which dominant ARS mutations cause phenotypes that can be rescued by 
over-expression of the wild-type allele, which would suggest an overall loss of ARS function is 






Figure 1.4. Cartoon map of ARS variants associated with dominant peripheral neuropathy. 
 
Cartoon illustrations of the protein domains of GARS1, HARS1, YARS1, AARS1, and WARS1 are 
shown. The WHEP domain is shown in purple, the catalytic domains in gray, the anticodon-
binding domain in light blue, and the editing domain for AARS1 in dark blue. Patient variants 
with evidence for pathogenicity are shown using vertical lines to indicate where they map on the 




One argument for a dominant-negative mechanism is that only homodimeric ARS have been 
implicated in disease to date. It will be important to determine if mutations in monomeric 
enzymes, such as MARS1, can cause dominant axonal neuropathy, since a dominant-negative 
mechanism would not be possible for monomeric enzymes. Identifying MARS1 variants that 
segregate with disease in large pedigrees or demonstrating that MARS1 variants cause dominant 
peripheral neuropathy in animal models would be important steps toward resolving this issue. 
 
For the gain-of-function model, it will be important to show that any novel protein-protein 
interactions—whether with NRP1, TRIM28, Trk receptors, HDAC6, or other proteins—are 
specific to mutations associated with neuropathy, and that these interactions do not occur with 
nonpathogenic protein variants. Additionally, showing that multiple mutant ARS enzymes can 
participate in the same aberrant interaction, or different aberrant interactions that lead to the 
same cellular effect, will add weight to this model. Finally, demonstrating that mutations in other 
components of these pathways also lead to peripheral neuropathy, which has not been shown yet, 
would be a strong confirmation of this mechanism. 
 
After refining the loss- and gain-of-function models, the next step will be to determine if there is 
any interplay between the two mechanisms that may affect phenotypic outcome. For example, 
some mutations, like G598A162 and ∆ETAQ GARS1170 are linked to an early-onset, severe spinal 





ARS genes are emerging as a significant cause of rare inherited diseases, including recessive 
mitochondrial disorders, recessive multisystem disorders, and dominant axonal neuropathies. All 
of the 37 human ARS enzymes have been implicated in a genetic disease phenotype. However, 
the full phenotypic and allelic spectrum of these disorders is undefined. In particular, it is 
unknown if additional ARS genes can cause dominant peripheral neuropathy, or what the 
mechanism of dominant disease is for AARS1, GARS1, HARS1, WARS1, and YARS1 mutations. 
In this dissertation, I will present and functionally characterize ARS alleles that have been newly 
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identified in patients with multi-system recessive disorders or dominant peripheral neuropathies 
(Chapter 2). These efforts will broaden our understanding of the allelic spectrum of these 
diseases, as well as shed light on how these enzymes function and tolerate variation. I will also 
present a model organism-based prediction pipeline to implicate additional ARS in dominant and 
recessive phenotypes, which I apply to threonyl-tRNA synthetase (TARS1). These studies 
resulted in the identification of a hypomorphic TARS1 allele and characterization of recessive 
TARS1 phenotypes in worm and mouse (Chapter 3). Finally, I will address the mechanism of 
dominant ARS-mediated disease by showing that dominant pathogenic variants in alanyl-tRNA 
synthetase (AARS1) exert a dominant-negative when co-expressed with wild-type AARS1 in 
yeast (Chapter 4). This work aims to contribute to the known clinical, locus, and allelic spectrum 
ARS-mediated disease; expand the role of model organism research in predicting pathogenic 
ARS alleles and investigating related phenotypes; and advance efforts to test a dominant-
negative mechanism of ARS-mediated peripheral neuropathy.
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Chapter 2  






All 37 members of the ARS gene family have been implicated in either dominant or recessive 
human genetic diseases. Bi-allelic variants in 36 ARS genes have been found in patients with 
multisystem recessive phenotypes, which frequently includes central nervous system 
pathology.68,377 These patients are either homozygous for hypomorphic missense alleles, 
compound heterozygous for two hypomorphic alleles, or compound heterozygous for one 
hypomorph and one null; complete loss of ARS function is not compatible with life.68 Based on 
the patient genotypes and functional studies of these variants, a loss-of-function mechanism is 
responsible for these recessive disorders.  
 
Mono-allelic variants in 5 ARS genes have been confidently implicated in dominant phenotypes, 
and all cause similar dominant axonal peripheral neuropathies. Here, these variants comprise 
missense mutations or small in-frame deletions. While these variants impair ARS function in 
vitro or in vivo,68 haploinsufficiency for these genes does not appear to cause peripheral 
neuropathy (as discussed in Section 1.3.4). A pathogenic mechanism encompassing both loss of 
enzymatic function and dominant toxicity is currently under investigation (Chapter 4).  
 
For recessive ARS-mediated disorders, there is broad clinical and allelic heterogeneity that 
remains to be fully defined. For dominant ARS-mediated disease, the full spectrum of ARS loci 
and variants that can cause dominant peripheral neuropathy is not known. The studies presented 
in this Chapter contribute to resolving these questions by evaluating previously uncharacterized 
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alleles in five ARS genes for a role in recessive or dominant disease based on genetic and 
functional evidence. 
 
One of the strongest forms of evidence for the pathogenicity of a variant is co-segregation with 
disease in a large pedigree, with known genotypes of affected and unaffected individuals.378 The 
first pathogenic variants in aminoacyl-tRNA synthetases were identified through this approach, 
using co-segregation of disease with chromosomal markers (linkage analysis) in large pedigrees, 
followed by targeted gene sequencing to identify the precise genetic lesion.106,160,275,379 However, 
as next-generation sequencing has become a more accessible diagnostic tool, more aminoacyl-
tRNA synthetase variants have been found in small families or as de novo events. The number of 
ARS genes known to cause disease has also grown, from just 7 in 2010,75,79,106,160,195,241,275 to all 
37 members of the gene family in 2021.144,221,222,377 One major challenge facing the ARS 
research and clinical community is the interpretation of novel patient variants as benign or 
pathogenic, particularly in the absence of sufficient genetic data.  
 
There are multiple forms of genetic evidence that can provide robust evidence for pathogenicity.  
If a variant co-segregates with disease in a small pedigree comprising only a few genotyped 
individuals, it is possible that this co-segregation is due to chance. However, if the variant co-
segregates with disease in a large, multi-generational pedigree with many genotyped individuals, 
it becomes highly unlikely that such segregation is due to chance,378 and provides compelling 
evidence that the variant is responsible for the phenotype. For example, the variant R329H 
AARS1 was initially found in a large French family with 23 affected individuals, 17 of whom 
were genotyped (6 unaffected individuals were also genotyped).106 This data provides strong 
genetic evidence that R329H is a pathogenic allele. 
 
Another form of genetic evidence for pathogenicity is variant enrichment in affected populations, 
compared to unaffected control populations. Overall, ARS-mediated disease is too rare to have 
identified many affected individuals with the same variant. Again, R329H AARS1 is an 
illustrative example. Since it was initially reported by Latour et al. in 2010, it has been identified 
in an additional 9 families on at least 3 independent haplotypes, bringing the total published 
number of individuals with R329H AARS1-mediated CMT to at least 46 (this conservative  
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Table 2.1. R329H AARS1 is a recurrent pathogenic allele. 
 
Family or Cohort Study Number of affected, genotyped individuals 
Ethnicity/Geographic 
Location Reference 
Family 17 French Latour et al. 2010 
Family 3 French Latour et al. 2010 
Family 8 Australian McLaughlin et al. 2012 
Family 3 UK Bansagi et al. 2015 
Family 1 UK Bansagi et al. 2015 
Family 2 UK Bansagi et al. 2015 
Family 2 UK Bansagi et al. 2015 
Family 2 Ireland Bansagi et al. 2015 
Cohort Study 1 Mediterranean Bacquet et al. 2018 
Cohort Study 1 Mediterranean Bacquet et al. 2018 
Family 3 Canary Islands Lousa et al. 2019 
Family 2 Korean Lee et al. 2020 




estimate considers that two individuals identified in a French cohort study may have been 
previously identified by Latour et al.) (Table 2.1). It is also necessary to consider the frequency 
of R329H AARS1 in unaffected populations.  
 
One accessible tool for this work is gnomAD, a database of variants that have been identified in 
large-scale sequencing projects, along with the variant’s allelic frequency. This data excludes 
individuals with severe pediatric disease and their first-degree relatives, providing a glimpse of 
allelic variation in all other individuals.334 However, it does not exclude individuals  
with adult-onset diseases such as ARS-mediated peripheral neuropathy, making it an imperfect 
control population for these analyses. Despite these limitations, the fact that R329H is not 
present in gnomAD indicates that it is an extremely rare allele. This suggests that its 
identification in 11 families with Charcot-Marie-Tooth disease is unlikely to be due to chance. 
 
A final piece of genetic information that can be used to build an argument for or against 
pathogenicity is conservation analysis. Aminoacyl-tRNA synthetases are found in all unicellular 
and multi-cellular organisms. If an amino acid is invariant across multiple different biologically 
diverse organisms, it is presumed to be important to enzyme function; any amino acid changes 
that are deleterious would have undergone purifying selection. As an example, the R329 residue 
in AARS1 is conserved between humans and bacteria,107 suggesting that this arginine is important 
for enzyme function, and changing it to a different amino acid may be deleterious.   
 
Investigating the conservation and population frequency of an ARS variant are important initial 
steps in assessing the evidence for its pathogenicity. However, in the absence of substantial 
genetic evidence (co-segregation in families and/or recurrence in multiple affected individuals), 
it is still difficult to determine its contribution to disease. Here, it can be useful to assess the 
impact of the variant on gene function, either through in vitro aminoacylation assays or in vivo 
models. If a variant has a similar effect as a high-confidence, known pathogenic variant, this 
lends support to an argument for pathogenicity.  
 
One way to determine if an ARS variant impacts enzyme function is to express recombinant 
human ARS in bacteria, purify it, and perform an in vitro aminoacylation assay. Here, wild-type 
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or mutant ARS enzyme is incubated with its substrates: ATP, tRNA and (radiolabeled) amino 
acid.297 The first step of the reaction—in which the ARS enzyme binds ATP and the amino acid, 
and releases pyrophosphate—can be measured by addition of a colorimetric reagent that 
recognizing free pyrophosphate.298 To investigate the complete aminoacylation reaction, the 
amount of charged tRNA can be measured; at various time points within the first 5 minutes of 
the reaction, aliquots of the mixture are spotted on filter paper soaked with trichloroacetic acid 
(TCA).297 After the tRNA precipitates are washed and dried, the amount of radiolabeled amino 
acid that been ligated to the tRNA is measured with a scintillation counter.297 These assays 
should be performed according to Michaelis-Menten conditions, and data should be fit to the 
Michaelis-Menten equation, in order to accurately detect defects in aminoacylation.297  
 
Aminoacylation assays for high-confidence pathogenic ARS alleles demonstrate that these 
variants reduce enzymatic function. For example, R329H AARS1 shows 1/50th of the enzymatic 
activity of wild-type AARS1.107 Other high-confidence variants in GARS1 and YARS1, all of 
which were identified through linkage analysis,160,296,380,275,379,381 show similar defects. L129P 
and G240R GARS1 both significantly reduce enzymatic activity,300,371 as does a high-confidence 
YARS1 variant, G41R.275,382 In the case of another high-confidence YARS1 variant, E196K, there 
is conflicting evidence between reduced activity in a pyrophosphate release assay275 and no 
effect on enzyme activity in a steady state aminoacylation assay.382 E196K does impair gene 
function in yeast complementation assays275,383; these discrepancies highlight the importance of 
using multiple functional assays to build a consensus on the variant’s effect. 
 
Yeast complementation assays test the ability of an ARS variant to support yeast growth in the 
absence of the endogenous yeast ARS gene. Yeast viability is maintained by expressing the wild-
type yeast gene from a maintenance vector bearing a URA3 auxotrophic marker. Then, the 
pathogenic ARS variant is transformed into the strain (either modeled in the yeast gene or the 
human open reading frame). Yeast are plated on media containing 5-fluoroorotic acid (5FOA), 
which selects for spontaneous loss of the maintenance vector,299 and yeast growth is supported 
solely by the function of the wild-type or mutant ARS under investigation. An ARS variant that 
reduces yeast growth compared to the wild-type allele is defined as a loss-of-function allele. This 
assay has been validated with high-confidence pathogenic dominant alleles. For example, R329H 
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AARS1 causes a loss-of-function in yeast complementation assays, either when modeled in the 
yeast ortholog ALA1107 or human AARS1 (Section 4.3.1). The pathogenic YARS1 alleles G41R 
and E196K also reduce yeast growth in complementation assays when modeled in either the 
yeast ortholog TYS1275 or human YARS1,383 as does the pathogenic GARS1 allele L129P in the 
yeast ortholog GRS1301, and the pathogenic GARS1 allele G240R in the human gene (Figure 1.1). 
 
In vitro aminoacylation assays and yeast complementation assays can also be employed to 
investigate recessive ARS variants. Here, the KARS1 variant R505H is a useful illustration. This 
variant has been identified in six individuals with leukoencephalopathy and hearing loss, either 
in the homozygous state191 or in trans to other KARS1 missense alleles (P533S72,187 or A526V190. 
Although it has not been identified in any large pedigrees, this degree of recurrence in a small 
patient population with a consistent phenotype provides strong evidence of pathogenicity. 
R505H KARS1 is found in gnomAD at an allele count of 1 in 251,414,334 indicating that it is a 
rare allele. Conservation analysis shows that it is invariant between humans, fruit flies, and 
yeast.72 Functional assessment using in vitro aminoacylation assays demonstrate that it has 1/20th 
the activity of wild-type KARS1, and when modeled in the yeast ortholog KRS1, it causes a mild 
reduction of yeast growth72. Both in vitro and in vivo evidence is consistent with R505H KARS1 
partially reducing KARS1 function as a hypomorph. Because R505H KARS1 has been found in a 
homozygous individual with leukoencephalopathy,191 it is unsurprising that it retains partial 
function, since complete loss of function would be incompatible with life. Consistent with this, it 
has been identified in trans with P533S in four individuals,72,187 a variant with 1/200th of wild-
type activity in aminoacylation assays.72 It is likely that the partial enzymatic function of R505H 
KARS1 significantly contributes to the viability of these patients.  
 
There are limitations to in vitro aminoacylation assays and yeast complementation assays. 
Although they provide clues about a variant’s effect on gene or enzyme function, neither assay is 
a model of the human tissue affected in ARS-related diseases, and neither can provide evidence 
of the variant’s impact in that biological context. This is especially true for hypomorphic alleles, 
where the deleterious effects of the variant may be modulated by the cellular environment, such 
as amino acid availability, tRNA levels, and protein translation demands.  
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A major limitation of all experimental approaches that detect a loss-of-function effect is that, 
while impaired enzyme function explains the recessive disease mechanism, it is only one 
component of the dominant mechanism. In addition to reducing enzyme function, dominant ARS 
mutations are also toxic, particularly to long neurons. As discussed in Section 1.3.4 and 1.3.5, 
this may be related to the decreased enzyme function through a dominant-negative mechanism, 
or could be through a neomorphic gain-of-function mechanism (or some combination of the 
two). It is currently unclear what differentiates a toxic loss-of-function mutation from a non-toxic 
loss-of-function mutation. Testing patient variants for a dominant toxic effect in neurons 
currently requires over-expressing ARS variants in flies,384 worms,174 or fish110,350 then assessing 
motor behavior or neuron morphology in these organisms. Alternately, mouse models can be 
generated and evaluated for peripheral neuropathy phenotypes170, which is even more expensive 
and time consuming. An inexpensive and rapid assay in an easily manipulated model, such as 
yeast, is required to effectively test large numbers of patient variants for dominant toxicity. This 
is discussed further in Chapters 4 and 5.  
 
All data from functional assays must be evaluated in the context of the genetic evidence for 
pathogenicity, and ideally in the context of other functional assays. Although each approach has 
limitations, validating these assays with high-confidence pathogenic ARS variants provides a 
framework with which to investigate newly identified patient variants of uncertain significance. 
In this Chapter, I will present six studies that describe previously unreported ARS variants 
identified in patients, evaluate their impact on gene function, and assess their contribution to 
disease pathology. These studies span both dominant and recessive diseases, as well as variants 
in both established and candidate ARS disease genes. Such efforts contribute to building a 
catalog of pathogenic ARS variants, which helps define the full genetic and phenotypic spectrum 
of these diseases. They also contribute to defining disease mechanisms and understanding how 
mutations in the translation machinery affect cellular health and tissue function. 
 
Parts of this chapter are adapted from: “A recurrent GARS mutation causes distal hereditary 
motor neuropathy” published in Journal of the Peripheral Nervous System (Volume 24, Issue 4, 
pages 320-323, October 19 2019, License Number 5114850026750); “Substrate interaction 
defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy,” published 
 53 
in Human Mutation (Volume 39, Issue 3, pages 415-432, December 26 2017, License Number 
5114850191607); and “MARS variant associated with both recessive interstitial lung and liver 
disease and dominant Charcot-Marie-Tooth disease,” published in European Journal of Medical 
Genetics (Volume 61, Issue 10, pages 616-620, October 2018). For the latter, I retain the right to 
include this Elsevier article in a thesis or dissertation. Permission was requested for reproduction 
of data through the Copyright Clearance Center (see license numbers above). Additionally, the 
Contracts, Rights, and Permissions Coordinator from IOS press granted use of materials from 
 “A novel mutation in MARS in a Patient with Charcot-Marie-Tooth Disease, Axonal, Type 2U 
with Congenital Onset,” published in the Journal of Neuromuscular Diseases (Volume 6, Issue 
3, pages 333-339, July 22 2019). The author performed all the studies in this chapter with the 
following exceptions: the clinical evaluations, phenotypic classifications, and diagnostic 
sequencing was performed by clinical collaborators; Jamie Abbott performed the aminoacylation 
assays for HARS1 variants (Table 2.2). Christina del Greco assisted with cloning R131H, V372I, 
R619C, Q639P, and R663Q TARS1, and performed the yeast complementation assays for these 
variants (Figure 2.6).  
 
2.2 Materials and methods 
 
2.2.1 Identification of patient variants 
ARS variants were identified in patients using a CMT gene panel (G327R GARS1 Patient 1, 
Y330C HARS1) or whole-exome sequencing (G327R GARS1 Patient 2, V155G HARS1, S356N 
HARS1, A397T MARS1, R619C MARS1, Y307C MARS1, ∆M236 NARS1, S461F NARS1, 
C342Y NARS1, R663Q TARS1, R619C TARS1, and Q639P TARS1). The TARS1 variants R131H 
and V327I were identified by a combination of homozygosity mapping and whole-exome 
sequencing. For the R619C/Y307C MARS1 patient, compound heterozygous variants in TG and 
VPS13C were also identified. The ∆M236 NARS1 patient was also heterozygous for a variant in 
SQSTM1. No other additional variants were reported.  
 
2.2.2 ClustalW alignments 
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Multiple-species alignments were generated using Clustal Omega software.385 Protein sequences 
were obtained from the NCBI Protein Database. For glycyl-tRNA synthetase, the accession 
numbers were: BAA06338.1 (H. sapiens), AAH21747.1 (M. musculus), CCD72866.1 (C. 
elegans), KZV13199.1 (S. cerevisiae), AUP44736.1 (E. coli). For histidyl-tRNA synthetase, the 
accession numbers were: NP_002100.2 (H. sapiens), NP_032240.3 (M. musculus), AAB38116.1 
(C. elegans), QHB12288.1 (S. cerevisiae), B1XAY9.1 (E. coli). For methionyl-tRNA synthetase, 
the accession numbers were: NP_004981.2 (H. sapiens), NP_001165053.1 (M. musculus), 
CAA97803.1 (C. elegans), CAA97293.1 (S. cerevisiae), A7ZNT3.1 (E. coli). For asparaginyl-
tRNA synthetase, the accession numbers were: NP_004530.1 (H. sapiens), NP_001136422.2 (M. 
musculus), CAA95808.1 (C. elegans), GHM92552.1 (S. cerevisiae), BAL38068.1 (E. coli). For 
threonyl-tRNA synthetase, the accession numbers were: AAH10578.2 (H. sapiens), 
AAH55371.1 (M. musculus), CAA93762.1 (C. elegans), P04801.2 (S. cerevisiae), P0A8M3.1 
(E. coli). 
 
2.2.3 Generation of ARS expression constructs 
For all yeast complementation assays, the human ARS proteins were expressed from a ADH1 
promoter on the gateway-compatible pYY1 construct,159,386 which harbors a 2-micron origin of 
replication resulting in a high plasmid copy number per cell and bears a LEU2 auxotrophic 
marker. The open reading frames (ORFs) of wild-type human MARS1, HARS1, NARS1, and 
TARS1 were amplified from HeLA or fibroblast cDNA with using primers containing the attB1 
and attB2 recombination sequences (primer sequences in Appendix A). The GARS1 ORF was 
previously amplified with attB-containing primers from the original pYY1 vector.159,386 All PCR-
generated ORFs were purified with Qiagen Spin Miniprep columns and recombined into 
pDONR221 using the Gateway cloning technology (Invitrogen) BP reaction. The reaction was 
transformed into Top10 cells (Invitrogen). Clones were isolated and grown in media containing 
kanamycin to select for the presence of the kanamycin resistance cassette on pDONR221. 
Plasmid DNA was purified from these clones using the Qiagen Spin Miniprep kit, then digested 
with BsrGI to identify clones with successful insertion. These clones were sequence-verified to 
ensure there were no PCR amplification errors. Then, the QuickChange II XL Site-Directed 
Mutagenesis Kit (Agilent) was used to introduce patient variants into the appropriate wild-type 
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ORF (primer sequences in Appendix A). The reaction was transformed into Top10 cells 
(Invitrogen) and grown in kanamycin-containing LB to select for the presence of the kanamycin-
resistance gene on the pDONR221 plasmid. The plasmids were extracted and purified for Sanger 
sequencing using the Qiagen Miniprep kit. Sequencing ensured that the desired mutation was 
generated and that there were no additional off-target mutations. Then, the Gateway LR reaction 
was performed to recombine wild-type and mutant ORFs into the pYY1 vector. The reaction was 
transformed into Top10 cells, which were grown in ampicillin-containing LB to select for the 
presence of the ampicillin-resistance gene on the pYY1 vector. The plasmids were then 
extracted, purified, and digested with BsrGI (New England Biolabs) to identify recombinants.  
 
2.2.4 Yeast complementation assays 
Yeast complementation assays were performed using strains with the yeast ARS ortholog deleted 
(ΔHTS1,175 ∆MES1,216 ∆GRS1,387 ∆DED81 (Horizon Discovery, Clone ID 20982), and ∆THS1 
(Horizon Discovery, Clone ID 21471). These strains maintain viability by carrying a pRS316 
vector that expresses the yeast ARS gene from its endogenous promoter, contains a yeast 
centromere sequence that results in a low copy number per cell, and bears the auxotrophic 
marker URA3. The pYY1 vector (expressing the human ARS ORF or an empty control) was 
introduced into the appropriate strain using lithium acetate yeast transformation, performed at 
30°C with 200ng of plasmid. Transformed yeast were grown on solid media lacking uracil and 
leucine to select for cells with both the pRS316 maintenance vector and the pYY1 experimental 
vector. After 3 days of growth at 30°C, individual colonies were picked into 2mL liquid media 
lacking uracil and leucine. They were grown for 2 days at 30°C, shaking at 275 rpm until 
saturated. 1 mL of saturated culture was then centrifuged at 15,000 rpm for 1 minute and re-
suspended in 50µl water. Serial 1:10 dilutions were made to 1:100 or 1:1,000, and then 10µl of 
each diluted mix (including undiluted) was spotted on plates containing 0.1% 5-fluoroorotic acid 
(5-FOA) (Teknova). Yeast growth was visually assessed after 3 to 5 days. In each experiment, at 
least two independently generated clones were tested for each mutation. 
 
2.2.5 HARS1 aminoacylation assays 
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Aminoacylation assays were performed using a modified version of the previously described 
Uhlenbeck-Wolfson assay.388,389 Multiple turnover experiments were conducted in buffer 
comprised of 50 mM HEPES pH 7.5, 150 KCl, 10 mM MgCl2, 5 mM β-ME, 2 U/ml PPase 
and 32P-labeled tRNAHis. A fixed concentration of enzyme (5 nM for WT HARS1 and 20 nM for 
CMT variants) was used with saturating concentrations of two of the three substrates. The 
saturating concentrations of tRNAHis, ATP, and histidine were 5 µM, 10 mM, and 5 mM, 
respectively. The variable concentrations of these substrates were 100 nM to 15 µM, 25 µM to 5 
mM, and 1 µM to 5 mM, for tRNAHis, ATP and histidine, respectively. Experiments with mutant 
HARS1 typically required a 2-3 fold higher final concentration of the variable substrate than the 
wild-type HARS1. To calculate the initial rates, the reactions were typically sampled during the 
first minute. After the reaction was terminated with quenching buffer (400 mM NaOAc [pH 4.5] 
and 0.1% SDS), the tRNA was digested to single nucleotides with 0.1ug of P1 nuclease (Sigma) 
for 40-60 minutes at room temperature. Radiolabeled aminoacylated A76 was separated from 
non-aminoacylated A76 by thin-layer chromatogragraphy on PEI-cellulose plates (Scientific 
Adsorbents) with a mobile phase of 0.1M ammonium acetate and 5% acetic acid. Radioisotopic 
imaging on a phosphor screen (Bio-Rad Molecular Imager FX) was used to detect radioactive 
products. The concentration of aminoacylated tRNAHis was quantified by comparing the ratio of 




2.3.1 A recurrent GARS1 mutation causes distal hereditary motor neuropathy. 
Two patients with a similar peripheral neuropathy were examined by neurologists at the 
University of Iowa or the University of Pennsylvania, respectively. Both patients were young 
women with an adolescent onset of distal weakness in the legs and arms. Clinical 
electrophysiology showed decreased motor axon (but not sensory axon) conduction velocities, 
indicating a distal motor neuropathy. Whole-exome or gene panel sequencing was performed, 
which revealed a c.979G>A variant in both (presumably) unrelated patients that changes glycine 
at amino acid number 327 to arginine (G327R). In both patients, the variant likely arose de novo; 




Figure 2.1. Identification and characterization of G327R GARS1. 
 
(A) Pedigrees of patients 1 and 2. The individuals in brackets were adopted into the family. (B) 
Conservation analysis of the affected residue. The position of G327 GARS1 is shown with 
flanking amino acid acids from evolutionarily diverse species. G327 is highlighted in pink. (C) 
Representative images of haploid yeast lacking the endogenous GRS1 transformed with an empty 
construct (“Empty pyy1”), wild-type human ∆MTS∆WHEP GARS1, or an expression construct 
with G327R ∆MTS∆WHEP GARS1. Four independently generated G327R GARS1 expression 
clones were tested (across the top, 1-4) and two independent colonies were evaluated per 
transformation (Set 1 and Set 2). Each colony was plated undiluted or diluted on media 
containing 5-FOA. Yeast were grown at 30°C.  
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Table 2.2. gnomAD allele counts of characterized ARS variants. 
 
Gene Variant Allele Count Allele Number Allele Frequency Number of homozygotes 
GARS1 G327R Not present N/A N/A N/A 
HARS1 
V155G Not present N/A N/A N/A 
Y330C Not present N/A N/A N/A 
S356N 6 282,884 2.12E-05 0 
MARS1 
A397T Not present N/A N/A N/A 
Y307C 2 251,470 7.95E-06 0 
R618C 3 282,892 1.06E-05 0 
NARS1 
∆M236 Not present N/A N/A N/A 
C342Y Not present N/A N/A N/A 
S461F Not present N/A N/A N/A 
TARS1 
R663Q Not present N/A N/A N/A 
R131H 31 281,744 1.10E-04 0 
V372I 49 251,318 1.95E-04 0 
R619C Not present N/A N/A N/A 
Q639P Not present N/A N/A N/A 
 




mother and sister of Patient 2 (the father was unavailable, but was not known to have a 
neuropathy) (Figure 2.1A). G327R is absent in gnomAD (Table 2.2) and affects a glycine 
residue conserved between humans, mice, worms, and yeast (Figure 2.1B). Therefore, it was  
prioritized for functional evaluation using a yeast complementation assay. This assay 
demonstrated that wild-type human GARS1 can support formation of yeast colonies in the 
absence of the endogenous yeast ortholog GRS1 (Figure 2.1C). However, G327R GARS did not 
rescue the deletion of GRS1, indicated by an absence of yeast growth; these data strongly suggest 
that G327R impairs gene function (Figure 2.1C).  This is consistent with the loss-of-function 
pattern observed in pathogenic GARS1 variants from patients with peripheral 
neuropathies,170,171,301,371 and strengthens the argument that G327R GARS is a pathogenic allele. 
In sum, G327R GARS1 adds to the increasing catalog of loss-of-function missense GARS1 
mutations linked to dominant peripheral neuropathies.  
 
2.3.2 Newly identified HARS1 variants in patients with dominant peripheral neuropathy  
Mutations in HARS1 have been found to segregate with dominant peripheral neuropathy in 
several multi-generational pedigrees174; however, only a small number of pathogenic HARS1 
mutations have been described.174,175. Here, we discuss three newly identified HARS1 variants in 
three families with a motor-predominant axonal neuropathy. In the first family, the variant 
V155G was present in five individuals with motor neuropathy, and absent in one unaffected 
individual (Figure 2.2A). In the second family, the variant Y330C was present in two individuals 
with motor-predominant peripheral neuropathy, but absent in two unaffected individuals (Figure 
2.2A). The third family comprised an affected daughter with a mild to moderate motor-
predominant peripheral neuropathy, who was heterozygous for S356N HARS1. Notably, her 
unaffected mother was also heterozygous for S356N, indicating that this variant either does not 
cause a fully penetrant phenotype or is not pathogenic (Figure 2.2A). Neither V155G nor Y330C 
are present in gnomAD (Table 2.2). S356N is present at a low frequency, with an allele count of 
6/282,884. All three affected amino acids are evolutionarily conserved from human to mouse, 
worm, and yeast; Y330 is also conserved in bacteria (Figure 2.2B) This suggests that these 





Figure 2.2. Identification and characterization of V155G, Y330C, and S356N HARS1. 
 
(A) Pedigrees of three identified families with HARS1 variants. A diagonal line indicates the 
individual is deceased. Genotypes are shown for individuals with available DNA samples. (B) 
Conservation analysis of V155, Y330, and S356N. Each residue is shown in pink, with flanking 
amino acids from evolutionarily diverse species. (C) Yeast complementation assay for V155G, 
Y330C, and S356N. Representative images from haploid yeast lacking HTS1, transformed with 
either an empty vector (“Empty pyy1”), wild-type HARS1, V155G HARS1, Y330C HARS1, or 
S356N HARS1. Yeast were spotted in 1:10 dilutions on media containing 5-FOA, and were 
grown at 30°C. 
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To test this possibility, in vitro aminoacylation assays were performed. Here, to carefully assess 
the effect of each individual mutant on substrate recognition, assays were performed with a fixed 
concentration of enzyme and varying concentrations of substrate. The initial velocity of the 
reaction and substrate concentration were fit to the Michaelis Menten equation, which provided 
estimates of Km (the concentration of the substrate which permits the enzyme to reach half of its 
maximum velocity, or Vmax) and kcat (the turnover number). From this, kcat/Km was calculated, a 
value that represents the overall efficiency of the enzyme in both binding the substrate and 
performing the reaction. In the first reaction, the tRNA concentration was varied, while ATP and 
histidine concentrations were held at saturating concentration. None of the three HARS1 mutants 
showed increased Km values for tRNA (Table 2.3). In the second reaction, histidine 
concentration was varied. Here, Y330C and V155G exhibited a 25-fold and 85-fold increase in 
Km value, respectively, indicating these mutations required significantly increased histidine 
concentration to reach half of Vmax, and suggesting a decreased affinity for histidine relative to 
the catalytic turnover (Table 2.3). In the third reaction, ATP concentration was varied. Here, the 
Km for Y330C increased 40-fold, and maximum velocities could not be reached for S356N and 
V155G even at saturating concentrations (Table 2.3). These data suggest that a major contributor 
to the decrease in the catalytic activity for these enzymes comes from a significant increase in 
Km for ATP. In all three experiments, each HARS1 mutation decreased substrate turnover (kcat), 
as well as the overall catalytic efficiency (kcat/Km) (Table 2.3). 
 
To determine how these in vitro deficiencies impact cellular function in vivo, the three mutations 
were tested for the ability to rescue yeast growth when the endogenous yeast ortholog, HTS1, 
was deleted. Wild-type HARS1 was able to support colony formation, indicating that human 
HARS1 can at least partially complement loss of HTS1 (Figure 2.2C). In contrast, V155G HARS1 
lead to significantly reduced yeast growth, and neither Y330C nor S356N supported any growth 
(Figure 2.2C). These data are consistent with all three mutations reducing gene function. In this 
assay, Y330C and S356N HARS are functionally null alleles, while V155G is hypomorphic, with 
enough gene function to support limited colony formation. 
 
In sum, the above functional studies indicate that V155G, Y330C, and S356N impair HARS1 
function. For V155G and Y330C, the combination of the functional data and the segregation  
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Table 2.3. Steady state kinetics of tRNAHis aminoacylation by wild-type and neuropathy-
associated mutations in HARS1. 
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with disease in the affected families provides strong evidence that these variants are pathogenic. 
Although S356N clearly affects HARS1 function, the minimal genetic data (i.e., the incomplete  
penetrance within a small pedigree) makes it difficult to know whether S356N is pathogenic. 
Importantly, in the absence of convincing genetic evidence, a loss-of-function effect is not 
sufficient to determine pathogenicity, because loss of function is likely necessary but not 
sufficient for an ARS mutation to cause dominant peripheral neuropathy.68 To further inform the 
interpretation of this variant, further investigation is required in an informative model system that 
can reveal dominant, neurotoxic properties of ARS mutations. 
 
2.3.3 A MARS1 variant of uncertain significance in Charcot-Marie-Tooth disease 
Here, we evaluate a MARS1 variant found in an 11-year-old girl who presented with a severe 
motor peripheral neuropathy that began in her first year of life. Exome sequencing was 
performed, and a heterozygous MARS1 variant, A397T, was identified. The patient’s unaffected 
mother did not carry the mutation, and the father was not available for testing (Figure 2.3A). 
MARS1 variants have been previously described in patients with adolescent or adult-onset 
dominant peripheral neuropathy.216–218 The genetic evidence is weak for all of these cases, 
although one variant has been functionally evaluated in a yeast complementation assay and 
reduces gene function when tested in the yeast ortholog MES1216. Based on the motor neuropathy 
presentation of the A397T/+ proband, the fact that A397 is conserved to yeast (Figure 2.3B), and 
the absence of A397T from gnomAD (Table 2.2), this variant was prioritized for further study. 
To determine if this variant reduced gene function similar to known pathogenic dominant 
variants in other ARS genes, it was assessed for a loss-of-function effect in a yeast 
complementation assay.  
 
Here, we performed a yeast complementation assay with the human MARS1 coding sequence. 
Wild-type human MARS1 supported robust yeast growth in the absence of the yeast gene MES1 
(Figure 2.3C). However, four independent clones of A397T MARS1 only lead to sporadic colony 






Figure 2.3. Identification and characterization of A397T MARS1. 
 
(A) Pedigree information of an individual heterozygous for A397T MARS1. (B) Conservation 
analysis of A397, shown in pink. Surrounding amino acids from evolutionarily diverse species 
are shown. (C) Representative images from haploid yeast lacking MES1, transformed with either 
an empty vector (“Empty pyy1”), wild-type MARS1, or four independently generated A397T 
MARS1 constructs. Yeast were spotted in 1:10 serial dilutions on media containing 5-FOA, and 




2.3.4 Identification and characterization of MARS1 variants in patients with recessive disease 
Previous studies have shown that bi-allelic MARS1 variants cause a severe recessive disorder 
predominantly characterized by interstitial lung and liver disease; to date, a total of 12 mutations 
have been found across 36 patients.210–212,214,215,390 We identified a case of MARS1-mediated 
recessive disease in a male infant who presented with transfusion-dependent anemia, 
hypothyroidism, cholestasis, developmental delay, and interstitial lung disease. Through whole-
exome sequencing, the patient was found to be compound heterozygous for two MARS1 variants; 
a Y330C variant was inherited from his mother and, interestingly, the same R618C mutation that 
was previously identified in a small pedigree with CMT disease216 was inherited from his father 
(Figure 2.4A). The R618 residue is conserved to E. coli; in contrast, Y330 is conserved in mouse 
and worm, but not in yeast or bacteria (Figure 2.4B). R618C is found in 3/282892 alleles in 
gnomAD, and Y330C is found in 2/251470 alleles (Table 2.2). 
 
To determine the functional consequences of R618C and Y307C MARS1, a yeast 
complementation assay was performed, modeling these variants in the human open-reading 
frame as previously described. Consistent with previous data studying R618C in the yeast gene 
MES1, R618C MARS1 failed to support yeast growth, supporting its loss-of-function designation. 
Y307C MARS1 lead to yeast growth comparable to that of wild-type MARS1, indicating that in 
this assay it does not substantially impair function (Figure 2.4C). Considering that a complete 
absence of MARS1 function should be incompatible with life, it is expected that at least one of 
two MARS1 alleles retain some function. Due to the phenotypic similarities of this patient and 
other MARS1-mediated recessive disease, it is likely that Y307C is a pathogenic allele, and that 
the yeast complementation assay does not have sufficient resolution to detect mildly 
hypomorphic variants.  
 
2.3.5 NARS1 is a candidate gene for dominant peripheral neuropathy 
Here, we present data implicating an additional ARS gene—NARS1—in dominant peripheral 
neuropathy. NARS1 is the sixth dimeric49, cytoplasmic ARS to be mutated in patients with 




Figure 2.4. Identification and characterization of R618C and Y307C MARS1. 
 
(A) Pedigree displaying the inheritance pattern of R618C and Y307C MARS1. (B) Conservation 
analysis of MARS1 variants. Y307 and R618 are shown in pink, surrounded by flanking amino 
acid sequences from evolutionarily diverse species. (C) Representative images from haploid 
yeast lacking MES1, transformed with either an empty vector (“Empty pyy1”), wild-type 
MARS1, Y307C MARS1, or R618C MARS1. Yeast were spotted in 1:10 serial dilutions on media 
containing 5-FOA, and were grown at 30°C. 
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neuropathy. In the first family (Family A), the variant S461F NARS1 co-segregates with disease 
in five affected individuals (three unaffected individuals were genotyped and do not carry this 
allele) (Figure 2.5A). In the second family (Family B), the variant C342Y NARS was identified 
in three affected individuals (six unaffected individuals were genotyped and did not carry this 
allele) (Figure 2.5A). Finally, one case of a de novo in-frame deletion (∆M236 NARS1) was 
found in a patient who had sensorimotor neuropathy in addition to cerebellar ataxia, cognitive 
impairment, and abnormal eye movements (Figure 2.5A). None of these three variants are found 
in gnomAD (Table 2.2), indicating that they are rare. All three affect conserved residues: S461 
NARS1 is conserved between humans, mouse, worm, and yeast; C342 NARS1 is conserved 
between humans, mouse, and worms; M236 NARS1 is conserved between humans and mouse 
(Figure 2.5B) 
  
A yeast complementation assay was performed to assess the consequence of these variants on 
gene function. Wild-type human NARS1 supported yeast growth in the absence of the yeast 
ortholog DED81. However, none of the three patient NARS1 variants (S461F, C324Y, or 
∆M236) lead to colony formation, indicating that all three are loss-of-function alleles in this 
assay (Figure 2.5C). These data are consistent with the pattern of loss-of-function mutations 
found in other ARS-mediated dominant neuropathies. Together with the pedigree information for 
S461F and C342Y, these experiments suggest that NARS1 is a candidate gene for dominant 
peripheral neuropathy. However, because NARS1 has not been previously implicated in this 
phenotype, additional models to test for neurotoxic dominant properties are required to more 
confidently link it to disease. In this case, determining if one of the NARS1 variants with stronger 
genetic evidence (S461F or C342Y) can cause peripheral neuropathy in a mouse model would be 
the strongest evidence to implicate NARS1 in dominant disease.  
 
2.3.6 Expanding the phenotypic spectrum of TARS1-mediated recessive disease 
Bi-allelic loss-of-function mutations in threonyl-tRNA synthetase (TARS1) were recently 
identified in two patients with triochothiodystrophy (TTD)253, a rare neuro-ectodermal condition 
marked in part by brittle hair.391 One of these two patients presented with the characteristic TTD 




Figure 2.5. Identification and characterization of NARS1 variants in individuals with 
dominant peripheral neuropathy.  
 
(A) Pedigrees of three families with NARS1 variants. Hearsay cases of peripheral neuropathy are 
marked in gray. Clinically evaluated patients are marked with an asterisk. In Family A, the 
Generation III individual marked with gray is oligosymptomatic. (B) Conservation analysis of 
M236, C324, and S461, marked in pink. Flanking residues from evolutionarily diverse species 
are shown. (C) Representative images from haploid yeast lacking the yeast ortholog DED81, 
transformed with an empty vector (“Empty pyy1”), wild-type NARS1, ∆M236 NARS1, C342Y 
NARS1, or S461F NARS1. Yeast were serially diluted on media containing 5-FOA, and were 
grown at 30°C. 
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development, acromandibular dysplasia, and recurrent respiratory tract infections.253 The other 
patient also had hair with the “tiger-tail” banding pattern, was born a collodion baby encased in a 
shiny membrane, and had ichthyosis.253 Functional evidence from yeast complementation assays 
and primary fibroblasts convincingly demonstrated that these mutations significantly impair 
TARS1 function and stability.253  
 
However, these are not the only phenotypes associated with reduced TARS1 function. Here, we 
report three additional patients with bi-allelic TARS1 mutations. These patients all present with 
infantile-onset or childhood-onset severe neurological symptoms, including seizures, 
microcephaly, intellectual disability, spasticity, and ataxia. They also have musculoskeletal and 
craniofacial dysmorphism. Although neurological symptoms are the most prominent aspect of 
the presentations, there are some skin and hair phenotypes reminiscent of TTD: the proband from 
Family 3 has thin and fragile hair, as well as translucent and easily scratched skin. The proband 
from Family 2 is noted to have sparse eyebrows. 
 
Six TARS1 variants were identified in these patients. Proband 1 is a Pakistani individual born to 
consanguineous parents who is homozygous for a complex allele containing two variants, 
R131H and V372I TARS1 (Figure 2.6A). Interestingly, these variants are both present in 
gnomAD at a low frequency in the South Asian population (Table 2.2). Proband 2 is an Egyptian 
individual who is compound heterozygous for R619C TARS1 (inherited from their father) and 
Q639P TARS1 (inherited from their mother) (Figure 2.6A). Neither of these variants are present 
in gnomAD (Table 2.2). Proband 3 is homozygous for R663Q TARS1 (Figure 2.6A), which is 
also not found in gnomAD (Table 2.2). The older sibling of Proband 3 was stillborn at full term 
with multiple abnormalities. Although there is no known consanguinity in the Family 3, they are 
noted to come from a small Italian town. All six TARS1 variants are conserved across diverse 
species; R131H and R619C are conserved between human, mouse, worm, and yeast, and V372 
and R663 are conserved between human, mouse, worms, yeast, and bacteria (Figure 2.6 B). In 
this analysis, Q639 is only conserved between human and mouse (E.coli also show a Q at this 
residue, although the surrounding region does not appear to have high conservation with 





Figure 2.6. Identification and characterization of recessive TARS1 variants. 
 
(A) Pedigrees of three families with TARS1 variants. (B) Conservation analysis of TARS1 
variants. R131, V372, R619, Q639, and R663 are all marked in pink. Each affected residue is 
shown with surrounding sequences of evolutionarily diverse species. (C) Representative images 
from haploid yeast lacking THS1, transformed with an empty vector (“Empty pyy1”), wild-type 
TARS1, or mutant TARS1 (in the first panel, R131H and V372, tested independently and in cis; in 
the second panel, R619C and Q639P; in the third panel, R663Q). Yeast were spotted on media 
containing 5-FOA in serial 1:10 dilutions, and were grown at 30°C. 
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To assess the functional consequence of these variants, we performed a yeast complementation 
assay in a strain with the endogenous threonyl-tRNA synthetase gene, THS1, deleted. Wild-type 
human TARS1 supported yeast growth in the absence of THS1 (Figure 2.6 C). R131H and V372I 
TARS1 were tested individually and in cis, to determine if one variant or both variants together  
impacted TARS1 function. Interestingly, when tested individually and in cis, R131H and V372I 
TARS1 supported yeast growth comparable to wild-type TARS1 (Figure 2.6 C). A similar result 
was obtained for both R619C and Q639P TARS1, which were identified in trans; neither variant 
significantly reduced yeast growth (Figure 2.6 C). One possibility is that this yeast 
complementation assay does not have the resolution to detect mild to moderate defects in TARS1 
function, and that a more sensitive assay (for example, an in vitro aminoacylation assay) is 
required to determine if they impact enzyme activity. 
 
In contrast, the R663Q TARS1 mutation, which was found in the homozygous state, does not 
support any yeast growth, indicating that it significantly impairs TARS1 function (Figure 2.6 C). 
In light of what is known about the relationship between impaired ARS function and severe 
multisystem disorders, and previous work demonstrating the role of reduced TARS1 function in 
disease253, these data indicates that R663Q TARS1 is likely a pathogenic allele. This case serves 
as a useful reminder that the function of a human ARS in a yeast system may not directly 
translate to the function in an affected patient cell—although this mutation does not support any 
yeast growth, a complete loss of function in a human patient would be incompatible with life. 
Therefore, it is probable that R663Q TARS1 is a pathogenic mutation that significantly impairs, 




Here, we present the identification and functional characterization of 15 previously unreported 
ARS variants across 4 studies of dominant disease and 2 studies of recessive disease. These 
efforts contribute to expanding the known genetic and phenotypic heterogeneity of ARS-
mediated disease and to defining the features of pathogenic ARS variants. 
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Two of these studies examine novel patient variants in two well-characterized ARS disease 
genes, HARS1 and GARS1. In these cases, the patients’ presentations—adolescent to adult-onset 
dominant peripheral neuropathy with mild to moderate severity—is consistent with previously 
described HARS1- or GARS1-mediated disease. Although the G327R GARS1 variant arose de 
novo, its reoccurrence in two individuals with similar phenotypes provides strong genetic 
evidence of pathogenicity. For HARS1, two of the three variants—Y330C and V155G HARS1—
segregate with disease in the patient’s families, although one (S356N HARS1) shows incomplete 
penetrance. Additionally, all four of these novel mutations impair gene function, consistent with 
previous reports of pathogenic GARS1 and HARS1 mutations.170,174,175,371 In total, these data 
support the pathogenicity of G327R GARS1, Y330C HARS1, and V155G HARS1, whereas 
S356N HARS1 requires further investigation. 
 
The MARS1 cases described here provide an example of both recessive and dominant phenotypes 
associated with a single gene. The patient with recessive developmental delay, cholestasis, and 
interstitial lung disease presents with a phenotype previously linked to bi-allelic loss-of-function 
MARS1 mutations. For this individual, although only the R618C MARS1 variant significantly 
impaired MARS1 function in a yeast complementation assay, it is likely that Y307C MARS1 is 
also a pathogenic allele based on the similarity of the phenotype with the known hallmarks of 
MARS1-mediated recessive disease. Of note, this patient inherited the R618C MARS1 allele from 
his father. Although nerve conduction velocity studies were not available, the father was 
reportedly healthy. Explicit questioning did not reveal any family history of a peripheral 
neuropathy that might match the phenotype previously attributed to R618C. It is still possible 
that R618C causes a mild, late-onset phenotype with reduced penetrance; however, the absence 
of a family history of peripheral neuropathy contributes to the uncertainty surrounding R618C 
MARS1 as a pathogenic variant. 
 
A newly identified MARS1 variant, A397T, was identified in an individual with early-onset 
dominant peripheral neuropathy. While our functional data are suggestive of pathogenicity, the 
minimal genetic information available for this variant makes it impossible to confidently 
implicate A397T in the patient’s phenotype. There is also a significant disparity between the 
severe childhood-onset phenotype associated with A397T and the later-onset CMT phenotype 
 73 
seen in patients with R618C, P800T, or R737W MARS1.216–218 It is possible that differential 
MARS1 impairment correlates with differential severity, or that environmental or genetic 
modifiers might lead to variable phenotypes. Alternately, it is possible that none of these MARS1 
variants are pathogenic. To date, no MARS1 mutations have been shown to segregate with CMT 
in large, multigenerational families, nor have any been tested for a dominant neuropathy 
phenotype in a multicellular model system. Whether MARS1 will ultimately be confirmed as a 
bona-fide CMT disease gene will have significant bearing on a proposed mechanism of disease, 
as it would be the first implicated ARS gene to function as a monomer.392 This would rule out a 
dominant-negative effect, which is dependent on homo-dimerization, as a predominant unifying 
mechanism. 
 
By this logic, the argument for a dominant-negative mechanism is strengthened by implicating 
yet another homodimeric, cytoplasmic enzyme in dominant disease. Here, we present data to 
support the argument that variants in NARS1—which encodes a homodimeric49, cytoplasmic 
enzyme—causes dominant peripheral neuropathy. We identify three loss-of-function NARS1 
variants in individuals with dominant sensorimotor neuropathy. Two of these variants segregate 
with this phenotype in multigenerational pedigrees, which, combined with the functional data, 
builds a strong case for pathogenicity (the third variant is de novo). 
 
Two recent studies have implicated NARS1 in recessive disorders that include 
neurodevelopmental defects, seizures, and microcephaly.221,222 Interestingly, the phenotypic 
spectrum of recessive NARS1 disease also includes peripheral neuropathy,222 indicating that the 
peripheral nervous system is sensitive to decreased NARS1 function; this also supports a 
dominant-negative mechanism for dominant NARS1-mediated disease. One of these studies also 
identified eight patients with mono-allelic de novo NARS1 mutations, who presented with global 
developmental delay, intellectual disability, seizures, dysmorphic features, spasticity, ataxia, and 
microcephaly, as well as some cases of demyelinating neuropathy.222 Six of these patients were 
heterozygous for a premature stop codon, R534* NARS1. The effect of this truncation on mRNA 
and protein stability was not thoroughly addressed, but the authors determined that NARS1 
enzymatic activity in patient lymphoblast cells was reduced by approximately 80% compared to 
unaffected control cells.222 Although the authors propose that a dominant-negative mechanism is 
 74 
responsible, it is also possible that these patients have a non-coding NARS1 variant in trans, 
which would not be detected by whole exome sequencing. This would also explain the 
phenotypic similarity between these patients and the other individuals with bi-allelic NARS1 
mutations presented in the same study.   
 
The ataxia and intellectual impairment described in these patients may overlap with the 
phenotypes of the ∆M236/+ NARS1 individual described here, who presents with both peripheral 
neuropathy and other central nervous system disorders. It is possible that the ∆M236/+ NARS1 
individual also has a non-coding variant in trans that was not detected with whole exome 
sequencing. It is also possible that this patient may have multiple genetic disorders, with a 
second unrelated variant accounting for the additional central nervous system phenotypes. 
Notably, this patient is heterozygous for the SQSTM1 variant A33V, which has been associated 
with ALS and FTD.393,394 Interestingly, bi-allelic variants in SQSTM1 cause a neurodegenerative 
disorder including ataxia, cognitive decline, and gaze palsy.395 This description matches the 
patient’s additional phenotypes of cerebellar ataxia, cognitive impairment, and abnormal eye 
movement. Therefore, this patient may have an undetected non-coding variant in SQSTM1 in 
trans with A33V, and their multifaceted phenotype may be a result of both SQSTM1 recessive 
disease and NARS1 dominant disease.  
 
We also have expanded the limited phenotypic spectrum of described TARS1 phenotypes from 
trichothiodystrophy (TTD) to include a broader range of neurological symptoms. Here, the 
functional consequences of some patient variants are unclear—specifically, the complex allele 
containing R131H and V327I TARS1, and the individual variants R619C and Q639P TARS1. 
These require experimental approach with higher resolution than a yeast complementation assay. 
However, the R663Q TARS1 variant clearly impairs TARS1 function, and is likely the cause of 
the neurological and dysmorphic symptoms in a homozygous individual. It is also striking that 
this individual has thin and brittle hair, similar to the phenotype originally described in TTD 
patients. One possibility is that the hair and skin are less susceptible to mutations that mildly 
impair TARS1 (like the R131H and V372I allele or the R619C/Q639P variants in trans) than the 
central nervous system, but that more significant impairment affects both systems. Of note, the 
records of the previously reported TTD patients253 were from early in life, and both individuals 
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were lost to follow-up. It is unknown whether these patients may have also developed more 
pronounced neurological symptoms. Moving forward, it will be critical to identify additional 
patients and develop appropriate model systems to understand the full phenotypic spectrum of 
TARS1-related disease, and to understand how reduced threonine-tRNA charging causes these 
symptoms.   
 
This body of work has added to the known range of dominant and recessive disorders caused by 
mutations in aminoacyl-tRNA synthetase genes. It has also continued to demonstrate the 
relevance of testing patient variants for loss-of-function effects. However, caution is warranted 
when interpreting negative results from a yeast complementation assay given the limited 
resolution for hypomorphic alleles. Caution is also required when interpreting positive results 
from a yeast complementation assay, particularly for dominant peripheral neuropathy variants, as 
all loss-of-function mutations are not necessarily dominantly toxic to neurons. Overall, this work 
contributes to a building a large catalog of pathogenic ARS variants that will be an invaluable 
resource for research and clinical communities. It will also play an essential role in deciphering 
the mechanism of ARS-mediated disorders and understanding how mutations in these genes 






Chapter 3  
Designing Predictive Models to Assess Threonyl-tRNA Synthetase 




To date, five of the thirty-seven ARS genes (AARS1, GARS1, HARS1, YARS1, WARS1) have 
been confidently implicated in dominant peripheral neuropathy.68 It is currently unknown if there 
are any unique characteristics of these five genes that might explain their role in this disease, or, 
if the pathology is due to a defect in tRNA charging, whether mutations in any other ARS gene 
could also cause dominant peripheral neuropathy. The only known shared characteristics of 
AARS1, GARS1, HARS1, YARS1, and WARS1 is that they perform their canonical role of 
tRNA charging in the cytoplasm, and that they all function as homodimeric enzymes (Table 1.1). 
This raises the possibility that mutations in any additional cytoplasmic, homodimeric ARS 
enzymes could also cause disease. 
 
Previous research into the mechanism of pathogenic ARS mutations has yielded two important 
findings: 1) the majority of recessive and dominant ARS mutations cause a reduction of gene 
function in vitro or in yeast complementation assays (as discussed in Section 1.3.4) and 2) 
expression of dominant ARS mutations in multicellular organisms causes neuronal dysfunction, 
including morphological and behavioral defects. Dominant ARS variants have been studied in: 
Drosophila models of GARS1 and YARS1 mutations, where they cause neuromuscular junction 
defects and motor impairment306,384; zebrafish models of HARS1 mutations, where they lead to 
shortened and misguided axons350; and C. elegans models of HARS1 and AARS1 mutations, 
which affect neuron morphology.174,175,307 For example, when HARS1 mutations are expressed in 
GABA-ergic neurons in worms, 40-50% of the worms have aberrant neuron projections from the 
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ventral nerve cord to the dorsal nerve cord, with a branching phenotype that suggests impaired 
axon guidance.174 These worms also display a thinning of the dorsal nerve cord and impaired 
locomotion in a swimming assay. However, these models are limited in their ability to 
recapitulate the human peripheral neuropathy phenotype. In humans, the neuropathy usually 
progresses in a length-dependent manner, with the longest axons of the peripheral nervous 
system affected first. The neurons of flies, fish, and worms are relatively short, making it 
difficult to understand this length-dependent aspect of ARS toxicity. Additionally, these models 
rely on transgenic approaches that over-express ARS proteins. While this may help exacerbate a 
phenotype in shorter neurons, it does not accurately reflect the approximately equal expression of 
wild-type and mutant alleles in humans.  
 
Mouse models can circumvent some of these limitations, and offer the benefit of an established 
mammalian system for studying human genetic diseases. There are currently three mouse models 
of dominant ARS disease, all caused by mutations in glycyl-tRNA synthetase (Gars1). Only one 
of these lines was designed to study a human variant—the ∆ETAQ GARS1 mutation, which 
causes a severe, early-onset SMA-like phenotype in humans.170 Gars∆ETAQ/+ mice develop 
neuromuscular junction (NMJ) defects by 6 weeks of age and motor defects by 12 weeks.170. The 
other two Gars1 mouse models derive from spontaneous or ENU-induced mutagenesis. The 
spontaneous P234KY Gars1 mutation causes severe neuromuscular dysfunction by 3 weeks of 
age and dramatically shortened lifespan.69 The milder C201R Gars1 mutation causes notable 
behavioral defects in grip strength by 1 month of age, although it does not affect lifespan.347 
Based on the early-onset phenotypes in these two lines and their similarity to the ∆ETAQ model, 
it is likely that the human equivalent of P234KY Gars1 and C102R Gars1 would be more akin to 
the severe SMA-like phenotype caused by ∆ETAQ. Although these mice lines are relevant 
resources for studying the early-onset form of GARS1-mediated neuropathy, they are not 
representative of the less severe, adult-onset form of ARS-mediated peripheral neuropathy. 
 
Other genetic causes of dominant axonal peripheral neuropathy have been modeled in mice. 
These include mutations in the microtubule motor protein KIF1B-β,396 the dynein heavy chain 
protein DHC,397 the neurofilament protein NEFL,398,399 and the chaperone protein HSPB1.373 
These mice show impaired neuromuscular function in a series of behavioral assays that include 
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rotarod tests, measurements of grip strength, and gait analysis. Although some of these mice 
display mild symptoms as early as three months of age,397 others do not show overt signs of a 
neuropathy until 6 months,373 9 months,399, or even 12 months of age.396 It is likely that a mouse 
model of an ARS mutation that causes a later-onset, milder human phenotype would more 
closely resemble these models. 
 
Currently, only five ARS genes—AARS1, GARS1, HARS1, WARS1, and YARS1— are 
confidently implicated in dominant peripheral neuropathy. It is currently unclear if there are 
special characteristics of these five genes that can enable them to cause dominant peripheral 
neuropathy, or if variants in any ARS could cause this disorder. The only known shared function 
between them is their canonical role of tRNA charging in the cytoplasm. Therefore, if there is a 
common mechanism of peripheral neuropathy, it is likely to be related to altered axoplasmic 
tRNA charging, which could also be caused by mutations in other cytoplasmic ARS genes. 
Additionally, these five ARS genes all encode homodimeric enzymes (Table 1.1), suggesting 
that homodimerization is important for disease pathology. Therefore, we predict that mutations 
in another homodimeric, cytoplasmic ARS could also cause dominant peripheral neuropathy. 
 
We sought to test this hypothesis in the absence of convincing patient data, relying on the model 
organisms that have been previously used to characterize known dominant pathogenic variants in 
other ARS genes. These pathogenic variants impair gene function in yeast complementation 
assays,174,175,307 and cause morphological and behavioral defects when over-expressed in C. 
elegans neurons.174,175,307 We set out to identify similar variants in an ARS gene that is not yet 
implicated in dominant neuropathy and that encodes a homodimeric, cytoplasmic enzyme—
threonyl-tRNA synthetase (TARS1)56. At the time, TARS1 had not been implicated in dominant 
or recessive disease. This presented an additional opportunity to discover recessive variants in 
TARS1 and define the related phenotypes.  
 
To design TARS1 variants that were likely to be deleterious and dominantly toxic, missense 
mutations were introduced at highly conserved residues. These were tested in yeast 
complementation models to identify those that reduced gene function; loss-of-function variants 




Figure 3.1. Flow-chart of the prediction pipeline designed to identify novel ARS candidates 
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mutation that was dominantly toxic to C. elegans neurons was then modeled in mouse to 
determine if it caused a peripheral neuropathy (Figure 3.1). Additionally, this pipeline was 
effective at identifying a novel hypomorphic TARS1 allele, which lead us to a preliminary 
characterization of recessive TARS1 phenotypes in worm and in mouse (Figure 3.1). Although 
TARS1 has now been linked to a form of recessive trichothiodystrophy,253 this mouse model 
provides an important resource to further explore the phenotypic spectrum of TARS1-related 
disease and to investigate whether reduced threonine-tRNA charging differentially affects 
mammalian tissues. 
 
The studies presented in this Chapter represent a collaborative effort between the author and 
multiple mentors with expertise in C. elegans or mouse biology. The author of this chapter 
performed the yeast complementation assays (Figure 3.2), generation and characterization of 
tars-1 knock in worms (Figure 3.4 through 3.7), and lead efforts to breed, genotype, and 
characterize mouse lines (Figure 3.8 through Figure 3.18). Stephanie Oprescu generated an 
initial panel of THS1 variants that lead to the identification of the three candidate TARS1 variants 
studied in this Chapter. Dr. Asim Beg generated and characterized worms over-expressing the 
tars-1 alleles in GABA-ergic neurons (Figure 3.3). All mouse lines were generated by Dr. 
Thomas Saunders and the University of Michigan Transgenic Core, and guidance and assistance 
in mouse husbandry, genotyping, dissection, and behavioral analysis was provided by Dr. 
Miriam Meisler, Dr. Young Park, Dr. Guy Lenk, and Jennifer Pierluissi. Mouse behavioral 
testing was performed by the author, Dr. Young Park, and Steven Whitesall of the Molecular and 
Integrative Physiology Phenotyping Core. Analysis of mouse footprints was performed by the 
author, Dr. Young Park, and Jennifer Pierluissi. Nerve conduction studies were performed by 
John Hayes of the Michigan Mouse Metabolic Phenotyping Center. Preparation of histology 
sections was performed by Histoserv, Inc., and analysis of pup H&E and PAS histology was 
performed by Dr. Jerrold Ward. Dr. Marina Grachtchouk dissected adult mouse skin for 
histology, and Dr. Andrzej Dlugosz interpreted the pathology and provided guidance on 
analyzing the mouse hair phenotype. Matthew Pun and Molly Kuo assisted with the 
computational analysis of the mouse proteome. 
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3.2 Materials and methods 
 
3.2.1 Generation of TARS1 expression constructs 
The open reading frame (ORF) of TARS1 was amplified from HeLa cell cDNA, using primers 
with the attB1 and attB2 gateway recombination sequences (primer sequences in Appendix A). 
These amplicons were purified with Qiagen Spin Miniprep columns and recombined into 
pDONR221 using Gateway cloning technology (Invitrogen). The recombination reaction was 
then transformed into Top10 cells (Invitrogen) to isolate clonal populations. Individual bacterial 
colonies were selected and grown in media containing kanamycin, which selected for the 
kanamycin resistance cassette on pDONR221. Plasmids were then isolated using the Qiagen 
Miniprep kit and genotyped by digesting with BsrGI (New England Biolabs) to detect the 
presence of the TARS1 insert. Clones with successful insertions were analyzed by Sanger 
sequencing to ensure absence of mutations introduced by amplification errors. To introduce 
variants into the TARS1 ORF, site-directed mutagenesis was performed with the QuickChange II 
XL Site-Directed Mutagenesis Kit (Agilent) (primer sequences in Appendix A). The reaction 
was transformed into Top10 cells and grown in LB containing kanamycin to select for 
pDONR221. Plasmid DNA was isolated and sequenced as above, to ensure successful 
mutagenesis. Then, the Gateway LR reaction was used to recombine the wild-type or mutant 
TARS1 into the vector pYY1. This vector has a 2-micron origin of replication, resulting in a high 
copy number per cell, as well as the ADH1 promoter, resulting in strong constitutive TARS1 
expression. Recombinants were transformed into Top10 cells, which were plated on ampicillin to 
select for the ampicillin resistance cassette on pYY1. Then, plasmids were extracted, purified, 
and digested with BsrGI to identify successfully recombined clones.  
 
3.2.2 Yeast complementation assay 
Yeast complementation assays were performed with the ∆THS1 strain (Horizon Discovery, 
Clone ID 21471). Yeast viability was maintained with a pRS316 vector that expressed wild-type 
THS1 from its endogenous promoter. pRS316 also carries the auxotrophic marker URA3, and has 
a yeast centromere sequence which results in a low copy number per cell. The pYY1 vector 
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(expressing wild-type TARS1, mutant TARS1, or an empty control) was transformed into yeast 
with a standard lithium acetate transformation, performed at 30°C with 200ng of plasmid. Yeast 
were grown on solid media without uracil and leucine, which selected for cells with both pRS316 
and pYY1. Yeast were grown for 3 days at 30°C, then individual colonies were picked into 2mL 
liquid media lacking uracil and leucine. These cultures were grown for 2 days at 30°C, shaking at 
275 rpm. Then, 1mL of saturated culture was centrifuged at 15,000 rpm for 1 minute and cell 
pellets were re-suspended in 50µl water. Yeast were serially diluted to 1:10, 1:100, or 1:1000 
using water. 10µl of each dilution (included undiluted yeast) was spotted on complete media 
containing 5-FOA (Teknova), which selects for cells that have spontaneously lost the pRS315 
vector expressing URA3 and THS1.400 After 3 to 5 days, yeast growth was visually inspected. 
 
3.2.3 Cloning tars-1 expression constructs 
Wild-type tars-1 was amplified from C. elegans cDNA with primers containing the attB1 and 
attB2 Gateway recombination sequence (sequences found in Appendix A), then purified and 
recombined into pDONR221 using the Gateway BP reaction (Invitrogen). Clones were isolated 
as described above, and successful recombination into vectors was confirmed by BsrGI digest 
followed by Sanger sequencing. Site-directed mutagenesis using the QuickChange II XL Site-
Directed Mutagenesis Kit (Agilent) was performed on wild-type tars-1 in pDONR221 
(mutagenesis primer sequences in Appendix A). Plasmids were transformed into Top10 cells, 
purified, and verified via Sanger sequencing. Wild-type or mutant tars-1 was recombined into 
the expression vector using the Gateway LR reaction. This resulting expression vector contains a 
unc-25 promoter and let858 termination sequence, which is active specifically in worm GABA-
ergic neurons.401 The LR reaction was transformed into Top10 cells, purified, and verified by 
BsrGI digest. 
 
3.2.4 Overexpressing tars-1 in GABA-ergic neurons 
To inject worms with tars-1, the following mixes were prepared for each construct: 50ng/µl 
expression plasmid bearing tars-1, 47.5ng/µl 1kb+ ladder (which facilitates uptake of the 
plasmid), and 2.5 ng/µl pCFJ90 plasmid, a co-injection marker that leads to transient expression 
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of mCherry in the pharynx. This mix was delivered to the worm gonadal tract using standard 
microinjection techniques,402 using an inverted microscope (Olympus IX71) and 
micromanipulator (Narishige). The oxIS12 worm strain was used for these experiments. These 
worms harbor a transgene for GFP expression in GABA motor neurons (Punc-47::GFP), which 
allows visualization of commissural processes.403 
 
3.2.5 CRISPR-Cas9 genome editing in worm 
CRISPR-Cas9 genome editing was performed according to previously described methods.404 
Briefly, the gonadal tract of P1 adult worms was injected with an injection mix of: 300mM KCl, 
20mM HEPES, 2.5 ng/µl pCFJ90, 50ng/µl single stranded oligonucleotide homologous donor 
repair template (Integrated DNA Technologies), 5µM single guide (sg) RNA (Synthego), and 
5µM Cas9 protein (Integrated DNA Technologies). Sequences for the repair templates and guide 
RNAs can be found in Appendix A. Injected worms were then placed on single 35mm plates of 
nematode growth media (NGM) and fresh OP50 bacteria as a food source. Approximately 2 days 
after injection, plates were screened for the presence of F1 progeny expressing the pCFJ90 
marker, which expresses mCherry in the pharyngeal muscles. This enriches for worms that were 
exposed to the injection mix, increasing the likelihood of identifying a worm subjected to 
genome editing. 
 
The mCherry-positive F1s were singled to individual plates and allowed to produce their own 
offspring (F2). Then, the F1 worms were placed in lysis buffer (50mM KCl, 10mM Tris-HCl pH 
8.3, 2.5mM MgCl2, 0.45% NP-40, 0.45% Tween-20, 1mg/mL proteinase K) and lysed with 
incubation at -80°C for one hour, incubation at 65°C for one hour, and incubation at 95°C for 
fifteen minutes. To genotype worms, the targeted tars-1 region was amplified by PCR (primer 
sequences in Appendix A) using Q5 PCR mix (New England Biolabs). Amplicons were then 
purified with DNA Clean and Concentrator kits (Zymo Research) and digested with the 
appropriate restriction enzyme (EagI for G541R or SacI for R433H, New England Biolabs). 
Digested PCR products were separated on a 1% agarose gel and analyzed to identify successful 
integration of the restriction site. Then, the undigested PCR product from F1s with successful 
gene editing events was submitted for Sanger sequencing to confirm proper insertion of the 
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restriction site and the desired tars-1 mutation. The offspring of these F1 worms were then 
maintained for subsequent experiments. 
 
3.2.6 Back-crossing and balancing worm strains 
To reduce possible off-target mutations caused by CRISPR-Cas9 editing, G541R/+ tars-1 worms 
were back-crossed to the ancestral N2 strain five times, and R433H/+ tars-1 worms were back-
crossed six times. To analyze G541R in the heterozygous state, wild-type and G541R/+ worms 
were balanced with the mIN1 inversion. This inversion stretches across the tars-1 locus,405 which 
prevents recombination with the G541R allele. This balancer allele also contains a transgene 
driving GFP expression in the pharynx, as well as a recessive dpy mutation that confers the Dpy 
phenotype to any homozygous worms.405 Thus, possible phenotypes and genotypes from the 
offspring of a balanced hermaphrodite worm are: GFP and Dpy (+/+ tars-1), GFP and non-Dpy 
(G541R/+ tars-1), and non-GFP non-Dpy (G541R/G541R).  
 
3.2.7 Analysis of worm axonal morphology 
To visualize changes in GABA-ergic neuron morphology, worms were crossed to a oxIS12 
background, which contains a transgene expressing GFP in GABA-ergic neurons.403 These 
worms were then age-synchronized by placing fertile adult hermaphrodites on a plate to lay 
embryos for 2-5 hours, then removing the adults and letting the offspring grow to adulthood. 
When worms reached L4 or P1, sets of 25-30 worms were moved to fresh plates and 
continuously transferred to fresh plates every other day until P7, when they were analyzed. 
Approximately 5µl of polystyrene beads (Polysciences Incorporated) were placed on a 10% 
agarose pad, and 5-7 worms were deposited in the beads. A coverslip was gently placed on top of 
the worms to encourage immobilization in the beads. Then, worms were imaged on a Nikon 
Eclipse Ti microscope. Any axon breaks, thinning of the dorsal nerve cord, or axonal branching 
were scored as abnormalities. This experiment was performed blinded to genotype.  
 
3.2.8 Analysis of worm development 
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To identify differences in the rate of development, R433H/R433H tars-1 worms and wild-type 
N2 worms were first age-synchronized by placing approximately 25 adult worms on a 60 mm 
plate with NGM and OP50, letting them produce embryos for 4-5 hours, and then removing the 
adults. After 48 hours, worms were transferred to unseeded 35mm NGM plates in batches of 4-5 
worms. These worms were filmed and analyzed using the WormLab System (MBF Biosciences). 
Plates were filmed for 30-second intervals, with the camera set at 4.81um/pixel for 
R433H/R433H worms (Setting 1 on the Wormlab camera apparatus [MBF Bioscience]) and 
8.47um/pixel for N2 worms (Setting 3 on the Wormlab camera apparatus [MBF Bioscience]). 
After filming, worms were moved to new NGM plates seeded with OP50. Filming was repeated 
every 24 hours up to 168 hours, or 7 days, after birth (as R433H/R433H worms increased in size, 
filming was performed with the camera setting at 8.47um/pixel). All videos were analyzed with 
the WormLab software (MBF Bioscience), and the worm length parameter was extracted to 
compare the size of R433H/R433H tars-1 worms and N2 worms over the course of development. 
 
3.2.9 Worm thrash assays 
Thrash assays were performed to detect changes in worm movement. The bottom of a 66mm 
well (Thermo Scientific) was coated with 2.5% agar. 500µl liquid M9 media (22mM H2KO4P, 
42 mM HNa2O4P, 85 mM NaCl, 1mM MgSO4) was added to each well, and 1-5 worms (wild-
type or R433H/R433H tars-1) were placed in the M9. Worms were allowed to acclimate for 30-
60 seconds before they were filmed with the WormLab System (MBF Biosciences) for 1 minute. 
Only worms with at least 1,000 frames of high-quality video were included in subsequent 
analysis. To identify defects in locomotion, the WormLab “Speed” parameter was analyzed; this 
parameter calculates changes in the center point of the worm over time. 
 
3.2.10 Generation of G541R and R433H Tars1 mouse lines 
The G541R mutation was introduced into mouse Tars1 using CRISPR-Cas9 mediated gene 
editing, performed by the University of Michigan Transgenic Animal Core. A single-stranded 
oligonucleotide (ssODN) was designed to introduce the G541R mutation in cis with silent 
mutations that introduced a HhaI cut site and destroyed the PAM site. A mixture of Cas9, 
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sgRNA, and ssODN was injected into 308 hybrid C57BL/6J x SJL/J zygotes, and the 280 
surviving zygotes were transferred to 11 pseudopregnant female mice. These mice produced 59 
offspring, which were all genotyped by PCR-amplification (primer sequences in Appendix A) 
and HhaI digestion to identify successful introduction of the repair template. PCR products were 
submitted for Sanger sequencing to ensure the proper integration of the entire repair template. 
Mice carrying the G541R Tars1 allele were then mated to C57BL/6 mice to establish germline 
transmission. 
 
A similar approach was taken to generate the R433H Tars1 mutation. Synonymous mutations in 
the repair template in cis with R433H ablate a BglI cut site that is present in the wild-type allele, 
and prevent binding of the guide RNA after repair. Cas9, sgRNA, and ssODN was injected into 
hybrid zygotes, which were then implanted into pseudopregnant females. These mice produced 
32 pups, which were genotyped to by PCR-amplification (primer sequences in Appendix A) and 
BglI digestion to identify mice that had incorporated the repair template. Amplicons were then 
submitted for Sanger sequencing to identify mice with proper integration of the repair template. 
These mice were then mated to C57BL/6 mice to establish germline transmission. 
 
3.2.11 Mouse behavioral assays 
To analyze gait, mouse paws were painted with non-toxic paint (the back paws with red paint 
and the front with paws blue paint). Mice were prompted to walk down a strip of paper fitted 
inside a narrow walkway. After the paint had dried, three subsequent footsteps in the middle of 
the strip were analyzed. The length between each step and the width of the mouse stance was 
measured. To test mice for general motor function, an accelerated rotarod test was used. Mice 
were placed on a rotating horizontal bar 10 inches above the desktop, rotating at 4 rpm. The 
speed was gradually increased to 40 rpm over the course of 5 minutes; if the mouse fell, the time 
to fall was recorded. Mice were also tested for their ability to run on a treadmill. Each mouse was 
placed on a treadmill in front of an electric grid. The treadmill began moving at 9 meters/minute, 
then increased by 1 meter/minute each minute. If a mouse fell off, it received a light electrical 
shock. The time until a mouse received three electrical shocks (counted as at least one second 
with multiple paws on the grid) was recorded. The test was stopped after 22 minutes. An 
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alternate test of activity was performed using a running wheel. Mice were placed in cages 
containing food, water, and a running wheel. This wheel recorded the total time the mice spent 
running on the wheel, as well as the total distance they traveled. Mice were housed in these cages 
for 7 days, and the total distance traveled each day was recorded. To test motor strength, a “wire 
hang” test was performed. Mice were placed on a wire grid lying horizontally on the table top. 
The grid was then turned upside down and held approximately 10 inches above an empty cage 
for 3 minutes. The time to fall was recorded with a stopwatch. To test grip strength, a Grip 
Strength Meter (Columbus Instruments) was used. Mice were held and allowed to hold the test 
apparatus with their fore paws. Then, gentle and uniform force was applied at the base of its tail 
until the force applied exceeded the mouse’s ability to maintain its grip. The peak force was then 
recorded as the mouse’s grip strength. Each mouse was tested in 5 subsequent trials. All 
behavioral analyses were performed blinded to genotype.  
 
3.2.12 Mouse nerve conduction measurements  
To assess defects in nerve conduction amplitude and velocity, nerve conduction studies were 
performed according to published protocol.406 In short, mice were anesthetized and core 
temperature was maintained at 34 °C with a heating lamp. Skin temperature was monitored with 
an infrared probe (Fluke, Everret, WA) and kept at 32 °C. Stainless steel needle electrodes 
(Natus, Middleton, WI) were cleaned with 70% alcohol between animals. Sural sensory nerve 
conduction velocity (NCV) was determined by recording at the dorsum of the foot and 
antidromically stimulating with supramaximal stimulation at the ankle. Nerve conduction 
velocity was calculated by dividing the distance by the take-off latency of the sensory nerve 
action potential. Sciatic-tibial motor NCV was determined by recording at the dorsum of the foot 
and orthodromically stimulating with supramaximal stimulation first at the ankle, then at the 
sciatic notch. Latencies were measured in each case from the initial onset of the compound 
muscle action potential. The sciatic-tibial motor NCV was calculated by subtracting the 
measured ankle distance from the measured notch distance. The resultant distance was then 
divided by the difference in the ankle and notch latencies for a final nerve conduction velocity. 
Amplitude was calculated at the dorsum to ankle measurement. Amplitude was calculated from 
the onset of the compound muscle action potential to the peak of the negative deflection.  
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3.2.13 Mouse dissections 
The author assisted Dr. Guy Lenk (Meisler Laboratory, University of Michigan) with dissections 
on two Tars1+/+ mice, two Tars1G541R/+ mice, and two Tars1F538Kfs*4/+ mice. All mice were eleven 
weeks old. Mice were euthanized by cervical dislocation and decapitation. Brains were dissected 
and lysed with 1mL RIPA buffer (Thermo Scientific) and 1x Halt Protease Inhibitor Cocktail 
(Thermo Scientific) in a dounce homogenizer. Then, lysate was centrifuged at 4,500xg for 5 
minutes at 4°C. Supernatants were removed and aliquoted for protein analysis. 
 
3.2.14 Western blots from mouse brain 
Total protein concentration was measured using the Thermo Scientific Pierce BCA Protein 
Assay Kit. 6.25µg, 12.5µg, or 25µg of lysate was analyzed. Samples were prepared with 1X 
Novex Tris-Glycine SDS sample buffer (Invitrogen) and 2-mercaptoethanol (BME), and were 
boiled at 99°C for 5 minutes. Protein samples were separated on precast 4-20% Novex 
Wedgewell Tris-glycine gels (Invitrogen) at 150V for 1 hour and 15 minutes. PVDF membranes 
(Millipore Sigma) were pre-washed in 100% methanol for 1 minute, then soaked in 1X transfer 
buffer (Invitrogen) and 10% methanol between two pieces of filter paper (Thermo Fisher 
Scientific). Samples were transferred from the Tris-Glycine gel to the PVDF membrane using a 
Mini Trans-Blot Electrophoretic Transfer Cell (Biorad) at 0.03A for 18-20 hours. The membrane 
was then blocked in 2% milk in 1X TBST overnight at 4°C. After blocking, the membrane was 
washed with 1X TBST three times, with each wash comprising five minutes of rocking at room 
temperature. Primary antibody was applied in the 2% milk solution: anti-TARS1 (Thermo Fisher 
PA5-30690) was applied at 1:500 dilution, and anti-actin (Sigma A5060) was applied as a 
loading control at 1:5,000 dilution. Primary antibody was incubated overnight at 4°C. 
Membranes were then washed three times with 1X TBST as above, and secondary antibodies 
(anti-mouse HRP [1:2,000; Thermo Fisher Scientific] for TARS1 and anti-rabbit HRP [1:5,000; 
EMD Millipore] for actin) were applied in 2% milk solution. The blots were rocked for 1 hour at 
room temperature before incubating with SuperSignal West Dura substrate (Thermo Scientific) 
according to the manufacturer’s instructions.  
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3.2.15 Preparation of mouse tissues for histology 
To investigate P0 pups for gross histological changes, dead pups were collected and live pups 
were sacrificed by decapitation. Pups were individually fixed in neutral-buffered formalin, 
rocking overnight at room temperature. Then, pups were placed in 70% ethanol and stored at 
4°C. To investigate histological changes in the hair and skin of adult mice, three 
Tars1R433H/F538Kfs*4 mice and their age-matched, sex-matched Tars1R433H/+ littermates were 
sacrificed. The mice were shaved, and skin was collected from the dorsal trunk, ventral trunk, 
ears, tail, and paws, as well as from the area of the head with visible hair loss. Skin samples were 
placed on 0.45µm HA filters (Millipore) wetted in PBS and strips were cut parallel to the 
direction of hair follicle growth. All strips were then fixed overnight in neutral-buffered formalin 
at room temperature, then transferred to 70% ethanol and stored at 4°C. 
 
Samples were shipped to Histoserv, Inc. for embedding and sectioning. Briefly, samples with 
bone were decalcified; then, tissues were dehydrated, and water inside of the tissues was 
replaced with paraffin wax. Tissues were then embedded into wax blocks of paraffin. Blocks 
were then sectioned and affixed to slides (two sagittal sections were taken for the P0 pups). 
Adult skin sections were stained with H&E; P0 pup sections were stained with either H&E or 
PAS, which detects glycoproteins and mucins.407  
 
3.2.16 Analysis of epidermal thickness in P0 pups 
Dorsal skin from H&E-stained sections was used to analyze the epidermal thickness of four 
Tars1R433H/F538Kfs*4 mice and three Tars1R433H/+ littermates. Five 1mm areas were selected, evenly 
spaced out across the back. In each 1 mm area, the thickness of the epidermis was measured by 
drawing lines in Adobe Illustrator that span the width of the epidermal layer, then using the 
200um scale in each image to convert line length to um. Five measurements were made that 





3.3.1 Identification of three loss-of-function TARS1 mutations 
Previous work in the Antonellis group had assessed a panel of variants in the yeast threonyl-
tRNA synthetase gene, THS1. Three of these variants reduced yeast growth and were therefore 
selected for study in the human TARS1 open reading frame. The three variants—N412Y, R433H, 
and G541R—were designed to affect residues conserved between human, mouse, worm, and 
yeast (Figure 3.2A). To assess whether these variants affected the function of human TARS1, a 
complementation assay was performed using a yeast strain with the endogenous THS1 deleted. 
Yeast viability was maintained with a pRS316 vector expressing the yeast THS1, along with 
URA3. The pYY1 vector expressing either wild-type or mutant human TARS1 was transformed 
into yeast, then yeast were plated on 5-FOA, which selects for the loss of the maintenance vector 
expressing URA3 and THS1. Wild-type TARS1 supported yeast growth, demonstrating that 
human TARS1 can function in yeast (Figure 3.2B). Transformation with N412Y TARS1 or 
G541R TARS1 did not lead to formation of colonies, indicating that these two mutations 
significantly impair gene function. Transformation with R433H TARS1 did support yeast growth, 
but lead to significantly fewer colonies than wild-type TARS1, indicating it was a partial loss-of-
function allele (Figure 3.2B). Based on these data, all three variants were prioritized for studies 
in worm to determine whether they were dominantly toxic to C. elegans neurons. Of note, the 
variant nomenclature used in this Chapter will remain consistent with the amino acid numbers of 
the human alleles for ease of comprehension. However, the C. elegans and mouse numbers differ 
from the human by one amino acid residue (Table 3.1). 
 
3.3.2 Over-expression of G541R tars-1 is dominantly toxic to C. elegans neurons 
Pathogenic loss-of-function variants in HARS1 and AARS1 are dominantly toxic to C. elegans 
neurons when over-expressed from a transgene, causing a branching morphology in GABA-ergic 
neurons and a failure to reach from the ventral nerve cord to the dorsal nerve cord.174,175,307 To 
determine if the TARS1 loss-of-function variants could cause a similar phenotype, they were 




Figure 3.2. Conservation and yeast complementation analyses for three designed TARS1 
variants. 
 
(A) Conservation analysis of N412, R433, and G541 TARS1. The targeted residues are shown in 
pink, surrounded by flanking sequences from evolutionarily diverse species. (B) Representative 
images of yeast haploid strains with THS1 deleted, transformed with an empty vector (“Empty”), 
wild-type TARS1, N412Y TARS1, R433H TARS1, or G541R TARS1. Yeast were spotted on 
media containing +5FOA in serial dilutions, then grown at 30°C. 
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Table 3.1. Comparison of amino acid numbering between human TARS1, worm tars-1, 








R433H R432H R432H 




motor neurons that innervate body wall muscles, are required for locomotion,408 and have 
defined projections across the circumference of the worm that are easily visualized with GFP 
(Figure 3.3B). N412Y, R433H, and G541R were each introduced to the tars-1 coding sequence, 
which was expressed from the GABA-ergic neuron promoter unc-47.403 In this construct, tars-1 
is separated from a mCherry reporter by a SL2 splice site, which allows mCherry signal to mark 
proper transgene expression without introducing a tag onto the tars-1 protein409 (Figure 3.3A). 
Expressing wild-type tars-1 did not lead to any morphological defects, indicating that increased 
levels of wild-type tars-1 is not toxic. Similarly, R433H tars-1 did not cause changes in neuronal 
morphology. However, G541R tars-1 caused failure of commissures to reach the dorsal nerve 
cord, aberrant commissure branching, and thinning of the dorsal nerve cord (Figure 3.3C) This 
phenotype recapitulated the morphological defects previously seen with hars-1 and aars-2 
mutants.174,175,307 Worms expressing N412Y tars-1 could not be recovered. These findings were 
based on small numbers of animals, so statistical significance cannot be assessed. However, 
based on the compelling neuronal morphology defects, G541R TARS1 was pursued to model in 
the endogenous locus. R433H TARS1 was also knocked into the endogenous locus as a potential 
candidate for recessive TARS-mediated phenotypes, as it was a partial loss-of-function allele in 
yeast but was not dominantly toxic to worm neurons. 
 
3.3.3 Introduction of tars-1 variants to the endogenous worm locus  
A major limitation of the above tars-1 transgenic studies is the inability to control for the 
expression level of the mutant protein. In this plasmid-based method, the number of plasmid 
copies that are incorporated into extrachromosomal arrays can be variable, as can the degree of 
array silencing.410 This leads to inconsistencies from cell to cell, and from worm to worm. To 
address these limitations, CRISPR-Cas9 mutagenesis was used to introduce R433H or G541R 
into the endogenous tars-1 locus, using previously detailed methods for site-specific gene editing 
in worm.404 In addition to the desired tars-1 missense mutation, silent mutations were included in 
the ssODN repair template to introduce unique restriction enzyme cut sites (EagI in cis with 
G541R and SacI in cis with R433H). These enable quick identification of worms that are 




Figure 3.3. Over-expression of G541R tars-1 is dominantly toxic to worm GABA-ergic 
neurons. 
 
(A) Cartoon of the construct injected into C. elegans gonadal tract. A GABA-ergic neuron 
promoter, Punc-47, drives expression of wild-type or mutant tars-1, followed by a mCherry 
reporter and the unc-54 termination sequence. (B) Worms were analyzed in the oxIS12 
background, which expresses GFP in GABA-ergic neurons for easy visualization of the ventral 
nerve cord (VNC) and its projections across the body to the dorsal nerve cord (DNC). (C) 
Images of GABA-ergic neurons from worms over-expressing wild-type tars-1 (left), R433H 
tars-1 (middle), or G541R tars-1 (right). Transgenic expression is indicated by mCherry signal. 
Aberrant neuronal morphology in worms expressing G541R is highlighted with white arrows. 
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digesting with the relevant enzyme to detect the restriction site marker of successful homology-
directed repair. This approach was used to screen the progeny of injected worms and identify 
worms that were heterozygous for G541R (Figure 3.4A) and worms that were either 
heterozygous or homozygous for R433H (Figure 3.4B).  
 
3.3.4 G541R tars-1 is homozygous lethal in worm 
An additional advantage of gene editing is the ability to stably propagate a mutation and follow 
its inheritance pattern across subsequent generations. Variation from the expected 1:2:1 pattern 
of allele segregation indicates that a mutation is deleterious. To assess the viability of G541R and 
R433H tars-1 worms, individual unbalanced heterozygote hermaphrodites were moved to 
separate plates, where they self-fertilized to produce dozens of offspring. Upon maturation to the 
L4 or P1 stage of development, each progeny was individually genotyped. The observed ratio of 
homozygote wild-type, heterozygote mutant, and homozygote mutant was compared to the 1:2:1 
ratio expected for allelic segregation. Out of 91 offspring, no G541R/G541R offspring were 
recovered, indicating that G541R is a loss-of-function allele (Figure 3.5A). This confirms the 
results from the yeast complementation assay. In contrast, R433H/R433H homozygotes were 
recovered, but at a lower frequency than would be expected for a benign variant (Figure 3.5B). 
This may indicate that R433H homozygotes were born less often R433H heterozygotes and wild-
type worms, or that there were fewer homozygotes on the plate that had reached the genotyping 
L4/P1 (adolescent/adult) stage, leading to an under-sampling of this genotype. In either scenario, 
the data indicate that homozygosity—but not heterozygosity—for R433H is deleterious but not 
lethal. This also agrees with the yeast complementation data indicating R433H is a hypomorphic 
allele.  
 
3.3.5 R433H tars-1 causes recessive developmental delay and locomotion defects in worm 
The depletion of R433H/R433H tars-1 worms in the above Mendelian analyses could be due to 
under-sampling of this genotype, which would happen if developmental delay prevented them 
from reaching adulthood at the same rate as wild-type or R433H/+ tars-1 worms. To investigate 




Figure 3.4. CRISPR-Cas9 strategies to introduce G541R or R433H into the endogenous 
tars-1 locus. 
 
(A) Top: Cartoon of the G541 locus in tars-1, aligned with the repair template sequence and 
guide RNA. Introduction of point mutations that change the glycine to arginine (blue) 
simultaneously ablate the PAM site (green) and introduce an EagI restriction site (purple) for 
genotyping. Bottom left: cartoon depicting PCR amplification of the targeted region, with a 
representative chromatogram above it. Bottom right: EagI digestion of amplicons from a wild-
type or heterozygous worm. (B) Top: cartoon of the R433 locus in tars-1, aligned with the repair 
template and guide RNA sequence. The repair template encodes the arginine to histidine change 
(red), as well as synonymous mutations that introduce a SacI cut site (purple) and prevent re-
editing after repair. Bottom left: cartoon depicting PCR amplification of the targeted region, with 
a representative chromatogram of a homozygous worm above it. Bottom right: SacI digestion of 




Figure 3.5. Mendelian analysis of G541R/+ tars-1 offspring and R433H/+ tars-1 offspring. 
 
(A) Genotype analysis of 91 offspring from G541R/+ tars-1 hermaphrodites. A representative 
genotyping gel image is shown. The observed and expected number of each genotype is listed.  
(B) Genotype analysis of 177 offspring from R433H/+ tars-1; a representative image from a 
genotyping gel is shown. The observed and expected number of each genotype is shown. For 
both analyses, a Chi-square was performed to determine if the difference between observed 





synchronized and the size of worm cohorts was tracked for over 7 days. At 48 hours after worms 
were hatched, worm length was measured each day using the WormLab video and software 
system. R433H/R433H tars-1 worms were consistently smaller than wild-type controls until Day 
7 (Figure 3.6A). Whereas wild-type worms reach a mature size of approximately 1mm 3-4 days 
after birth, R433H/R433H tars-1 worms do not reach this size until 6-7 days after birth.  
 
To assess whether R433H/R433H tars-1 causes behavioral defects, a thrash assay was performed 
with adult worms 9 days after they reached adulthood (P9). Here, R433H/R433H tars-1 worms 
were age-matched to wild-type N2s by synchronizing embryo production, as described in 
Section 3.2.7. The WormLab video capture and analysis system was used to record one-minute 
videos of worms swimming in M9 buffer, track their motion, and calculate locomotion 
parameters. R433H/R433H worms moved at a significantly reduced speed compared to wild-
type worms (Figure 3.6B), indicating that reduced tars-1 function affects the neuromuscular 
circuitry governing worm locomotion.  
 
3.3.6 Morphological defects are absent in G541R/+ GABA-ergic neurons 
To determine if G541R/+ worms could re-capitulate the GABA-ergic neuron defects seen when 
over-expressing G541R tars-1, they were crossed into the oxIS12 strain (which expresses GFP in 
the GABA-ergic neurons) and examined for neuronal abnormalities at P7.  R433H/R433H tars-1 
worms at P9 were also included in these studies; if the dominant toxicity of G541R was due to a 
dominant-negative effect that decreased overall tars-1 function, then homozygosity for a 
hypomorphic allele might also reduce tars-1 function enough to cause neuronal defects. Worms 
were scored as having aberrant axons based on the presence of neuronal commissure branching, 
breakage, or incorrect guidance, as well as thinning of the dorsal nerve cord. Although some 
striking examples of aberrant morphology were identified in G541R/+ tars-1 and R433H/R433H 
tars-1 worms (Figure 3.7A), neither genotype caused a significant increase in the percentage of 
worms with morphological defects (Figure 3.7B and C). Based on the strength of the neuronal 
phenotype when G541R was over-expressed, G541R was selected for validation in a mammalian 
model, with the expectation that longer mouse peripheral nerves would be more sensitive to 




Figure 3.6. Developmental and locomotion defects in R433H/R433H tars-1 worms. 
 
(A) Body length measurements of R433H/R433H tars-1 worms and wild-type tars-1 worms 
(N2) across six days after hatching. 3 R433H/R433H worms were measured on Day 2, then 18-
30 worms each day after. 18-30 wild-type worms were measured each day. Bars indicate the 
mean worm length for each day, along with 95% confidence intervals. Statistical significance 
was calculated with an unpaired t-test; ****, p<0.000001; ns = not significant.  (B) Movement 
speed of 28 P9 wild-type worms (N2) and 27 P9 R433H/R433H tars-1 worms is shown. Speed 
was calculated by analyzing the track length of the worm over time. Bars indicate mean speed 





Figure 3.7. GABA-ergic neuron morphology in G541R/+ and R433H/R433H tars-1 worms. 
 
(A)  Images of GABA-ergic neurons from wild-type worms with the mIn1 balancer, G541R/+ 
worms with the mIn1 balancer, and R433H/R433H worms. Morphological defects in G541R/+ 
worms and R433H/R433H worms are highlighted with white arrows. (B) Percentage of wild-
type worms and G541R/+ worms with aberrant GABA-ergic neuron morphology. (C) Percentage 
of wild-type worms (N2) and R433H/R433H worms with abberant GABA-ergic neuron 




3.3.7 Establishment of G541R and R433H Tars1 mouse lines 
The mouse TARS1 ortholog, Tars1, was edited using CRISPR-Cas9 to introduce the G541R 
variant in cis with silent mutations that form a HhaI cut site and ablate the PAM site. Two 
founders carrying the G541R variant were identified and mated to establish germline 
transmission, then back-crossed to C57BL/6 mice twice for further analysis. Genotyping was 
performed by PCR-amplification of Tars1 exon 14, followed by HhaI digestion to identify 
successful introduction of the repair template (Figure 3.8A). All PCR amplicons from the 
founder cohort were also Sanger-sequenced to identify insertions or deletions that might produce 
a frameshift and a premature stop codon. As a result, we identified a mouse carrying an 11 base 
pair deletion that ablates a HaeIII cut site and that leads to a premature stop codon shortly 
downstream of the PAM site (F538Kfs*4). When this region is amplified and digested with 
HaeIII, the presence of an undigested upper band indicates the frameshift allele (Figure 3.8B). 
Founder Tars1F538Kfs*4/+ mice were also mated to C57BL/6 mice to establish germline 
transmission. 
 
A similar approach was taken to identify mice that had undergone successful CRISPR-Cas9 
editing of the R433H Tars1 mutation. Here, silent mutations in cis with R433H ablate a BglI cut 
site and the PAM site. In this genotyping strategy, Tars1 exon 12 is amplified with PCR and 
digested with BglI; amplicons that remain undigested indicate the R433H mutation (Figure 
3.8C). Two Tars1R433H/+ founders were identified and mated to establish germline transmission. 
One Tars1R433H/+ line was backcrossed to C57BL/6 mice twice for further analysis. 
 
3.3.8 Homozygosity for G541R or F538Kfs*4 is not compatible with life in mouse models 
If G541R is a loss-of-function allele in mouse, as it is in yeast and worm, homozygosity for 
G541R Tars should not be compatible with life. To test this, three litters from TarsG541R/+ x 
TarsG541R/+ mating pairs were genotyped to assess whether the G541R allele segregated 
according to 1:2:1 Mendelian ratios. Out of 19 mice, no TarsG541R/G541R genotypes were detected 
at 3 weeks of age (Figure 3.9A). As a comparison, the same experiment was performed with the 




Figure 3.8. CRISPR-Cas9 genome editing to introduce G541R and R433H into the Tars1 
locus. 
 
(A) Left: chromatogram of a G541R/+ Tars1 mouse, with the sequence of the wild-type and 
mutant alleles below. The HhaI site introduced by the repair template is highlighted in blue, and 
the introduced arginine in red. Middle, right: genotyping strategy for amplifying exon 14 and 
identifying the G541R mutant allele by HhaI digest. (B) Left: chromatogram of a mouse with an 
11 base pair deletion in Exon 14. This deletion causes a frameshift and a premature stop codon at 
amino acid 541 (F538Kfs*4). It also ablates a HaeIII cut site (blue). Middle, right: genotyping 
strategy for amplifying exon 14 and identifying the frameshift allele by HaeIII digest. (C) Left: 
chromatogram of a R433H/+ mouse, with the sequence of the wild-type and mutant alleles 
below. The nucleotides changed to convert arginine into histidine also ablate a BglI cut site in the 
wild-type allele (blue). Middle, right: genotyping strategy for amplifying exon 12 and identifying 





Figure 3.9. Mendelian ratios of mutant Tars1 mouse lines. 
 
(A) Genotype analysis of 19 offspring from Tars1G541R/+ x Tars1G541R/+ mating pairs. (B) 
Genotype analysis of 28 offspring from Tars1F538Kfs*4/+ x Tars1F538Kfs*4/+ mating pairs. (C) 
Genotype analysis of 43 offspring from Tars1R433H/+ x Tars1R433H/+ mating pairs. All mice were 
genotyped at approximately 3 weeks of age. Chi-square tests were performed to determine if the 




transcript that is predicted to undergo nonsense mediated decay. From a total of 28 offspring, no 
TarsF538Kfs*4/F538Kfs*4 mice were identified (Figure 3.9B). These data indicate that both G541R 
Tars1 and F538Kfs*4 Tars1 are loss-of-function mutations in mouse. In contrast, TarsR433H/R433H 
mice were born at a frequency that did not deviate from expected Mendelian ratios (Figure 
3.9C). This is consistent with R433H TARS1 retaining some function, as predicted by the yeast 
and worm studies.  
 
3.3.9 Tars1G541R/+ mice do not develop a detectable peripheral neuropathy by one year of age 
To determine if G541R Tars1 could cause a dominant peripheral neuropathy in mouse, cohorts 
of Tars1G541R/+ mice and their littermate Tars1+/+ controls were evaluated for behavioral 
indications of neuromuscular defects. First, two Tars1G541R/+ founders were mated with C57BL/6 
mice to establish two independent lines carrying the mutation (Line A and Line B). The Line A 
founder produced a litter of four males (two Tars1G541R/+ and two Tars1+/+). At 2 months of age, 
this cohort was evaluated for behavioral defects that might indicate neuromuscular impairment. 
Gait analysis revealed that the two Tars1G541R/+ showed a 20% reduction in stride length, and 
took a 14% wider stance with their front paws (Figure 3.10A). However, there were no 
significant differences in rotarod performance (Figure 3.10B), ability to hang on a wire mesh 
(Figure 3.10C), or grip strength (Figure 3.10D) across five sequential days of testing.  
 
To increase the sample size of this cohort, three Tars1G541R/+ and three Tars1+/+ males from the 
Line B founder were added. All ten mice were then subjected to the same battery of behavioral 
assays at 5-6 months of age. The stride length of all ten mice were assessed in a gait analysis; as 
before, Tars1G541R/+ mice took shorter steps Tars1+/+ mice (Figure 3.11B), despite no difference 
in body size between the two genotypes (Figure 3.11A). Stride width was only measured for the 
four Line A mice; again, the Tars1G541R/+ mice took slightly wider stances with their front paws 
(Figure 3.11B). The combined Line A and Line B cohort was then tested for their grip strength, 
ability to hang from a wire mesh, ability to run on a treadmill, and performance on a rotarod. 
There was no difference in grip strength (Figure 3.12A) or latency to fall off the wire mesh 
(Figure 3.12B) between Tars1G541R/+ and Tars1+/+ mice. Tars1G541R/+ mice did perform poorly on 





Figure 3.10. Tars1G541R/+ mice have a shorter gait and wider stance at 2 months of age. 
 
(A) Gait analysis for two male Tars1G541R/+ mice and two male Tars1+/+ littermates. 36-37 steps 
front paw steps and 36-37 hind paw steps were analyzed for each genotype. An unpaired t-test 
with Welch’s correction was performed to determine statistical significance. (B) Rotarod 
performance data across five consecutive days (C) Latency to fall from a wire grid, measured for 
five consecutive days. (D) Grip strength, measured for five consecutive days. For (B)-(D), 
unpaired t-tests were performed to determine statistical significance. **** p<0.0001, ** p<0.01, 




Figure 3.11. Tars1G541R/+ mice have a shorter gait and wider stance at 5-6 months of age. 
 
(A) Weight of 5 male Tars1G541R/+ mice and 5 male Tars1+/+ littermates at 5-6 months of age. (B) 
Gait analysis for 5 male Tars1G541R/+ mice and 5 male Tars1+/+ littermates. For stride length 
measurements, 85-90 front paw steps and 85-90 hind paw steps were analyzed for each 
genotype. For stride width measurements, only 2 male Tars1G541R/+ mice and 2 male Tars1+/+ 
mice were assessed; 36 steps front paw steps and 36 hind paw steps were analyzed for each 
genotype. For (A) and (B) an unpaired t-test with Welch’s correction was performed to 




Figure 3.12 No difference between Tars1G541R/+ mice and Tars1G541R/+ mice in motor function 
or grip strength at 5-6 months of age.  
 
(A) Grip strength of 5 male Tars1G541R/+ mice and 5 male Tars1+/+ littermate, measured for three 
consecutive days. (B) Latency to fall from a wire grid, measured for three consecutive days. (C) 
Length of time spent running on a treadmill, measured for three consecutive days. (D) Rotarod 
performance data, measured for three consecutive days. All bars represent mean value with 95% 
confidence intervals. Unpaired t-tests were performed for each assay to determine statistical 
significance. ** p<0.01, * p<0.05, ns = not significant. 
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in the subsequent two days of testing (Figure 3.12C and Figure 3.12D). Similar gait changes 
have been seen in other mouse models of dominant peripheral neuropathy373,399 and are 
indicative of neuromuscular dysfunction. However, additional behavioral evidence was required 
to build a compelling argument for neuromuscular dysfunction in Tars1G541R/+ mice. We pursued 
three strategies to more rigorously test the phenotype. One Tars1G541R/+ line (Line B) was back-
crossed an additional time to C57BL/6 mice to increase the amount of C57BL/6 genetic 
background, which served the additional purpose of continuing to cross away any possible off-
target mutations induced during CRISPR-Cas9 mutagenesis. Then, a larger cohort of 
Tars1G541R/+ mice was generated—8 Tars1G541R/+ and 8 Tars1+/+ from a total of three litters born 
within three weeks of each other— to provide the statistical power to detect subtle differences 
between the groups. Finally, this larger cohort was assessed at 1 year of age, which is more 
consistent with phenotypes observed in other mouse models of axonal CMT disease.396 Indeed, 
because ARS-mediated peripheral neuropathy is a degenerative disorder, older mice were 
expected to show a more severe phenotype.  
 
Surprisingly, when gait was assessed for 1-year-old mice, Tars1 G541R/+ mice took longer strides 
and smaller stances than their wild-type littermates (Figure 3.13A), the opposite of what was 
noted for the previous cohorts. Although these differences are statistically significant, it is 
difficult to interpret their biological relevance. However, we can conclude that this cohort of 
Tars1 G541R/+ mice does not display the hallmarks of neurodegenerative gait impairment. They are 
also not deficient at running on a wheel (Figure 3.13B), although the lack of a statistically 
significant signal may be partially due to the wide range of running activity of the wild-type 
mice. Finally, motor nerve conduction amplitude, sciatic motor nerve conduction velocity, and 
sural nerve conduction velocities were measured. Axonal peripheral neuropathy is marked by a 
primary defect in the axon, which causes decreased nerve conduction amplitudes.411 This 
degeneration can also affect the integrity of the myelin sheath and cause secondary decreases in 
nerve conduction velocities as well.411 However, consistent with the absence of a behavioral 






Figure 3.13. Behavior and nerve conduction analysis for Tars1G541R/+ mice at 12 months of 
age. 
 
(A) Gait analysis for 10 male Tars1G541R/+ mice and 10 male Tars1+/+ littermates at 1 year of age. 
For stride length and width measurements, 330-353 front paw steps and 330-353 hind paw steps 
were analyzed for each genotype. (B) Distance traveled on a wheel, measured for 7 consecutive 
days. (C) Nerve conduction amplitudes in the motor nerves of Tars1G541R/+ and Tars1+/+ mice (D) 
Nerve conduction velocities for the sciatic motor nerves of Tars1G541R/+ and Tars1+/+ mice (E) 
Nerve conduction velocities for the sural nerves of Tars1G541R/+ and Tars1+/+ mice. All bars 
represent the mean value, with 95% confidence intervals. For all comparisons, an unpaired t-test 
with Welch’s correct was performed to determine if the differences between Tars1G541R/+ and 
Tars1+/+ mice were statistically significant. **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05, 
ns = not significant. 
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3.3.10 Tars1G541R/+ mice have reduced Tars1 levels 
To determine if G541R Tars1 reduced Tars1 protein levels, protein lysates were obtained from 
the brains of 11-week-old mice with +/+, G541R/+, and F538Kfs*4/+ genotypes. Two mice from 
each genotype were assessed. Total TARS1 abundance was analyzed with immunostaining. 
Here, we used an antibody that recognized both human TARS1 and mouse Tars1, and included 
lysate from yeast expressing human TARS1 as a size control (both human TARS1 and mouse 
Tars1 are predicted to be 83.4 kilodaltons). To more accurately compare protein abundance 
across genotypes, Tars1+/+ lysates were included in a gradient of 6.25µg, 12.5µg, and 25µg. 
25µg of Tars1F538Kfs*4/+ lysate was detected at a similar intensity as 12.5µg of Tars1+/+ lysate, 
consistent with decreased expression from the F538Kfs*4 allele (Figure 3.14) (One important 
caveat is that the TARS1 antibody recognizes an epitope between 346 and 657 amino acids, and 
may not be able to recognize a truncated protein at 541 amino acids.) Notably, 25µg of 
Tars1G541R/+ lysate lead to an intermediate Tars1 band intensity, between that of Tars1F538Kfs*4/+ 
and Tars1+/+ . This suggests that although G541R does not fully destabilize TARS1 protein, it is 
not expressed at wild-type levels. This may explain why over-expression of G541R caused 
neuronal phenotypes in worm, but endogenous levels of expression in worm or mouse did not.  
 
3.3.11 P0 deaths are enriched for Tars1R433H/F538Kfs*4 mice 
Many individuals with recessive ARS-mediated disease are compound heterozygous for a 
hypomorphic missense allele and a null allele.68 The above studies in yeast and worm indicate 
that R433H TARS1 is a hypomorphic allele, and the mouse studies of F538Kfs*4 Tars1 
homozygous lethality indicate that it is a null allele. To investigate a genotype relevant to human 
patients, Tars1R433H/R433H mice were crossed to Tars1F538Kfs*4/+ mice to obtain compound 
heterozygous offspring. One expectation was that these offspring would develop phenotypes 
similar to those seen in patients with other ARS-mediated recessive disease, such as 
microcephaly, developmental delay, or small stature.126,221,233 Another expectation was that 
reduced Tars1 function would preferentially affect tissues with a high requirement for threonine 
in proteins. To identify these proteins, we sorted the mouse proteome by threonine content and 
removed uncharacterized proteins, along with proteins with a Uniprot annotation score under 




Figure 3.14. Tars1G541R/+ mice show reduced Tars1 expression in brain tissue. 
 
Representative western blot image for Tars1 protein in brain tissue of a Tars1G541R/+ mouse, 
Tars1+/+ mouse, and Tars1F538Kfs*4/+ mouse. Human TARS1, expressed in yeast, is shown on the 
left as a size control. For Tars1+/+ samples, 6.25µg, 12.5µg, and 25µg lysate was loaded. For 
Tars1G541R/+ and Tars1F538Kfs*4/+ samples, 25µg was loaded. The top blot shows signal from a 
TARS1 antibody; the bottom blot shows signal from an actin antibody, as a loading control. An 




preliminary search may miss proteins with a lower overall threonine percentage but a localized 
high threonine content. The identified proteins composed of at least 15% threonine are primarily 
glycoproteins and mucins (Table 3.2).  
 
Mucins are the primary structural component of the mucus membranes that coat all wet epithelial 
surfaces in the body, including the lungs and the stomach.412 Mucin backbones are composed of 
tandem repeats of proline, threonine, and/or serine. These repeats are densely modified by O-
linked glycosylation, which maintains the integrity of the mucous membrane.412 The importance 
of threonine to these proteins is also supported by previous reports that intestinal mucin synthesis 
can be improved with threonine supplementation413 or impaired with threonine reduction.414 
Threonine deprivation and knockdown of TARS1 can decrease translation of a mucin protein 
(MUC1) in pancreatic cancer cells, without affecting global translation415. Therefore, it is 
possible that mice with reduced Tars1 function will be unable to incorporate sufficient threonine 
into mucin proteins to support proper mucous formation in tissues like the lungs or the gut.  
 
Offspring of the Tars1R433H/R433H and Tars1F538Kfs*4/+ mice were genotyped at 3 weeks of age. 
Based on Mendelian segregation, 50% of offspring were expected to be R433H/+ and 50% to be 
R433H/F538Kfs*4. However, there was a significant depletion of R433H/F538Kfs*4 at this 
stage of life (Figure 3.15A), indicating decreased viability prior to genotyping. Since no 
mortality was observed in developing pups, this death likely happens in utero or shortly after 
birth. In general, there is a base rate of neonatal mortality in laboratory mice, especially for the 
C57BL/6 strain.416 However, an analysis of neonate deaths across four litters showed that pups 
that died at P0 were strikingly enriched for the R433H/F538Kfs*4 genotype. Out of 15 
genotyped neonatal deaths, 13 were R433H/F538Kfs*4 mice (Figure 3.15B).  
 
3.3.12 P0 Tars1R433H/F538Kfs*4 mice lack air in their lungs and PAS+ material in their bronchiolar 
club cell epithelia 
To gain insights into the reduced viability of Tars1R433H/F538Kfs*4 mice, a cohort of four P0 
Tars1R433H/F538Kfs*4 pups and three age-matched Tars1R433H/+ littermates was collected for 
histology studies. The four Tars1R433H/F538Kfs*4 pups were all found dead within a few hours after  
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Table 3.2. Threonine-rich proteins in the mouse proteome. 
 




Muc19 Mucin-19 22% Submandibular gland 
Muc4 Mucin-4 19% Lung 
Muc20 Mucin-20 18% Lung, kidney 
Muc6 Mucin-6 18% Brain, liver, stomach, intestine 
Timd4 T-cell immunoglobulin and mucin domain-containing protein 4 17% 
Brain, liver, 
stomach, intestine 
Cd164 Sialomucin core protein 24 17% Kidney, liver, lung, pancreas, thymus 
Emcn Endomucin 17% Lung, heart, kidney 
Gp1ba Platelet glycoprotein Ib alpha chain 17% Platelets418 
Plin4 Perilipin-4 16% White adipose tissue419 
Defb26 Beta-defensin 16% Testis420 
Prg4 Proteoglycan 4 16% Liver 
Nup62 Nuclear pore glycoprotein p62 15% Widely expressed 
Muc16 Mucin-16 15% 
Eye, uterus, heart, 
lung, gastric tract, 
gall bladder421 
Plet1 Placenta-expressed transcript 1 protein 15% 
Colon, lung, salivary 
gland, keratinocytes, 
thymus422 
Ovgp1 Oviduct-specific glycoprotein 15% Oviduct423 






Figure 3.15. Neonatal lethality of Tars1R433H/F538Kfs*4 mice. 
 
(A) Genotype analysis of Tars1R433H/R433H and Tars1F538Kfs*4/+ offspring, genotyped upon weaning 
at 3 weeks of age. The observed and expected number of each genotype is shown. (B) Genotype 
analysis of 15 deceased pups, identified within one day after birth. The observed and expected 
number of each genotype is shown. For (A) and (B), a Chi-square test was used to determine if 
the difference between the number of observed and expected genotypes was statistically 
significant. (C) H&E staining of lung sections from three Tars1R433H/+ P0 pups (top row) and five 
Tars1R433H/F538Kfs*4 P0 pups (bottom row). All Tars1R433H/+ pups were alive when identified at P0. 
The first four Tars1R433H/F538Kfs*4 pups were identified dead at P0; the fifth was found alive with a 
gasping, labored breathing pattern. (D) PAS staining of lung sections from three Tars1R433H/+ P0 
pups (top row) and four Tars1R433H/F538Kfs*4 P0 pups (bottom row). Black arrows highlight the 
magenta PAS signal in the bronchioles of Tars1R433H/+ mice (top row), and the absence of PAS 
signal in the collapsed bronchioles of Tars1R433H/F538Kfs*4 mice (bottom row). 
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birth. Interestingly, in a separate litter, a Tars1R433H/F538Kfs*4 pup was found immediately after 
birth (traces of birth fluids were still visible) with visibly labored breathing and a failure to right 
itself. This additional pup was included in the cohort to investigate its breathing phenotype. All 
pups were fixed in formalin overnight, washed with 70% ethanol, and then sent for processing at 
Histoserv, where sagittal sections were taken for H&E staining and Periodic Acid Schiff (PAS) 
staining (which detects glycoproteins and mucins407).  
 
The four P0 Tars1R433H/F538Kfs*4 mice that were found dead had no air in their lungs. Whereas the 
alveoli of Tars1R433H/+ mice were expanded with air (Figure 3.15 C, top), the alveoli of 
Tars1R433H/F538Kfs* mice were collapsed (Figure 3.15 C, bottom). Based on the otherwise mature 
body development of these pups, this indicates that they died either shortly before or upon birth. 
Interestingly, the additional Tars1R433H/F538Kfs*4 pup found alive immediately after birth had only 
partially expanded alveoli, which correlates with the observed labored breathing. Moreover, 
although the bronchioles of Tars1R433H/+ mice are replete with the magenta PAS+ signal of 
secretory cells, this signal is absent from the collapsed bronchioles of Tars1R433H/F538Kfs*4 mice. 
(Figure 3.15D) Further work is needed to determine whether this is a result of an absent 
population of cells or a result of decreased glycoprotein production, or both (discussed further in 
Chapter 5). 
 
3.3.13 Surviving Tars1R433H/F538Kfs*4 mice have reduced body weight 
Tars1R433H/F538Kfs*4 mice that passed the P0 mark survived to adulthood with no apparent 
breathing abnormalities. However, these mice were on average smaller than their Tars1R433H/+ 
littermates (Figure 3.16A). Male and female mice from nine litters were weighed once every 
week until 23 weeks of age. Only litters containing both genotypes were included in the analysis. 
Reduced body weight was more consistent in females (Figure 3.16B) than males, who reach a 
normal body size by 7 weeks of age (Figure 3.16C). This reduced size is consistent with growth 
restriction phenotypes in human patients with ARS-mediated recessive disease, as well as the 
reduced size of mice homozygous for a hypomorphic Cars1 mutation, which is being 




Figure 3.16. Reduced body weight of Tars1R433H/F538Kfs*4 mice. 
 
(A) Image of four littermates at P11, grouped together for comparison of body size. Each mouse 
is labeled with its genotype. (B) The average weekly weights of female Tars1R433H/F538Kfs*4 mice 
and female Tars1R433H/+ littermates are shown, until 23 weeks of age. (C) The average weekly 
weights of male Tars1R433H/F538Kfs*4 mice and female Tars1R433H/+ littermates are shown, until 23 
weeks of age. For (B) and (C), bars represent the mean value and one standard deviation. An 
unpaired t-test was performed for each week to determine if the difference between the two 
genotypes was statistically significant. **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05. All 
values in (C) that are not marked with an asterisk are not significantly different. 
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3.3.14 Tars1R433H/F538Kfs*4 mice display hair and skin defects 
As these studies were underway, a report of two human individuals with bi-allelic TARS1 
variants and triochothioydstrophy (TTD) phenotypes was published.253 Both individuals 
presented with the classic “tiger-tail” banding pattern of the hair shaft and ichthyosis. One 
individual had follicular keratosis, the other was born as a “collodion baby”, encased in a tight 
shiny membrane.253 Interestingly, the described “collodion baby” phenotype was reminiscent of 
two Tars1R433H/F538Kfs*4 mice that were found dead shortly after birth. The bodies of these mice 
were encased in a tight membrane (Figure 3.17 A and B) with visible blisters (right image). One 
mouse (right image) was submitted for histopathology as described above; however, there was 
no immediately apparent signatures of a mouse collodion baby phenotype, such as a thickened 
stratum corneum. Further investigation is required to fully define this specific phenotype. 
Interestingly, the TarsR433H/F538Kfs*4 P0 pups did show evidence of other skin and hair 
abnormalities. In the cohort of four TarsR433H/F538Kfs*4 and three TarsR433H/+ littermates, 
TarsR433H/F538Kfs*4 mice had a thinner epidermal layer than control mice (Figure 3.17 B and C); on 
average, the epidermis was 35% thinner. Additionally, these four mice had follicular hypoplasia 
(i.e. less mature and/or fewer hair follicles).  
 
Adult Tars1R433H/F538Kfs*4 mice also displayed a striking hair phenotype. Of the mouse cohort that 
was followed and weighed over the course of 23 weeks, 10 out of 14 Tars1R433H/F538Kfs*4 mice 
(71.4%) lost hair on their heads and/or upper back by 23 weeks of age, compared to 1 out of 23 
Tars1R433H/+ littermates (4.35%). Hair loss onset occurred between 13 and 23 weeks of age 
(Figure 3.18A). It followed a stereotypic pattern of bald spots on the head and/or along the 
scapula of the upper back (Figure 3.18B). In more advanced stages, it would reach across the 
entire upper back (Figure 3.18C). To more thoroughly define this phenotype, histopathology was 
performed on hair samples from the affected regions for three Tars1R433H/F538Kfs*4 mice and three 
Tars1R433H/+ littermates; one pair was 2 months old, another was 12 months old, and the third was 
14 months old. Analysis of H&E staining did not reveal any gross abnormalities in hair follicles, 
although this analysis was complicated by the asynchronous hair cycling of adult mice. Further 





Figure 3.17. Skin abnormalities in Tars1R433H/F538Kfs*4 P0 pups. 
 
(A) Images of two Tars1R433H/F538Kfs*4 pups born encased in a tight membrane. A black arrow 
points to a blister on the right-hand mouse. (B) H&E staining of dorsal skin sections in P0 pups. 
Black arrows point to the dark pink epidermal layer. The upper image shows skin from a 
Tars1R433H/+ mouse, and the bottom image shows skin from a Tars1R433H/F538Kfs*4 mouse. (C) 
Measurements of epidermal thickness of four Tars1R433H/F538Kfs*4 P0 Pups and three Tars1R433H/+ 
P0 littermates. The mean epidermal thickness is decreased by 35% in Tars1R433H/F538Kfs*4 mice. 
Bars indicate the mean value and 95% confidence interval. Statistical significance was 
determined with an unpaired t-test with Welch’s correction. N=75 for R433H/+ values and 





Figure 3.18. Adult onset hair loss in Tars1R433H/F538Kfs*4 mice. 
 
(A) The cumulative percentage of Tars1R433H/F538Kfs*4 mice (pink) and Tars1R433H/+ (gray) mice 
with hair loss on the back of their head or upper back is shown, until 23 weeks of age. (B) 
Representative images of four individual Tars1R433H/F538Kfs*4 mice with hair loss; the consistent 
pattern of upper back bald patches is shown for #1620, 1674, and 1347. (C) (Bottom image) A 
representative image of extended hair loss stretching from the head to the middle of the back in a 
Tars1R433H/F538Kfs*4 mouse, 14 months of age. His Tars1R433H/+ littermate is shown above, with 




The work presented in this Chapter aimed to use the established characteristics of pathogenic 
ARS variants in model organisms (i.e., loss-of-function in yeast, dominantly toxic to C. elegans 
neurons) to build a pipeline for predicting the pathogenicity of variants in TARS1 for both 
recessive and dominant phenotypes. Through this process, we successfully identified a 
hypomorphic TARS1 allele, R433H. R433H reduced yeast growth in a complementation assay, 
caused developmental delay and thrashing defects in homozygous C. elegans, and caused 
premature death linked to lung failure, decreased body size, and hair defects in mouse when 
modeled in trans with a null allele. This pipeline also identified a candidate dominant variant, 
G541R TARS1, that was loss-of-function in a yeast complementation assay, was homozygous 
lethal to both worm and mouse, and was dominantly toxic to C. elegans neurons in an over-
expression system. However, G541R TARS1 did not cause reproducible neuromuscular defects 
in heterozygous worms or mice, likely due to insufficient abundance of the mutant protein in 
relevant tissues. Therefore, it is not possible to draw conclusions about TARS1 as a candidate for 
dominant peripheral neuropathy based on this specific variant. 
 
Reduced levels of the G541R Tars1 protein is the most likely reason that heterozygous worms 
and mice did not develop neurological phenotypes. In general, pathogenic dominant ARS 
variants do not significantly reduce protein abundance, to the extent that this can be detected in 
patient fibroblasts or lymphoblasts in vitro.170,301,348 However, it is also useful to consider the 
limitations of mice when modeling dominant axonal neuropathies. Mouse peripheral neurons are 
much shorter than humans, and may not be as sensitive to a variant that produces a late-onset, 
mild neuropathy in humans. For example, mouse models of patient variants in HSPB1 and MFN2 
(other dominant axonal Charcot-Marie-Tooth disease genes) show a significant discrepancy 
between transgenic models with high expression levels and knock-in variants with endogenous 
expression levels. While transgenic models develop multiple symptoms of peripheral neuropathy 
by 6 months of age,373,424,425 mice expressing endogenous levels of the pathogenic allele show no 
significant signs of neuromuscular defects as late as 18 or 20 months of age.426,427  
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If G541R TARS1 does not produce fully stable TARS1 protein, this could also explain the 
discrepancy seen between the two worm models of G541R tars-1. Over-expressing G541R in 
GABA-ergic neurons may have compensated for the reduced stability of the protein and allowed 
it to reach toxic levels that caused morphological defects. Endogenous levels of expression may 
not have been sufficient to produce these defects. Another possibility is that the axons in worm 
are not long enough to be sensitive to endogenous expression levels of a toxic ARS allele; further 
work with established pathogenic ARS alleles is required to determine if these morphological 
phenotypes can be reproduced with knock-in models. It will also be informative to determine if 
homozygosity for partial loss-of-function alleles can also produce these aberrant morphologies. 
If so, this would demonstrate that a loss of ARS function can cause morphological defects in 
GABA-ergic neurons, which would support a dominant-negative mechanism for the dominant 
alleles that produce these same defects. However, homozygosity R433H tars-1 did not produce 
this phenotype (Figure 3.7C), indicating that testing this hypothesis may require variants with a 
more significant impact on ARS function. 
 
Although modeling G541R in mouse Tars1 did not provide evidence that TARS1 alleles can cause 
dominant peripheral neuropathy, the homozygous lethal nature of G541R (and of F538Kfs*4) 
answers a different critical question. Threonyl-tRNA synthetase is unique among the ARS gene 
family; in addition to the gene encoding the cytoplasmic enzyme (TARS1) and the gene encoding 
the mitochondria enzyme (TARS2), there is a third paralog, TARS3 (Tarsl2 in mouse). TARS3 likely 
arose from a duplication event in eukaryotic history, and is found across mammalian species, as 
well as in birds and houseflies.428 Mouse Tars1 and Tarsl2 share 76.4% identity across all domains 
except the N-terminal extension, which is only 10.3% identical.429 Although Tarsl2 has not been 
fully characterized, it is reported to be ubiquitously expressed in mouse, localized to both the 
cytoplasm and the nucleus, and capable of charging tRNA with threonine in vitro.429 Although 
there is no known genetic redundancy for any cytoplasmic or mitochondrial ARS, redundancy 
between TARS1 and TARS3 had not been tested prior to this dissertation. If there was redundancy, 
we would not expect TARS1 variants to cause recessive disease. Our studies address this question 
by demonstrating that homozygosity for either of two loss-of-function Tars1 alleles (G541R or 
F538Kfs*4) is incompatible with life, indicating that Tarsl2 cannot fully compensate for loss of 
Tars1. It remains to be seen whether Tarsl2 might partially compensate, perhaps extending the 
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viability of homozygous null Tars1 embryos in utero. Regardless, if this threonyl-tRNA synthetase 
duplication has remained intact over mammalian evolution but is not redundant with Tars1, it may 
have acquired other non-canonical activities in the cell. The function of TARS3 should be the 
subject of future investigation. 
 
Finally, we identified a hypomorphic Tars1 allele (R433H) and, after determining that it reduced 
gene function in yeast and worm, used it to generate a mouse model of Tars1-mediated recessive 
phenotypes. Preliminary investigation of mice that are compound heterozygous for R433H and the 
null allele F538Kfs*4 revealed that these mice frequently die at birth without air in their lungs. 
Tars1R433H/F538Kfs*4 mice that survive are smaller than their littermates and develop hair loss in 
consistent patterns on their heads and upper back. Although additional work is required to further 
define these phenotypes, this model will be a valuable resource to investigate the effects of reduced 
Tars1 function across different cell populations, and provide mammalian tissues to investigate how 
reduced Tars1 function impacts protein translation. These future studies can inform the assessment 
of patients with recessive TARS1-mediated disease and aid efforts to develop therapies for ARS-
mediated recessive diseases more broadly. 
 
One possibility is that proteins with a particularly high threonine content, such as mucins, are 
especially sensitive to decreased Tars1 activity. This could lead to defects in the tissues that rely 
heavily on these proteins, such as the lung. Interestingly, the gut is also dependent on mucin 
synthesis.412 Although preliminary investigation of gut histology in P0 mice did not identify any 
changes in PAS signal, a careful analysis of gut mucin production should be included in future 
characterizations of this mouse. Another possibility is that decreased Tars1 activity reduces global 
protein translation by triggering phosphorylation of eIF2α. This might affect cells with a high 
demand for protein translation, such as differentiating stem cells. For example, if aging hair follicle 
stem cells cannot properly translate the proteins required for differentiation, this may explain a 
failure to regrow hair in the adult Tars1R433H/F538Kfs*4. These possibilities are further discussed in 
Chapter 5. 
 
Overall, research described in this Chapter has demonstrated the efficacy of using a tiered model 
organism approach to predict the pathogenicity of TARS1. Although it is still unclear whether 
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variants in TARS1 can cause dominant peripheral neuropathy, the lessons learned from studying 
G541R TARS1 will pave the way for future iterations of this process. Additionally, this work 
provides a template for predicting the pathogenicity of any ARS gene that has not yet been 
implicated in dominant or recessive disease, and for building the appropriate model systems to 
further investigate the mechanisms of these dominant or recessive phenotypes. 
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Chapter 4  
Testing Neuropathy-Associated AARS1 Alleles for a Dominant-




Hereditary peripheral neuropathies are a group of phenotypically and genetically heterogeneous 
clinical phenotypes. These diseases are characterized by decreased sensory and/or motor neuron 
function in the distal extremities. This leads to sensory loss and muscle atrophy, which often 
begins in the feet and lower leg muscles and may progresses to include the hands and forearms 
of the upper extremities.285 If a genetic peripheral neuropathy is restricted to impaired motor 
neuron function, it is classified as distal hereditary motor neuropathy (dHMN).295 If the 
symptoms include both sensory and motor neuron dysfunction, it is classified as Charcot-Marie-
Tooth (CMT) disease.285 CMT disease can arise from a primary defect in the myelinating 
Schwann cells of the peripheral nervous system, which is classified as CMT Type I.287 These 
defects are usually caused by mutations in genes that are important for myelin production or 
function, such as PMP22, which encodes a critical component of the myelin sheath; mutations in 
PMP22 account for over half of CMT disease cases.430 Alternately, CMT disease can be caused 
by a primary defect in the axon of the peripheral neuron, classified as CMT Type 2. The most 
common form of CMT Type 2 is caused by mutations in MFN2, which accounts for 20-30% of 
CMT Type 2 cases.431 Like ARS genes, MFN2 is a ubiquitously expressed, essential gene 
required for a basic cellular function (mitochondrial fusion).290 Peripheral neurons are thought to 
be particularly sensitive to defects in MFN2, because mitochondrial function is required across 




Mutations in five aminoacyl-tRNA synthetases have been linked to dominant peripheral 
neuropathies: alanyl-(AARS1),106 histidyl-(HARS1),174 glycyl-(GARS1),160 tryptophanyl-
(WARS1),264 and tyrosyl-(YARS1) tRNA synthetases.432 In addition, methionyl-tRNA synthetase 
(MARS1) variants have been identified in patients with CMT disease216; however, there is not 
convincing genetic evidence for pathogenicity of these MARS1 alleles. It remains to be seen how 
many additional ARS genes will be implicated in dominant peripheral neuropathy. Defining the 
locus and allelic heterogeneity of this disorder will be critical both for patient diagnosis and 
defining disease mechanisms. 
 
As discussed in Chapter 1, bi-allelic ARS variants that reduce enzyme function cause recessive 
disorders that are early-onset and that affect multiple tissues.68,377 In some cases, the 
constellation of recessive phenotypes includes peripheral neuropathy,126,433,222 demonstrating that 
peripheral neurons are sensitive to reduced ARS function. However, this reduction of ARS 
function is likely greater than 50%, because heterozygosity for a null ARS allele is not sufficient 
to cause a highly penetrant peripheral neuropathy—null alleles are not found in CMT patient 
populations, but are found in individuals who, to the best of our knowledge, are unaffected. 
Additionally, mice that are heterozygous for a Gars null allele do not develop a peripheral 
neuropathy.69 Based on all of these observations, haploinsufficiency is unlikely to be the disease 
mechanism for ARS-associated dominant neuropathy. 
 
The pathogenic ARS variants linked to dominant peripheral neuropathy are exclusively missense 
mutations or small in-frame deletions; the absence of frameshift alleles and premature stop 
codons indicate that an expressed mutant protein is required for pathogenicity. It is possible that 
these missense alleles act as neomorphs, exposing novel binding interfaces that facilitate aberrant 
protein interactions and lead to dysregulated neuronal pathways (Section 1.3.5). However, if 
there is a common mechanism to explain the role of all five ARS enzymes implicated in 
dominant neuropathy, it is unlikely that all mutations will cause the same neomorphic 
interaction. Rather, any common mechanism would likely be related to the shared canonical role 
in tRNA charging. 
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One notable commonality is that all five enzymes function as homodimers in the cytoplasm. This 
raises the possibility of a dominant-negative mechanism, in which decreased function of the 
mutant subunit reduces the function of the wild-type subunit in the dimeric holoenzyme; this 
would lower the overall ARS activity in the cell below 50%. A dominant-negative mechanism 
requires: 1) the mutant allele to reduce protein function, 2) the mutant allele to be stably 
expressed, and 3) the mutant allele to interact with the wild-type allele, repressing its function. 
This mechanism is supported by an abundance of data showing that the majority of neuropathy-
associated ARS variants reduce enzyme activity.110,176,307,170,171,264,434 Pathogenic variants also do 
not appear to affect the abundance of ARS protein detected in patient cells,170,301,333,347 nor do 
they abolish dimerization176,264,300,350432; these observations are also consistent with a dominant-
negative mechanism. Furthermore, models have shown that pathogenic ARS variants impair 
protein translation,264,306,350 which is consistent with the expected decrease in tRNA charging 
resulting from a dominant-negative effect. However, no study has adequately, explicitly 
addressed a dominant-negative mechanism for ARS-related dominant neuropathy. Addressing 
this question will test for a unifying mechanism of disease for all five implicated dimeric ARS 
enzymes. It will also provide a relevant framework to assess the pathogenicity of newly 
identified variants in patients with ARS-related CMT disease.  
 
Here, we generated a yeast model to test human AARS1 variants for a dominant-negative effect. 
We focused on well-characterized alleles in two critical domains of the enzyme: the anti-codon 
binding domain (R329H)106 and the amino acid activation domain (G102R).109 We found that 
R329H and G102R AARS1, as well as three additional AARS1 variants, are dominantly toxic to 
yeast growth when co-expressed with wild-type AARS1. We then engineered a dimer-disrupting 
variant in the C-terminal domain and expressed it in cis with the pathogenic AARS1 variants. 
These double-mutants rescued the impaired yeast growth, demonstrating that the dominant 
toxicity of mutant AARS1 is dependent on dimerization with wild-type AARS1, and that these 
AARS1 variants can be classified as dominant-negative (or antimorphic) alleles.  
 
The author performed all experiments presented in this Chapter, with the important exception of 
assessing R326W, R329C, and R329S AARS1 for a dominant-negative effect (Figures 4.9 and 
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4.10), which was performed by Sheila Marte. Additionally, Dr. Mike Shy and Shawna Feely 
contributed clinical and genetic information on four additional individuals with AARS1 variants.  
 
4.2 Materials and methods 
 
4.2.1 Yeast complementation and dominant toxicity assays 
All yeast assays were performed using the ptetO7-ALA1 strain from the Yeast Tet-Promoters 
Hughes Collection (YSC1180-202219317, Horizon Discovery). AARS1 variants were generated 
using site-directed mutagenesis (Agilent QuikChange II XL Site-Directed Mutagenesis Kit) 
against the AARS1 open reading frame in pDONR221 (primer sequences found in the Appendix 
A). All clones were verified via Sanger sequencing to ensure that the desired mutation was 
generated and that no amplification errors were present. The Gateway cloning (Invitrogen) LR 
reaction was used to recombine the wild-type or mutant AARS1 locus into pAG425GAL-ccdB 
(Addgene #14153), which is a Gateway-compatible vector with a 2-micron origin of replication 
that produces a high vector copy number, a GAL1 promoter to drive high expression of the target 
gene in a galactose-inducible fashion, and a LEU2 auxotrophic marker.  
 
To assess the function of AARS1 variants independent of wild-type AARS1, a p413 vector 
(ATCC #87370) with no AARS1 insert (‘Empty’) was introduced into ptetO7-ALA1 using lithium 
acetate yeast transformation. The p413 vector contains a ADH1 promoter to drive constitutive 
expression of the target gene, a centromeric origin of replication to produce a low plasmid copy 
number per cell, and a HIS3 auxotrophic marker for selection. This transformation was followed 
by pAG425 expressing wild-type or mutant AARS1. Colonies were grown on media lacking 
histidine and leucine (DO Supplement -His/-Leu, Takara Bio) to select for the presence of both 
vectors. After transformation, colonies were grown in 2mL liquid media in a 14mL round-
bottom conical tube (Fisher Scientific) for two days at 30°C, shaking at 275 rpm until saturated. 
Yeast were then diluted to 1:10, 1:100, and 1:1000 in water. 10µl of serial dilutions were spotted 
on plates containing glucose, galactose/raffinose (Takara Bio Minimal SD Bases), or 
galactose/raffinose with 10µg/ml doxycycline (Fisher Scientific BP26531). Plates were imaged 
after four days of growth. 
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To assess the dominant toxicity of AARS1 variants in the presence of wild-type AARS1, Gateway 
Cassette C (Invitrogen) was cloned into the p413 vector just downstream of (3’ to) the ADH1 
promoter using the SmaI restriction site, then sequence verified to confirm correct orientation. 
The LR Gateway reaction was used to recombine wild-type AARS1 from pDONR221 into p413. 
This construct was transformed into the ptetO7-ALA1 strain, followed by AARS1 (wild-type or 
mutant) in the pAG425 vector. Yeast were grown and spotted as detailed above. 
Complementation and dominant toxicity assays were performed side-by-side with the same 
pAG425 plasmid aliquots to enable direct comparisons.  
 
4.2.2 Yeast protein isolation 
The ptetO7-ALA1 strain was transformed with mutant AARS1 in pAG425 and grown on media 
lacking leucine (DO Supplement -Leu, Takara Bio). One colony was picked and placed into 3mL 
media and grown for 2-3 days shaking at 275rpm at 30°C until saturated, reaching an optical 
density (OD600) of approximately 2. Yeast were then centrifuged at 1000xg for 10 minutes, 
washed once with water, transferred to a 1.5mL Eppendorf tube, then centrifuged at 15,000 rpm 
for 1 minute. The supernatant was removed and the pellet was stored at -80°C. The pellet was 
thawed in 150µl yeast lysis buffer (50mM Na-HEPES pH 7.5, 100mM NaOAc, 1mM EDTA, 
1mM EGTA, 5 mM MgOAc, 5% glycerol, 0.25% NP-40, 3 mM DTT) with 1X Halt Protease 
Inhibitor Cocktail (Thermo Fisher Scientific). Approximately 100µl of 0.5mm cold glass beads 
(Biospec Products) were added to each sample. Samples were vortexed at 4°C for three minutes, 
followed by two minutes resting on ice, followed by three additional minutes of vortexing at 
4°C. To remove the lysate from the beads, a 26-gauge needle (BD PrecisionGlide) was used to 
make a hole in the bottom of the 1.5mL tube, which was then immediately inserted into a 14mL 
round bottom conical tube. Lysates were centrifuged at 200xg at 4°C for 5 minutes. The lysates 
were collected from the bottom of the conical tube and transferred to a 1.5mL Eppendorf tube, 
then were centrifuged at 13,200 rpm for 5 minutes at 4°C. Supernatants were collected for 
measurement using the Thermo Scientific Pierce BCA Protein Assay kit, and 50µg of protein per 
sample was analyzed by Western blot (see below). 
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4.2.3 Co-immunoprecipitation of wild-type AARS1 and mutant AARS1 
The LR Gateway reaction was used to recombine the wild-type or mutant AARS1 open reading 
frame from pDONR221 into pDEST40 (Thermo Fisher Scientific) or pTM3xFLAG (gift from 
Moran Laboratory, University of Michigan). These vectors allowed differential tagging of the 
mutant and wild-type AARS1 alleles; wild-type AARS1-3xFLAG was expressed from 
pTM3xFLAG using a CMV promoter, and either wild-type or mutant AARS1-6xHis was 
expressed from pDEST40 using a CMV promoter. 100mm plates (Falcon) were seeded with 1.5-
2 million HEK293T cells; the following day, these were transfected with 0.5pmol plasmid using 
Lipofectamine 3000 (Invitrogen). 48 hours after transfection, cells were harvested using Trypsin-
EDTA (Gibco, Fisher Scientific) and centrifuged at 2000rpm for 2 minutes at 4°C. Cells were 
then washed once with 1X PBS (Thermo Fisher Scientific), centrifuged again (as above), and 
then resuspended in 1mL lysis buffer (20mM Tris-HCl pH 8, 137mM NaCl, 2mM EDTA, 
1%NP-40, 0.25% sodium deoxycholate) with 1X Halt Protease Inhibitor Cocktail (Thermo 
Fisher Scientific) for 2 hours rocking at 4°C. Samples were then centrifuged for 15 minutes at 
13,200 rpm at 4°C. The supernatant was collected and protein concentration was measured using 
the Thermo Scientific Pierce BCA Protein Assay kit.  
 
To conjugate beads with individual antibodies, 25µl of Dynabeads Protein G (Fisher Scientific) 
were aliquoted per sample. All immunoprecipitations were performed using a MagnaRack 
(Invitrogen). Each aliquot was washed twice with 500µl Conjugation Buffer (0.5% BSA, 0.1% 
Triton X-100 in PBS), then suspended in 500µl Conjugation Buffer with 2µg 6xHis antibody 
(abcam 18184) or 2µg FLAG antibody (BioLegend 637302). Beads and antibody were incubated 
overnight rocking at 4°C. 
 
Prior to immunoprecipitation, lysates were pre-cleared to remove any proteins with non-specific 
affinity for the magnetic beads. An additional 25µl of Dynabeads per sample was aliquoted and 
washed once with lysis buffer. Then, 1mg of cell lysate in 500µl lysis buffer was added to the 
beads and rocked at 4°C for two hours. Supernatant from the antibody-conjugated beads was 
then removed, and the pre-cleared lysates were added. Samples were incubated for 3 hours 
rocking at 4°C. For anti-6xHis IPs, samples were washed four times with 1mL High Salt Buffer 
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(10mM Tris-HCl pH 7.5, 400mM NaCl, 1 mM EDTA, 1mM EGTA, 0.5% NP-40). For anti-
FLAG IPs, samples were washed three times with 1mL Low Salt Buffer (10mM Tris-HCl pH 
7.5, 137mM NaCl, 1 mM EDTA, 1mM EGTA, 0.5% NP-40). On the last wash, samples were 
moved to fresh 1.5 mL tubes to prevent co-elution of proteins bound to the tube walls. Samples 
were re-suspended in 50µl wash buffer with 50µl 2x Tris Glycine Buffer (Invitrogen). 4µl BME 
was added before samples were boiled at 99°C for 5 minutes and the supernatant was collected 
for Western blot (see below). Samples were divided in half and loaded in duplicate for 
immunoblotting with anti-AARS1, anti-6xHis, or anti-FLAG. 
 
4.2.4 Disuccinimidyl suberate crosslinking experiments 
To determine the degree of AARS1 dimerization in patient cells, AARS1 protein was crosslinked 
with disuccinimidyl suberate (DSS) and analyzed by Western blot. Patient and control fibroblasts 
were grown at 37°C in 5% CO2 and standard growth media (DMEM supplemented with 10% 
FBS, 2mM L-glutamine, 100U/mL penicillin, and 50ug/mL streptomycin [Invitrogen]). 
Approximately 1 million cells were harvested from each sample with Trypsin-EDTA (Gibco, 
Fisher Scientific) and centrifuged at 2,000 rpm for 2 minutes at 4°C. They were then washed 
once with 1X PBS (Thermo Fisher Scientific), transferred to a 1.5mL tube, and centrifuged again 
(as above). Cells were then re-suspended in 50mM HEPES 0.5% NP-40. The sample was 
divided in two, and 50mM DSS (Thermo Fisher Scientific) was added to one aliquot to a final 
concentration of 5mM. Both aliquots were incubated at room temperature for 30 minutes. The 
crosslinking reaction was then quenched with a final concentration of 30mM TrisCl pH 7.5 at 
room temperature for 15 minutes. Samples were centrifuged at 13,200 rpm for 10 minutes at 
4°C, and the supernatant was collected for Western blot analysis (see below). 20µg protein was 
analyzed for each sample. AARS1 antibody (Bethyl Laboratories A303-473A) was used at a 
dilution of 1:500. 
 
4.2.5 Co-immunoprecipitation of wild-type ALA1 and wild-type AARS1 
To investigate an interaction between yeast ALA1 and human AARS1, co-immunoprecipitation 
experiments were performed. First, the endogenous yeast ALA1 coding sequence was amplified 
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from a previously published107 pDONR221 clone with or without a C-terminal 6xHis tag 
encoded in the reverse primer (see primer sequences in Appendix A). Then, Gateway cloning 
was used to recombine these constructs into p413 (see above). The ptetO7-ALA1 strain was 
transformed with p413 to express either 6xHis-tagged or untagged ALA1, then subsequently 
transformed with pAG425 to express either R329H or G757* human AARS1. Colonies were 
grown for 2-3 days until saturated in -leu -his liquid glucose growth medium, then washed in 
water and re-suspended in 125-250mL -leu -his galactose liquid culture (Takara Bio Minimal SD 
Bases, Takara Bio DO Supplement -His/-Leu). Cultures were grown to saturation, then 
centrifuged at 1000xg at 4°C for 20 minutes. Yeast were washed with water and aliquoted evenly 
into 4-5 1.5mL tubes, where they were centrifuged at 15,000 rpm for 1 minute. The supernatant 
was removed, and pellets were stored at -80°C. The pellets were thawed in Yeast Lysis Buffer 
(50mM Na-HEPES pH 7.5, 100mM NaOAc, 1mM EDTA, 1mM EGTA, 5 mM MgOAc, 5% 
glycerol, 0.25% NP-40, 3 mM DTT) with 1X Halt Protease Inhibitor Cocktail (Thermo Fisher 
Scientific). Approximately 100µl of buffer was used for each 100mg of pellet. Cells were lysed 
using the methods detailed above (Section 4.2.2). 
 
25µl of Dynabeads Protein G (Fisher Scientific) were prepared for each of the samples. Beads 
were washed twice with 500µl Conjugation Buffer (0.5% BSA, 0.1% Triton X-100 in PBS), then 
re-suspended in 500µl buffer and 2µg anti-AARS (ab226259). Beads and antibody were 
incubated overnight rocking at 4°C. Yeast cell lysates were pre-cleared before 
immunoprecipitation: 25µl of magnetic beads were aliquoted and washed once with lysis buffer, 
before 2mg of yeast lysate in a total of 500µl lysis buffer was added. Samples were rocked at 
4°C for 1 hour. The supernatant was then removed from antibody-conjugated beads and replaced 
with the pre-cleared lysates. These were rocked for 2.5 hours at 4°C. After incubation, they were 
washed once with 500µl lysis buffer, once with 200µl lysis buffer, and then re-suspended in 
100µl lysis buffer before being transferred to a fresh 1.5mL Eppendorf tube. The supernatant 
was then removed, and beads were suspended in 25µl lysis buffer and 25µl 2x Tris Glycine 
Buffer (Invitrogen). Samples were boiled for 5 minutes with 2µl BME, and supernatants were 
removed to analyze in western blot assays.  
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4.2.6 Western blot analyses 
To assess the levels of specific proteins in each experiment we performed western blot analyses. 
Protein concentrations for each sample were measured using the Thermo Scientific Pierce BCA 
Protein Assay kit. Samples were prepared with 1X Novex Tris-Glycine SDS sample buffer 
(Invitrogen) and 2-mercaptoethanol (BME), and boiled at 99°C for 5 minutes. Protein samples 
were separated on precast 4-20% Novex Wedgewell Tris-glycine gels (Invitrogen) at 150V for 1 
hour and 15 minutes. PVDF membranes (Millipore Sigma) were pre-washed in 100% methanol 
for 1 minute, then soaked in 1X transfer buffer (Invitrogen) and 10% methanol between two 
pieces of filter paper (Thermo Fisher Scientific). The separated protein samples were transferred 
to the PVDF membranes using a Mini Trans-Blot Electrophoretic Transfer Cell (Biorad) at 100V 
for 1 hour. Membranes were then blocked for 1 hour with a 5% milk powder solution in 1X 
TBST. Primary antibodies were applied in 5% milk powder and membranes were incubated by 
rocking overnight at 4°C. The following day, membranes were washed three times with 1X 
TBST. Secondary antibodies against mouse (for the 6xHis primary antibody and PGK1 primary 
antibody), rabbit (for the AARS1 primary antibody and actin primary antibody), or rat (for the 
FLAG primary antibody) (Licor) were diluted in 5% milk powder solution at a concentration of 
1:20,000, along with 0.1% Tween-20 and 0.02% SDS. This solution was applied to membranes 
for one hour, rocking at room temperature. Membranes were then washed three times with 1X 
TBST before exposure using a Licor Odyssey CLx Imaging System. 
 
For yeast protein and HEK293T co-immunoprecipitation experiments, the AARS1 antibody 
(Bethyl Laboratories A303-473A) was used at 1:1,000 dilution. For fibroblast DSS assays, the 
same AARS1 antibody was used at 1:500 dilution. For HEK293T and yeast co-
immunoprecipitation experiments, the 6xHis antibody (abcam 18184) was used at a dilution of 
1:3,000. The FLAG antibody (BioLegend 637302) was used at a 1:2,500 dilution. The loading 
control was actin (Sigma A5060, 1:5,000) for mammalian protein blots and PGK1 (ab113687, 
1:3,000) for yeast protein blots. For co-immunoprecipitation studies of AARS1 and ALA1, the 
AARS1 antibody used was ab226259 at 1:500. Full length images of western blots are available 





4.3.1 Pathogenic AARS1 alleles suppress yeast cell growth in the presence of wild-type AARS1 
Yeast complementation assays have been successfully used to assess the effect of ARS variants 
on gene function.307 However, yeast have not been used to determine the effect of ARS variants 
in the presence of the wild-type allele, which is important for defining the mechanism of 
dominant ARS-related neuropathy. To investigate the dominant toxicity of AARS1 variants, we 
developed an assay to assess the combined effects of human wild-type AARS1 and human mutant 
AARS1 on yeast viability, using the ptetO7-ALA1 strain. In this strain, the yeast AARS1 ortholog, 
ALA1, is placed under control of a doxycycline-repressible promoter.435 This strain was 
transformed with: (1) a low-copy number, centromere-bearing vector (p413) containing a wild-
type AARS1 allele; and (2) a high-copy number vector (i.e., bearing a 2 micron origin of 
replication) with a galactose-inducible promoter (pAG425) directing high levels of expression of 
a mutant AARS1 allele (Figure 4.1B). Although this does not reflect the approximately equal 
allelic expression in human cells, we expect that high levels of mutant AARS1 are required to 
detect a dominant toxic effect in yeast cells, which are less likely to be sensitive to defects in 
AARS1 than a human peripheral nerve axon. To test mutant AARS1 alleles for a dominant toxic 
effect, yeast cells were grown in the presence of galactose (to express mutant AARS1) and 
doxycycline (to repress endogenous ALA1). Subsequent yeast growth was then solely dependent 
on the two forms of human AARS1: one wild-type and one mutant. 
 
To evaluate neuropathy-associated AARS1 variants for a dominant-negative effect, we focused 
on two well-characterized pathogenic AARS1 variants, R329H and G102R. R329H is a recurrent 
mutation in the tRNA binding domain that has been identified in 9 families with CMT disease 
(Table 2.1). It affects a highly conserved residue, and significantly impairs AARS1 enzymatic 
function when assessed in an in vitro aminoacylation assay that evaluates enzyme activity under 
Michaelis-Menten conditions.107 The G102R variant affects a highly conserved residue in the 
activation domain of AARS1 and was found in a family with dominant myeloneuropathy. Both 
G102R109 and R329H107 have been modeled at conserved codons in the yeast ortholog ALA1, and 




Figure 4.1. Yeast expression of human wild-type or mutant AARS1. 
 
(A) Cartoon of the AARS1 protein structure, with the junction between the editing domain (blue) 
and the C-terminal domain (pink) magnified. A chromatogram illustrates the five base pair 
insertion introduced at this junction to create a premature stop codon, G757*. This insertion also 
shifts the open reading frame to generate another stop codon 13 amino acids downstream. (B)  
Western blot of yeast protein lysates, from yeast expressing: an empty p413 vector or wild-type 
AARS1 from p413 (left); wild-type or mutant AARS1 from pAG425 (right). The top blot was 
probed with an antibody against AARS1, and the bottom with an antibody against the yeast 
housekeeping gene PGK1. Full-length AARS1 is predicted to migrate at 107kDa. The lower 
band likely corresponds to a downstream open-reading frame beginning at M44, which is 
predicted to produce a 102kDa AARS1 protein. A representative image from four biological 
replicates is shown 
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any dominant-negative properties of these variants from a purely loss-of-function effect, we also 
generated a premature stop codon, G757* (Figure 4.1A), which does not generate detectable 
levels of AARS1 protein (Figure 4.1B). Therefore, it is expected to be a loss-of-function allele 
that does not exert dominant-negative effects. This is a more precise negative control than an 
empty vector because it includes the AARS1 coding sequence, meaning yeast transformed with 
the G757* allele must replicate and express an almost identical vector as yeast expressing the 
G102R or R329H alleles. 
 
To confirm that R329H and G102R are loss-of-function alleles when tested in the human AARS1 
coding sequence, ptetO7-ALA1 yeast were first transformed with an empty p413 vector, then 
with either wild-type or mutant human AARS1 expressed from the GAL1 inducible promoter on 
pAG425. When plated on galactose and doxycycline, yeast expressing G757* did not form 
colonies (Figure 4.2A), indicating that yeast cannot grow without ALA1 expression or functional 
AARS1. Transformation with wild-type AARS1 lead to robust yeast growth, confirming that wild-
type AARS1 can complement loss of ALA1. Neither G102R AARS1 nor R329H AARS1 
supported yeast growth (Figure 4.2A), confirming previous reports that these are loss-of-function 
alleles.107,109  
 
To test for dominant toxicity, ptetO7-ALA1 yeast cells were transformed with wild-type AARS1 
on the low-copy p413 vector, then with wild-type or mutant AARS1 on the high-copy, glactose-
inducible pAG425 vector. Transformed strains were spotted on galactose (to induce expression 
from the pAG425 vector) and doxycycline (to repress ALA1 expression). The combination of 
wild-type AARS1 and G757* AARS1 supported growth, as did the combination of the two wild-
type AARS1 plasmids (Figure 4.2B). Importantly, over-expressing the G757* variant—a loss-of-
function AARS1 allele that does not lead to detectable protein (Figure 4.1B)—does not interfere 
with yeast growth. Similarly, over-expressing wild-type human AARS1 does not interfere with 
yeast growth. In contrast, the combination of wild-type AARS1 with G102R AARS1, and the 
combination of wild-type AARS1 with R329H AARS1, both caused significantly reduced yeast 
growth (Figure 4.2B). This demonstrates that these alleles are not only loss-of-function but also 
dominantly toxic to yeast cell growth, even in the presence of wild-type AARS1. This toxicity is 





Figure 4.2. G102R and R329H AARS1 are loss-of-function, dominantly toxic alleles in 
yeast. 
 
(A) Images of yeast strains expressing an empty p413 vector and (plated left to right) G757*, 
wild-type, G102R, or R329H AARS1 from a galactose-inducible, high copy number vector 
(pAG425). The top panel shows yeast spotted in 1:10 serial dilutions on glucose media lacking 
histidine and leucine. The bottom panel shows yeast spotted in 1:10 serial dilutions on galactose 
and raffinose media lacking histidine and leucine, with 10µg/mL doxycycline.  (B) Images of 
yeast strains expressing wild-type AARS1 from p413, a low copy number vector with an ADH1 
promoter. These strains also express (plated left to right) G757*, wild-type, G102R, or R329H 
AARS1 from pAG425. The top panel shows 1:10 serial dilutions on glucose media lacking 
histidine and leucine. The bottom panel shows 1:10 serial dilutions on galactose and raffinose 
media lacking histidine and leucine, with 10µg/mL doxycycline. For both (A) and (B), 13 (for 





Figure 4.3. ALA1 interacts with R329H AARS1. 
 
(A) Images of yeast strains expressing an empty p413 vector and G757*, wild-type, G102R, or 
R329H AARS1 from pAG425. (B) Representative images of yeast strains expressing a wild-type 
AARS1 from p413 and G757*, wild-type, G102R, or R329H AARS1 from pAG425. For (A) and 
(B), strains are spotted in 1:10 serial dilutions on galactose and raffinose media lacking histidine 
and leucine. These plates do not contain doxycycline to repress ALA1 expression. 13 (for 
G102R) or 16 (for R329H) biological replicates were performed. (C) Western blot of yeast lysate 
from strains expressing R329H or G757* AARS1, with 6xHis-tagged ALA1 or untagged ALA1 
(left). To the right, a western blot of immunoprecipitated AARS1 and co-immunoprecipitated 
ALA1-6xHis. Primary antibodies include anti-AARS1, anti-6xHis, and anti-PGK1 as the Input 
loading control. A representative image from two technical replicates is shown. 
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the dominant toxicity associated with R329H and G102R AARS1 is due to reduced alanine-tRNA 
charging. Interestingly, ALA1 does not fully rescue the toxicity of R329H. This may be related to 
the observation that human R329H AARS1 interacts with wild-type yeast; immunoprecipitation 
of R329H AARS1 co-immunoprecipitates 6xHis-tagged ALA1 (Figure 4.3C). This interaction is 
consistent with R329H AARS1 acting as a dominant-negative allele against ALA1. 
 
4.3.2 Pathogenic AARS1 variants do not significantly reduce dimerization 
The data presented in Figure 4.2 demonstrate that the pathogenic, loss-of-function G102R and 
R329H AARS1 variants are dominantly toxic to yeast cell growth; however, this experiment does 
not distinguish between a dominant-negative effect and some gain-of-function toxicity unrelated 
to AARS1 function. To directly test for a dominant-negative effect, we first investigated if 
mutant AARS1 dimerizes with wild-type AARS1. Ultracentrifugation analyses have 
demonstrated that isolated mutant ARS proteins retain homo-dimerization176,300,350; however, no 
studies have addressed hetero-dimerization between the AARS1 mutant and wild-type subunits. 
To address this, HEK293T cells were transfected with a vector expressing wild-type human 
AARS1 with an in-frame 3xFLAG tag, and a vector expressing wild-type or mutant AARS1 
(G102R or R329H) with an in-frame 6xHis tag (Figure 4.4A). After growth for 48 hours, cells 
were lysed and AARS1-6xHis was immunoprecipitated. Co-immunoprecipitated proteins were 
subjected to a western blot with an anti-FLAG antibody to detect AARS1-3xFLAG. The 
reciprocal immunoprecipitation was also performed, by immunoprecipitating AARS1-3xFLAG 
and immunoblotting for AARS1-6xHis. Both approaches detected comparable interactions 
between wild-type and wild-type, wild-type and G102R, and wild-type and R329H (Figure 4.4B 
and 4.4C). To assess dimerization of endogenous AARS1 in patient cells, fibroblasts from a 
patient heterozygous for R329H AARS1 were crosslinked with disuccinimidyl suberate (DSS), 
along with two independent control fibroblast cell lines. In untreated lysates (-DSS), AARS1 is 
detected between 100 and 130 kDa. In DSS-treated lysates, there is an additional band that 
migrates between the 130kDa and 250kDa markers, consistent with a dimeric AARS1 protein 
(Figure 4.5A). The percentage of AARS1 in dimeric form was not significantly different 






Figure 4.4. R329H and G102R do not impair dimerization with wild-type AARS1. 
 
(A) (Top) Cartoon of plasmid expressing wild-type AARS1 tagged with 3xFLAG and plasmid 
expressing wild-type or mutant AARS1 tagged with 6xHis. (Bottom) Western blot of HEK293T 
cells expressing wild-type AARS1-3xFLAG and/or wild-type, G102R, or R329H AARS1-6xHis. 
(B) Western blot demonstrating immunoprecipitation of 6xHis-tagged AARS1 protein and co-
immunoprecipitation of 3xFLAG-tagged wild-type AARS1. Five biological replicates were 
performed for R329H; three biological replicates were performed for G102R. (C) Western blot 
demonstrating immunoprecipitation of 3xFLAG-tagged wild-type AARS1 and co-
immunoprecipitation of 6xHis-tagged wild-type, G102R, or R329H AARS1. Two biological 
replicates were performed for both G102R and R329H. Primary antibodies include anti-FLAG, 






Figure 4.5. Chemical crosslinking of AARS1 in patient fibroblast cells. 
 
(A) Western blot of fibroblast lysates from a R329H/+ AARS1 individual and two +/+ controls. 
Lysates were crosslinked with DSS treatment (+DSS) or left untreated (-DSS), then separated on 
a gel and probed with an anti-AARS1 antibody. An image of the full blot is shown. (B) The 
percentage of AARS1 signal corresponding to the dimeric form of AARS1, quantified with 
ImageJ. The mean and standard deviation of four technical replicates is shown. Unpaired t-tests 
with Welch’s correction were performed to determine if there was a statistically significant 
difference between R329H/+ cells and either of the two wild-type controls. ns = not significant.  
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AARS1 proteins retain the ability to dimerize with wild-type AARS1, which is required for a 
dominant-negative effect. 
 
4.3.3 Designing dimer-disrupting AARS1 variants 
A dominant-negative mechanism for ARS variants requires an interaction between the wild-type 
and mutant subunits of the homodimer. Therefore, if neuropathy-associated AARS1 alleles 
function via a dominant-negative effect, placing a dimer-disrupting variant in cis with a 
dominant pathogenic variant should impair its ability to bind to the wild-type subunit. This 
should alleviate the dominant-negative effect and, in yeast, rescue the impaired growth. To 
identify dimer-disrupting variants, a series of deletions were designed in the C-terminal 
dimerization domain based on the published crystal structure.30 These engineered deletions 
targeted amino acids that have multiple contacts with the opposite subunit (Figure 4.6A, left). 
This series comprised a seven amino acid deletion to encompass several contact points 
(∆KNVGCLQ) as well as smaller deletions within or near this region for a more targeted 
approach (∆NVG and ∆QE). This series also included a deletion of C947, a cysteine residue that 
forms a putative disulfide bond with C773 on the opposite subunit30. Finally, a stop codon at 
Q855 was designed to ablate the entire terminal globular domain (Figure 4.6A, right). The panel 
of putative dimer-disrupting AARS1 alleles were cloned into the pAG425 vector and transformed 
into the ptetO7-ALA1 yeast strain, then tested for their ability to support yeast growth in a 
complementation assay, with the expectation that dimerization is required for AARS1 function.  
 
None of the deletions fully complemented loss of ALA1, indicating that they all reduce AARS1 
function, consistent with impaired dimerization and/or decreased protein expression (Figure 
4.6B). To distinguish between these two possibilities, each allele was also evaluated for an effect 
on AARS1 expression. The ∆NVG allele lead to no detectable AARS1 protein, providing an 
explanation for its failure to complement in yeast. The C947 deletion significantly reduced 
AARS1 expression (Figure 4.6C) but still showed partial complementation in yeast, indicating 
that the C947 residue may be more important for stability than for AARS1 function. The deletions 
∆KNVGCLQ and ∆QE also reduced AARS1 expression (Figure 4.6C) and lead to less yeast 





Figure 4.6. Designing and testing a deletion series in AARS1 dimerization domain. 
 
(A) (Left) Crystal structure of the AARS1 C-terminal dimerization domain. One subunit is 
shown in green, the other in purple. Amino acid residues that contact the opposite subunit are 
shown in dark green or dark purple. The residues targeted in this assay are shown in pink and 
labeled. (Right) Illustration of the dimerization domain with the Q855* mutation. The dashed 
circles indicate the globular domain that is ablated by the premature stop codon. (B) Yeast strains 
expressing the negative control G757* AARS1, the positive control WT AARS1, or each of the 
five deletions designed in the dimerization domain. Yeast are spotted in 1:10 serial dilutions on 
galactose and raffinose media lacking leucine, with 10µg/mL doxycycline. A representative 
image of four biological replicates is shown. (C) Western blot of yeast lysates from each of the 
dimerization deletion strains. Yeast were grown in galactose and raffinose media lacking leucine, 
with no doxycycline. Blots were treated with anti-AARS1 antibody or anti-PGK1 antibody. A 
representative image of three biological replicates is shown. 
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protein abundance. Only the globular domain deletion Q855* produced a loss-of-function protein 
with no detectable decrease in protein levels. This made it an ideal candidate to test for reduced 
dimerization. Overall, these data demonstrate that the dimerization domain of AARS1 is 
important for both the stability and the function of the protein, indicating that AARS1 must form 
a homodimer to successfully charge tRNA.   
 
To test if Q855* reduces binding to wild-type AARS1, HEK293T cells were transfected with 
wild-type AARS1-3xFLAG and either wild-type or Q855* AARS1-6xHis (Figure 4.7A). 
Immunoprecipitation of wild-type AARS1-6xHis co-precipitated wild-type AARS1-3xFLAG, 
indicating an interaction between the two tagged wild-type subunits (Figure 4.7B). However, 
immunoprecipitation for Q855* AARS1-6xhis did not co-precipitate wild-type AARS1-3xFLAG 
(Figure 4.7B), indicating that the Q855* truncation reduces binding to the wild-type AARS1 
protein. These findings were supported by performing the reciprocal experiment. Here, 
immunoprecipitation of wild-type AARS1-3xFLAG co-immunoprecipitated wild-type AARS1-
6xhis (Figure 4.7C). However, wild-type AARS1-3xFLAG did not co-immunoprecipitate Q855* 
AARS1-6xhis (Figure 4.7C).  These data demonstrate that the engineered Q855* AARS1 variant 
reduces interactions with wild-type AARS1 and confirms that the C-terminal globular domain is 
required for dimerization.   
 
4.3.4 Reducing the dimerization capacity of pathogenic AARS1 alleles rescues yeast growth 
If G102R or R329H AARS1 reduce yeast growth through a dominant-negative mechanism, then 
impairing their ability to dimerize with wild-type AARS1 should rescue yeast growth. To test 
this, the Q855* mutation was introduced in cis with either G102R or R329H using site-directed 
mutagenesis. These double mutants were then cloned into pAG425 and transformed into the 
ptetO7-ALA1 strain. Both G102R+Q855* AARS1 and R329H+Q855* AARS1 produced a stable, 
truncated AARS1 protein (Figure 4.8A). Complementation assays studying G102R+Q855* 
AARS1 and R329H+Q855* AARS1 in the presence of an empty p413 vector showed no yeast 
growth, consistent with the double-mutants acting as loss-of-function alleles (Figure 4.8B). 
These alleles were then tested in the presence of wild-type AARS1 expressed from the p413 




Figure 4.7. Q855* AARS1 impairs dimerization with wild-type AARS1. 
 
(A) (Top) Cartoon of plasmid expressing wild-type AARS1 tagged with 3xFLAG and plasmid 
expressing wild-type or Q855* AARS1 tagged with 6xHis. (Bottom) Western blot of HEK293T 
cells expressing wild-type AARS1-3xFLAG and/or wild-type or Q855* AARS1-6xHis. (B) 
Western blot showing immunoprecipitation of 6xHis-tagged AARS1 protein and co-
immunoprecipitation of 3xFLAG-tagged wild-type AARS1. ImageJ quantification of anti-FLAG 
band intensity is shown above. Bars indicate the mean value and one standard deviation for 3 
biological replicates. (C) Western blot showing immunoprecipitation of 3xFLAG-tagged wild-
type AARS1 protein and co-immunoprecipitation of 6xHis-tagged AARS1. ImageJ 
quantification of anti-6xHis band intensity is shown above. Bars indicate the mean value and one 
standard deviation for 3 biological replicates. For (A)-(C), primary antibodies include anti-
FLAG, anti-6xHis, anti-AARS1 and anti-actin as the Input loading control. Unpaired t-tests were 
performed to determine if the difference in band intensity between samples was statistically 




Figure 4.8. Reducing dimerization of G102R and R329H with wild-type AARS1 rescues 
yeast growth. 
 
(A) Western blots of yeast lysates from yeast expressing the negative control G757* AARS1, the 
positive control WT AARS1, G102R AARS1 alone or in cis with Q855*, or R329H AARS1 alone 
or in cis with Q855*. Yeast were grown in galactose and raffinose media lacking leucine, with 
no doxycycline. Representative images were selected from three biological replicates. Blots were 
treated with anti-AARS1 antibody and anti-PGK1 antibody as a loading control. (B) Yeast 
strains expressing an empty 413 vector and wild-type or mutant AARS1 from pAG425. (C) 
Yeast strains expressing wild-type AARS1 from p413, and wild-type or mutant AARS1 from 
pAG425. For (B) and (C), strains were spotted in a 1:10 dilution on galactose and raffinose 
media lacking histidine and leucine, with 10µg/mL doxycycline. Representative images from 8 
biological replicates are shown. 
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yeast growth, and both G102R AARS1 and R329H AARS1 repressed yeast growth. However, 
placing Q855* in cis with either G102R or R329H AARS1 ameliorated the phenotype and 
rescued growth. This rescued growth was comparable to the growth of yeast expressing the non-
toxic control alleles G757* or wild-type AARS1 (Figure 4.8C). These in vivo data demonstrate 
that disrupting the dimerization of G102R or R329H AARS1 with wild-type AARS1 is sufficient 
to rescue the dominant toxic phenotype, and shows that this phenotype is a result of mutant 
AARS1 dimerizing with wild-type AARS1. In sum, our yeast and biochemical data provide 
evidence that neuropathy-associated AARS1 alleles are loss-of-function variants that dominantly 
repress yeast growth through dimerization with the wild-type subunit; i.e. that they act via a 
dominant-negative mechanism. 
 
4.3.5 The AARS1 anticodon-binding domain is susceptible to dominant-negative mutations 
R329H AARS1 is a high-confidence pathogenic allele, as it has been identified in at least 46 
individuals across 9 families with dominant peripheral neuropathy (Table 2.1). This includes a 
newly identified family comprising three individuals, all with dominant axonal Charcot-Marie-
Tooth disease (Table 4.1). Therefore, characterizing R329H as a dominant-negative allele 
suggests that a dominant-negative effect is a relevant component of pathogenicity. If other 
AARS1 alleles with less robust genetic evidence—such as G102R—also have a dominant-
negative effect, this increases the likelihood that they too are pathogenic. To apply this 
dominant-negative assay to other AARS1 alleles, we first focused on a set of variants at the R329 
residue and the surrounding region. This includes R326W, a loss-of-function variant identified in 
a multi-generational family with CMT,110 and R329S, a recently identified variant in a patient 
with axonal neuropathy (Table 4.1). Interestingly, previous work by McLaughlin et al. identified 
a high degree of cytosine methylation in this area, making these nucleotides susceptible to 
cytosine deamination. This study predicted numerous missense variants that could arise from 
such CàT changes, including R326W and R329S, which have now both identified in 
individuals with dominant peripheral neuropathy.107 McLaughlin et al. also predicted that 
cytosine deamination could lead to the mutation R329C. Therefore, in addition to the now-
confirmed patient alleles, we included R329C in our functional studies with the hypothesis that it 
will be ultimately be identified in CMT patients. The R326W, R329S, and R329C variants were  
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Table 4.1. Clinical information of four additional patients with AARS1-mediated dominant peripheral neuropathy. 
 
Patient 




























































4.4 24 23 0.323 NR NR NR 
75292-







Normal Normal Normal 3.2 39 42 9.3 5.4 39 5.4 
75292-





Normal Normal Normal 2.9 49 50 8 4.5 43 4.9 
75292-







Normal Normal Normal 3.2 45 55 10.1 4.8 41 5.6 
 
CMTNS=CMT Neuropathy Score, LL=lower limb, UL=upper limb, DML=distal motor latency (upper limit of normal is 3.4 
milliseconds for the ulnar nerve and 3.5 milliseconds for the median nerve), NCV=nerve conduction velocity (lower limit of normal is 
49 or 50 meters per second for the ulnar nerve and 48 meters per second for the median nerve), CMAP = compound muscle action 
potential (lower limit of normal is 2.8 millivolts for the ulnar nerve and 3.5 for the median nerve). NR=no recording. 
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introduced into the AARS1 open reading frame with site-directional mutagenesis, then cloned 
into the galactose-inducible pAG425 expression vector and transformed into the ptetO7-ALA1 
yeast strain. G757* AARS1, R329H AARS1, and wild-type AARS1 were included as controls. To 
demonstrate that only pathogenic AARS1 alleles have a dominant toxic effect, G931S AARS1, a 
benign polymorphism found in the general population (with a gnomAD allele count of 
2,147/282,842, including 20 homozygous individuals334), was included as a negative control. As 
previously reported,110 R326W did not support yeast growth in the absence of ALA1 (Figure 
4.9A, top panel). Consistent with the functional importance of this region, R329S and R329C 
also did not support yeast growth (Figure 4.9A, top panel). G931S AARS1 supported yeast 
growth comparable to yeast expressing wild-type AARS1. These variants were then tested in the 
presence of the wild-type AARS1 allele expressed from p413. Similar to R329H and G103R, 
R326W, R329C, and R329S AARS1 repressed yeast growth compared to G757*, wild-type, or 
G931S AARS1 (Figure 4.9B, top panel). This shows that these three alleles also exert a dominant 
toxic effect. Notably, as was the case for G102R and R329H, this growth defect was improved 
when strains were plated on media with no doxycycline, which restores endogenous ALA1 
expression (Figure 4.9 A and B, bottom panels). This supporting the argument that the repressed 
growth phenotype is due to an alanine-tRNA charging defect.  
 
To determine if the toxicity of these alleles depends on their ability to dimerize with wild-type 
AARS1, the dimer-disrupting Q855* variant was introduced in cis with R326W, R329S, and 
R329C. These double-mutant alleles were transformed into yeast expressing wild-type AARS1 
from p413, and plated on galactose and doxycycline to express the double-mutant AARS1 allele 
and repress endogenous ALA1. Q855* rescued the yeast growth phenotype for all three variants 
(Figure 4.10B, top panel), indicating that R326W, R329S, and R329C exert their dominantly 
toxic effect through dimerization—i.e., they are also dominant-negative alleles. In sum with 
G102R and R329H, these experiments present convincing evidence that dominant pathogenic 






Figure 4.9. R326W, R329C, and R329S AARS1 are dominantly toxic to yeast. 
 
(A) Yeast strains expressing an empty 413 vector and wild-type or mutant AARS1 from 
pAG425. The blue asterisks indicates the spot is diluted at 1:10,000; the orange asterisk indicates 
the spot is diluted at 1:1,000 (B) Yeast strains expressing wild-type AARS1 from p413, and wild-
type or mutant AARS1 from pAG425. For top panels of (A) and (B), strains were spotted in a 
1:10 dilution on galactose and raffinose media lacking histidine and leucine, with 10µg/mL 
doxycycline.  For bottom panels of (A) and (B), strains were spotted in a 1:10 dilution on 
galactose and raffinose media lacking histidine and leucine, with no added doxycycline to 




Figure 4.10. Reducing dimerization of R326W, R329C, or R329S AARS1 with wild-type 
AARS1 rescues yeast growth. 
 
(A) Yeast strains expressing an empty 413 vector and wild-type or mutant AARS1 from 
pAG425. (B) Yeast strains expressing wild-type AARS1 from p413, and wild-type or mutant 
AARS1 from pAG425. Blue asterisks indicate a spot is diluted at 1:10,000; orange asterisks 
indicate a spot is diluted at 1:1,000. For top panels of (A) and (B), strains were spotted in a 1:10 
dilution on galactose and raffinose media lacking histidine and leucine, with 10µg/mL 
doxycycline.  For bottom panels of (A) and (B), strains were spotted in a 1:10 dilution on 






Here, we present a humanized yeast assay to study the dominant toxicity of CMT-associated 
AARS1 alleles. We demonstrate that multiple pathogenic, loss-of-function AARS1 variants 
repress yeast growth when co-expressed with the wild-type AARS1 allele, indicating that they are 
dominantly toxic. We also show that these variants retain the ability to dimerize with the wild-
type AARS1 protein, and that disrupting this interaction by deleting critical dimerization 
residues from the mutant protein is sufficient to rescue the repressed yeast growth. This provides 
strong evidence that these pathogenic AARS1 alleles can act via a dominant-negative mechanism 
to repress the activity of wild-type AARS1. 
 
An important consideration when interpreting results from this model is that the allelic 
expression is intentionally skewed, with the pathogenic allele over-expressed relative to the wild-
type one. This does not accurately reflect the approximately equal expression in human tissues; 
therefore, any dominant-negative effects in patients are likely to be much weaker than those 
demonstrated here, and less likely to have such significant consequences for cell viability. 
However, this would be more consistent with the patients’ late-onset and tissue-restricted 
phenotype. A terminally differentiated peripheral neuron that must maintain local protein 
translation far from the soma may be particularly susceptible to even mild dominant-negative 
effects of an ARS mutation. To fully determine if a dominant-negative effect drives dominant 
AARS1-mediated peripheral neuropathy, a knock-in animal model (e.g., mouse or worm) with an 
axonal pathology is required. Then, a dimer-disrupting variant such as Q855* can be introduced 
in cis with the pathogenic allele to determine if this ameliorates the neuronal phenotype. 
 
It will also be important to adapt this dominant-negative yeast model to study other pathogenic 
variants in not only AARS1, but in GARS1, HARS1, YARS1, and WARS1. We hypothesize that 
these alleles will also produce dominant-negative effects, because these genes also encode homo-
dimeric ARS enzymes (Table 1.1). Although there has been recent debate30,348 as to whether 
AARS1 functions as a dimer or a monomer, the results of our study demonstrate that it functions 
as a dimer. The C-terminal dimerization domain (beginning at G757) that was previously 
reported to be dispensable for aminoacylation in vitro30 is likely required for AARS1 stability in 
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vivo; truncating the protein at this residue leads to undetectable levels of AARS1 protein when 
expressed in yeast cells. Furthermore, the globular domain beginning at Q855*, while not 
required for protein stability in yeast or mammalian cells, is required for AARS1 dimerization 
and for AARS1 complementation in yeast, suggesting that dimerization is required for AARS1 
function in vivo. Finally, chemically crosslinked AARS1 from human fibroblast cells is detected 
at two molecular weights, one corresponding to a monomeric form and one corresponding to a 
dimeric form. In total, these data indicate that the dimerization domain is necessary for AARS1 
function. 
 
Although we hypothesize that dominant-negative effects will be a common theme for dominant 
pathogenic ARS variants, it is possible that this is only one component of the disease 
mechanism. For instance, there are rare exceptions to the loss-of-function pattern seen in patient 
alleles—the E337K AARS1 variant increases rather than decreases AARS1 function, despite its 
proximity to dominant-negative anticodon-binding domain alleles.110 It will be important to 
carefully reconsider the genetic evidence for the pathogenicity of E337K AARS1, as well as to 
assess it for a similar dominant-toxicity in yeast. If E337K is dominantly toxic in this system, 
comparing protein translation in yeast expressing E337K AARS1 to protein translation in yeast 
expressing R329H AARS1 may provide insights into the pathogenic mechanism of E337K, as 
discussed in Section 5.2.1.  
 
It is important to point out that dominant-negative and gain-of-function effects are not mutually 
exclusive as causes for ARS-related neuropathy. Indeed, these two mechanisms may work in 
concert to exacerbate neuronal pathology. A recent study showed that the pathogenic AARS1 
variants N71Y, G102R, and R329H each cause a conformational change that enables binding to 
Neuropilin-1,348 a widely expressed receptor that modulates a variety of signaling pathways, 
which is critical for neurovascular development.362 However, although such an interaction might 
compound the damage in patient neurons, our yeast model proves that a neuronal-specific (or 
mammalian-specific) interaction is not required to make G102R or R329H toxic to cells.  
 
To the best of our knowledge, there have been few yeast systems developed to test human 
pathogenic variants for a dominant-negative effect; notable examples include reporter assays to 
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test for dominant-negative p53 mutations436,437 and enzymatic evaluation of yeast expressing 
dominant-negative UDP-galactose4-epimerase (GALE) alleles.346,438 Here, we describe a 
tractable yeast model for rapidly evaluating patient variants in aminoacyl-tRNA synthetase genes 
for a dominant-negative effect. This system is likely applicable beyond aminoacyl-tRNA 
synthetases, and should be considered when evaluating dominant-negative patient variants in any 
essential, highly conserved human gene.  
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Chapter 5  




Aminoacyl-tRNA synthetases (ARSs) are a family of enzymes that ligate tRNA to cognate 
amino acids, forming a critical substrate for protein translation. Research over the past two 
decades has implicated ARS-encoding genes in dominant and recessive human disease 
phenotypes. Due to their essential function, the complete loss of an ARS-encoding gene is 
incompatible with cellular life. However, bi-allelic ARS mutations that significantly decrease 
enzymatic function (but do not ablate it) cause a wide array of complex human phenotypes; 
partial loss of mitochondrial ARS function causes severe mitochondrial disorders, and partial 
loss of cytoplasmic ARS function causes multisystem disorders that can include central nervous 
system pathologies, liver failure, interstitial lung disease, and global developmental delay.68 The 
full range of genotypes and phenotypes for these recessive disorders is not yet fully defined. It is 
also unclear how reduced ARS function impacts protein translation and cellular health, or why 
some tissues seem to be more sensitive to mutations in certain ARS genes than others (for 
example, why variants in MARS1 predominantly cause lung phenotypes210).  
 
In addition to recessive diseases, there is strong genetic evidence to implicate five ARSs—
AARS1, GARS1, HARS1, YARS1, and WARS1—in dominant disease, which is restricted to axonal 
peripheral neuropathies. All five genes encode cytoplasmic, homodimeric enzymes (GARS1 also 
acts in the mitochondria).13 Mutations in these genes cause motor and/or sensory neuron 
degeneration that leads to muscle wasting in the distal extremities, which usually begins in 
adolescence or adulthood. Moving forward, it will be important to determine if other ARS genes 
can also cause dominant neuropathy or if there is something unique about the five loci already 
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implicated. This will be critical for improving patient diagnosis and may also provide insight into 
common disease mechanisms. For example, if the remaining homodimeric ARS enzymes—but 
no monomeric ones—are found to cause dominant peripheral neuropathy, this would suggest 
dimerization is required for the molecular pathology and support a dominant-negative disease 
mechanism. In parallel to gene discovery, it will be important to build appropriate disease 
models to directly test mechanistic hypotheses in vivo. This dissertation work addressed several 
of these objectives; the results are summarized below. 
 
5.1.1 Summary of Chapter 2 
In Chapter 2, we evaluate novel ARS variants for a role in recessive or dominant disease. These 
variants are often discovered through diagnostic exome sequencing, and it can be difficult to 
obtain a complete family history and ascertain if the variant segregates with disease. In this 
context, determining the variant’s impact on protein function contributes to determining 
pathogenicity. To assess patient variants in GARS1, HARS1, MARS1, NARS1, and TARS1, yeast 
complementation assays were performed using the human coding sequence of each gene. Here, 
the endogenous yeast ARS gene is effectively replaced with the human ARS. If the growth of 
yeast carrying the patient allele is reduced compared to the growth of yeast carrying the wild-
type human ARS, this indicates that the patient variant impairs gene function. 
 
Variants in GARS1, HARS1, MARS1, and NARS1 were identified in individuals with dominant 
peripheral neuropathies. In yeast complementation assays, these variants reduced yeast viability, 
indicating that they impaired gene function. This is consistent with the pattern of impaired 
function seen across most dominant ARS alleles,68,307 and supports the argument that these 
variants are pathogenic. This work expands the spectrum of pathogenic variants in GARS1 and 
HARS1, and in the case of NARS1, contributes towards implicating an additional homodimeric 
ARS in dominant peripheral neuropathy. However, some of the loss-of-function variants—
specifically, M236del NARS1, S356N HARS1, and A397T MARS1— have limited genetic 




In Chapter 2, we also investigate bi-allelic variants in MARS1 and TARS1, which were identified 
in patients with multisystem recessive diseases. Only one of two MARS1 alleles (detected in 
trans) significantly decreased yeast growth compared to wild-type. However, yeast 
complementation assays often cannot detect mild hypomorphic alleles. Moreover, because the 
patient phenotype was highly consistent with the established lung-predominant MARS1 
phenotype, it is likely that both MARS1 variants are pathogenic in this individual. Similarly, only 
one of the four tested TARS1 alleles reduced yeast growth. Since the individual is homozygous 
for this allele, it is likely that this deleterious variant is pathogenic. The other three TARS1 alleles 
require additional experiments in a more sensitive assay to resolve their role in disease. 
 
5.1.2 Summary of Chapter 3 
In Chapter 3, we describe a model organism pipeline to predict the pathogenicity of novel 
variants in a homodimeric ARS that had not been associated with disease—TARS1. A panel of 
mutations in TARS1 was designed to affect highly conserved residues, then tested for reduced 
function in a yeast complementation assay. Loss-of-function mutations were then prioritized for 
testing in C. elegans. Over-expression of G541R tars-1 caused GABA-ergic neuron defects, 
similar to those caused by known pathogenic HARS1 or AARS1 alleles. However, these neuronal 
defects were not recapitulated when G541R was knocked into the endogenous tars-1 locus. 
 
To determine if G541R TARS1 causes a peripheral neuropathy in a mammalian system, this 
variant was edited into the mouse Tars1 gene. Tars1G541R/+ mice were evaluated at 2 months, 5-6 
months, and 1 year of age. Although there were behavioral indications of neuromuscular defects, 
these were not reproducible, and nerve conduction amplitudes and velocities were normal. 
Western blots from mouse brain lysate showed that Tars1 abundance was decreased in 
Tars1G541R/+ mice compared to Tars1+/+ littermates, suggesting that G541R Tars1 is not fully 
stable. This likely accounts for the absence of neuromuscular phenotypes in these mice. There 
are also broader limitations in modeling an axonal length-dependent phenotype in mice. Mice 
have shorter peripheral neurons than humans, and might require an over-expression of toxic 
protein to produce a phenotype. Overall, experiments assessing TARS1 for a role in dominant 
peripheral neuropathy were inconclusive. 
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An additional loss-of-function allele, R433H TARS1, was identified in the initial yeast 
complementation assays. This allele partially supported yeast growth, indicating that it is 
hypomorphic. R433H was not dominantly toxic when over-expressed in C. elegans neurons, but 
did lead to gross phenotypic differences when edited into the endogenous tars-1 locus. 
Homozygous R433H/R433H tars-1 worms were significantly developmentally delayed and had 
locomotion defects. This indicated that R433H was a candidate for studying recessive 
phenotypes in a mammalian model, because it reduced protein function enough to produce a 
phenotype, but not enough to be lethal. This variant was generated in mouse Tars1 using 
CRISPR-Cas9 editing. Tars1R433H/R433H mice were grossly normal, and were mated to mice that 
were heterozygous for a null Tars1 allele (F538Kfs*4). One striking phenotype of 
Tars1R433H/F538Kfs*4 mice was a high incidence of neonatal mortality. Histopathology of these 
pups found that they had no air in their lungs, a thinner dorsal epidermis, and follicular 
hypoplasia. Tars1R433H/F538Kfs*4 mice that survived past this stage lived to adulthood, but were 
smaller than their Tars1R433H/+ littermates. They also showed hair loss in consistent patterns on 
their heads and upper backs, beginning at 13 weeks old. This is particularly interesting in light of 
recent reports identifying bi-allelic TARS1 mutations in patients with trichothiodystrophy, a 
disorder marked by brittle hair. This mouse model will be a valuable resource for future work 
studying the consequences of reduced Tars function across different cell types and tissues, 
particularly in the lung and hair. 
 
5.1.3 Summary of Chapter 4 
Implicating an additional homodimeric ARS, like TARS1, in dominant peripheral neuropathy is 
one way to strengthen the argument for a dominant-negative mechanism. Another is to test a 
dominant-negative effect directly, as demonstrated in Chapter 4. Here, a standard yeast 
complementation assay was adapted to introduce both mutant and wild-type ARS into the cell 
and test their combined effect. This Chapter focused on two dominant pathogenic variants in 
AARS1, G102R and R329H. Both variants repressed yeast growth when co-expressed with wild-
type AARS1. Both variants also retained the ability to interact with wild-type AARS1, as 
determined by co-immunoprecipitation studies in HEK293T cells. To reduce this interaction, a 
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truncation mutation, Q855*, was designed in the dimerization domain. This mutation failed to 
support yeast growth, but still produced a stably expressed protein. It also significantly reduced 
dimerization with wild-type AARS. When this mutation was modeled in cis with G102R or 
R329H, the repressed yeast growth phenotype was fully rescued, demonstrating that the 
dimerization between the loss-of-function protein and the wild-type protein was responsible for 
the reduced growth. This provides direct evidence that G102R and R329H can act as dominant-
negative alleles. This assay was expanded to assess additional variants in the anti-codon binding 
domain (R326W, R329S, and R329C), all of which similarly behaved as dominant-negative 
alleles. 
 
In summary, this dissertation work made several important contributions to the field of ARS-
mediated disease. Through assessing patient variants for loss-of-function effects, and through 
designing a model organism pipeline to implicate novel ARS in mammalian phenotypes, this 
work expanded the known locus, allelic, and phenotypic heterogeneity of ARS-mediated disease. 
It also directly tested the hypothesis that pathogenic ARS alleles act through a dominant-negative 
mechanism, demonstrating that pathogenic AARS1 variants are dominant-negatives in a yeast 
cell. The development of this assay creates substantial opportunities to explore a dominant-
negative effect as a common mechanism of pathogenic ARS alleles, as discussed below.  
 
The author is the primary contributor to this Chapter. Matthew Pun and Molly Kuo assisted with 
the computational analysis of the yeast proteome. 
 
5.2 Future Directions 
 
Among the many remaining questions pertaining to ARS-mediated disease, there are two of 
particular interest: 1) What is the mechanism of dominant ARS-mediated peripheral neuropathy, 
and 2) How does reduced function of a ubiquitously expressed housekeeping gene affect certain 




We propose that dominant ARS variants act through a dominant-negative mechanism, which 
reduces the collective amount of functional ARS protein in the cell.  The large majority of 
pathogenic ARS variants are missense mutations that have been shown to decrease protein 
function, but do not impair protein stability. (The only ARS variant with multiple lines of 
evidence demonstrating that function is not reduced is discussed below in Section 5.2.1.) 
Importantly, the only five ARS genes with strong genetic evidence of dominant pathogenicity all 
function as homodimers. These lines of evidence are all consistent with a mechanism in which a 
mutant subunit of the dimer compromises the activity of the wild-type subunit. In this model, 
only the dimers comprising two wild-type subunits can charge enough tRNAs to meet the protein 
synthesis needs of the cell, which is insufficient in sensitive cells like peripheral neurons. In 
Chapter 4, we present evidence that five AARS1 alleles have a dominant-negative effect in yeast. 
This is a promising start to testing a broadly applicable dominant-negative mechanism of disease. 
To strengthen this argument, additional pathogenic variants in AARS1, as well as GARS1, 
YARS1, HARS1, and WARS1 need to be tested in this system. Demonstrating that pathogenic 
alleles across these five genes can have a dominant-negative effect in yeast would provide strong 
evidence that this is a common characteristic of disease alleles and as such, would suggest that a 
dominant-negative effect is relevant to the mechanism. Furthermore, if a dominant-negative 
effect that leads to reduced tRNA charging is a common mechanism, then similar loss-of-
function alleles in other cytoplasmic, homodimeric ARS are also candidates for dominant 
peripheral neuropathy.  Defining this mechanism will allow us to predict the allelic spectrum of 
dominant pathogenic alleles in these genes. 
 
ARS enzymes are ubiquitously expressed house-keeping proteins required in every cell. It is 
currently unknown why mutations in these genes can give rise to more severe phenotypes in 
some tissues than others. In the case of dominant disease, the phenotype is restricted to the 
peripheral nervous system. This may reflect the fact that these neurons are uniquely long, 
terminally differentiated, and perform protein synthesis at synapses far from the soma.439 As 
such, they might be uniquely sensitive to a decrease in ARS function caused by a dominant-
negative allele. In the case of recessive disorders, significantly reduced function of ARS activity 
broadly causes neurological phenotypes. However, some tissues are particularly sensitive to 
decreased function of particular ARS genes (for example, the lung is most predominantly 
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affected in patients with MARS1 and FARSB mutations145,210). We propose that this may be due 
to the production of critical proteins in these tissues that have a high requirement for the amino 
acid corresponding to the affected synthetase. In this model, decreased availability of the 
required charged tRNA may have an outsized impact on the synthesis of those critical proteins. 
Testing this hypothesis requires a model of ARS-mediated recessive phenotypes with 
specifically affected tissues, such as the compound heterozygous Tars1 mouse described in 
Chapter 3.  
 
5.2.1 Extended analysis of dominant-negative AARS1 alleles 
We have developed a yeast complementation assay that can be used to study both loss-of-
function and dominant-negative characteristics of AARS1 variants. This presents the opportunity 
to comprehensively evaluate all known pathogenic AARS1 alleles and to define the downstream 
consequences of these alleles for cellular health. These studies should be pursued with three 
major aims: (1) test additional dominant AARS1 alleles for a dominant-negative effect, (2) 
delineate the differences between loss-of-function dominantly toxic and loss-of-function non-
toxic AARS1 alleles, and (3) define the impact of hypomorphic and dominantly toxic AARS1 
variants on protein translation.  
 
First, additional AARS1 variants found in patients with dominant peripheral neuropathy should 
be assessed for a dominant-negative effect. These include N71Y and S627L, two variants that 
have been previously shown to reduce enzymatic function.107,110 This is an also an opportunity to 
test two variants that have not yet been functionally evaluated, D893N112 and E688G.111 These 
additional variants segregate with dominant peripheral neuropathy in small pedigrees and affect 
highly conserved residues (E668 is conserved between humans and bacteria, and D893 is 
conserved between humans and fruit flies).112,111 (Incidentally, using human AARS1 for this 
yeast assay allows residues that are not conserved to yeast, like D893, to be evaluated). If any of 
these additional AARS1 alleles are dominantly toxic when co-expressed with wild-type AARS1, 
they can then be placed in cis with Q855* to determine if decreasing dimerization improves 
yeast growth (this test does not apply to D893N, which would be cut off by the Q855* 
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truncation). Identifying additional dominant-negative AARS1 alleles would provide strong 
evidence of a loss-of-function disease mechanism.  
 
Another possibility is that these variants may have no effect, or increase enzymatic activity like 
E337K AARS1. E337K AARS1 was identified in a small pedigree with five genotyped affected 
individuals and only one genotyped, unaffected individual.110 All affected individuals were 
heterozygous for E337K AARS1, while the one unaffected individual did not carry the 
mutation.110 The E337 residue is conserved between humans and fruit flies,110 and is absent from 
gnomAD.334. E337K increases yeast growth in a complementation assay and increases in vitro 
aminoacylation activity, acting as a hypermorph.110 E337K is the only neuropathy-associated 
ARS variant known to cause a gain of enzymatic function; as an outlier, it will be important to 
continue to strengthen the genetic argument for pathogenicity by identifying additional patients 
with this variant. 
 
To functionally investigate E337K AARS1 further, it will be informative to co-express it with 
wild-type AARS1 in yeast to determine if it causes a dominantly toxic effect. If so, there are at 
least two possible explanations. The first possibility is that exceeding cellular demands for 
changed tRNAAla is actually detrimental to protein translation. The availability of tRNA for a 
given codon determines ribosome speed.440 Codons corresponding to highly abundant tRNAs are 
translated faster than codons corresponding to lowly abundant tRNAs (rare codons).440,441 Local 
pauses or slow-downs in ribosomal speed can provide a chance for the polypeptide that is being 
translated to fold properly.441,442 These slow-downs are often found when translating across the 
domain boundaries of multi-domain proteins, allowing time for the independent folding of the 
previously translated domain.441 Silent mutations that alter translational speed by swapping a rare 
codon for a common one, or vice versa, can impact the folding and function of disease-
associated proteins.443 If E337K AARS1 increases the proportion of charged tRNAAla in the 
tRNA pool, it may disrupt these carefully coordinated translation dynamics by increasing the 
translation speed through alanine codons. This could disrupt the timing of co-translational 
protein folding and, for proteins with sensitive folding dynamics, may cause them to misfold and 
be targeted for degradation. Alternately, E337K AARS1 could cause a broader increase in protein 
misfolding, trigger protein aggregations and/or inducing the unfolded protein response pathway 
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in the endoplasmic reticulum, which would trigger PERK to phosphorylate eIF2α and induce a 
global repression of translation initiation through preventing the recycling of eIF2.351 
 
Alternately, E337K could cause aberrant interactions with some component of the protein 
translation machinery, resulting in similar decreases in protein translation. This interaction could 
be increased binding to tRNAAla, which could decrease the availability of free tRNA for wild-
type AARS1; in vitro aminoacylation studies found that E337K AARS1 exhibited a 5-fold 
decrease in Km for tRNA relative to wild-type AARS1, indicating increased affinity for tRNA.110 
However, this did not result in increased turnover (kcat for E337K was 0.4, compared to 0.6 for 
wild-type).110 This data indicate that E337K could be dominantly toxic through altering tRNA 
binding dynamics. Another possibility is that E337K AARS1 causes aberrant interactions with 
ribosomes or other components of the translation machinery, leading to impaired protein 
synthesis similar to dominant-negative alleles. To further investigate these possibilities, co-
immunoprecipitation studies should be performed with E337K AARS1 to investigate protein 
binding partners using mass spectrometry, or tRNA binding partners using either Northern blots 
hybridization or RNA-seq methods suitable for detecting tRNA.444 
 
Second, the yeast assay developed in this thesis should be applied to compare loss-of-function 
toxic AARS1 alleles and loss-of-function non-toxic AARS1 alleles. It is currently unclear what 
distinguishes these two types of variants. The heterozygous parents of individuals with recessive 
disease have not been reported to have a peripheral neuropathy, although most have not been 
clinically evaluated, and there may be undetected late-onset or sub-clinical phenotypes. One 
possibility is that recessive missense variants are destabilizing, which would mean that an 
otherwise dominantly toxic protein does not accumulate to sufficient levels to have a toxic effect. 
Indeed, decreased protein stability has been demonstrated for some variants—individuals who 
are compound heterozygous for I699T and C901Y AARS1, or for T726A and T756I AARS1 show 
a 60-80% reduction in total AARS1 protein.105 The G931D AARS1 variant also reduces AARS1 
levels; individuals with the G931D/+ AARS1 genotype express less AARS1 protein than +/+ 
individuals, and individuals with the G931D/Y690Lfs*3 AARS1 genotype express less AARS1 
protein than +/Y690Lfs*3 individuals.103 Another possibility is that recessive AARS1 variants 
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reduce dimerization with the opposite subunit. In this scenario, they might only cause a very 
mild dominant negative effect in heterozygous carriers, or no dominant-negative effect at all.  
 
To test these two hypotheses, a panel of recessive missense AARS1 alleles should be expressed in 
yeast to evaluate the total amount of AARS1 protein generated by each isolated allele. Any 
stable recessive variants should then be co-expressed with the wild-type allele in a dominant-
negative assay, with the hypothesis that only dominant—but not recessive—missense alleles will 
have a dominant-negative effect. If recessive variants do act as dominant-negative alleles, it is 
possible that: (1) the variant may be stably expressed in yeast cells but not in human cells, (2) the 
variant may only cause weakly dominant-negative effects in a human peripheral neuron that is 
not sufficient to cause peripheral neuropathy, or (3) individuals heterozygous for this variant do 
develop neuropathy that is late-onset, mild, and/or goes undetected. However, if stably expressed 
recessive variants do not act as dominant-negative alleles, they should be further investigated to 
determine if they reduce dimerization. Here, the most sensitive assay to use is 
ultracentrifugation, which has previously been used to study dimerization of GARS300 and 
HARS.176,350 
 
Finally, generating appropriate models of both dominant and recessive AARS1 alleles in yeast 
will allow us to define the impact of these variants on protein translation, as discussed below. 
Ideally, these studies should be performed with a hypomorphic recessive allele, a dominant-
negative allele like R329H (co-expressed with wild-type), and E337K (co-expressed with wild-
type). We would expect that a recessive allele and a dominant-negative allele would have similar 
effects on protein translation. This would also be an opportunity to test the hypotheses proposed 
for E337K by determining if it affects protein translation, or acts through some other mechanism. 
 
Loss-of-function pathogenic AARS1 alleles may impair protein synthesis by increasing the pool 
of uncharged tRNAAla in the cell. This is recognized by GCN2, stimulating its kinase function to 
phosphorylate eIF2α, which then prevents eIF2B from recycling GDP-eIF2 into GTP-eIF2.3 This 
prevents eIF2 from delivering initiator tRNAMet to the ribosome to begin protein translation.3 To 
determine whether this pathway is activated in yeast expressing pathogenic AARS1 alleles, yeast 
lysate should be evaluated via Western blot for an increase in eIF2α phosphorylation. If yeast 
 164 
expressing the pathogenic AARS1 alleles have increased eIF2α phosphorylation, this indicates 
that there is likely reduced protein synthesis in the cell. Here, we would expect that a 
hypomorphic AARS1 allele and a dominant-negative AARS1 allele would both increase eIF2α 
phosphorylation. If E337K causes widespread protein misfolding, as proposed above, it may also 
trigger eIF2α phosphorylation through the unfolded protein response pathway.351 Alternately, if 
E337K acts by causing localized protein misfolding, sequestering tRNA or aberrantly binding to 
other components of translation machinery, we would not expect to see an increase in eIF2α.  
 
Subsequent effects on global protein translation can be tested by treating yeast with puromycin, 
an aminonucleoside that can be incorporated into nascent peptides.445 After treatment, yeast are 
lysed and puromycin incorporation is measured with immunoblotting.445 Here, we would expect 
that a hypomorphic, recessive AARS1 allele and a dominant-negative AARS1 allele would both 
show a large decrease in puromycin incorporation. If E337K acts to repress protein synthesis 
(either by triggering the unfolded protein response, sequestering tRNA, or aberrantly binding to 
translation machinery), we would also expect it to show decreased puromycin incorporation. 
These observations, in tandem with the eIF2α phosphorylation, would show that the dominant-
negative AARS1 allele reduces protein translation similar to a recessive hypomorphic AARS1 
allele. These observations would also indicate that, although E337K is not a dominant-negative 
allele, it causes similar defects in protein translation, which would help identify a unifying 
cellular pathology. 
 
If AARS1 alleles do not show global reductions in protein synthesis, this may indicate that there 
are amino-acid specific defects in protein translation. In theory, reducing the amount of amino 
acid that is ligated to tRNAs should have an effect similar to starving the cell for that amino acid.  
Here, studies that decrease arginine availability304 or inhibit histidine biosynthesis446 have 
demonstrated that these amino acid restrictions cause ribosomes to stall at histidine or arginine 
codons, respectively. Therefore, we might expect cells expressing pathogenic loss-of-function 
AARS1 alleles to stall at alanine codons, which could be detected with ribosome sequencing. 
Here, we would expect that yeast expressing a hypomorphic recessive AARS1 allele and a 
dominant-negative AARS1 allele to show increased pile-up of ribosomes at alanine codons, 
relative to yeast expressing wild-type AARS1. Ribosome profiling may also be a high-resolution 
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approach to discern the mechanism of E337K. For example, if E337K decreases the amount of 
charged tRNAAla in the cell by inappropriately sequestering uncharged tRNAAla, we would 
expect to see an increase in ribosome stalling similar to the loss-of-function alleles. On the other 
hand, if E337K overproduces charged tRNAAla and interferes with ribosome kinetics, we would 
expect to see a decrease in ribosome abundance at alanine codons compared to the wild-type 
allele. In this case, the identity of transcripts with this decreased ribosome abundance should be 
further scrutinized to determine if there is a corresponding decrease in protein abundance. If 
AARS1 alleles do not cause detectable ribosome stalling, this may reflect either a global 
repression of protein synthesis through eIF2α phosphorylation, or rapid turnover of stalled 
ribosomes that cannot be detected by ribosome profiling. In this case, such experiments may 
need to be performed in a yeast background that lacks factors that can dissociate stalled 
ribosomes (Dom34, Hbs1, and Rli1).446 
 
If hypomorphic and dominant-negative AARS1 alleles cause ribosome stalling at alanine codons, 
we would expect yeast proteins with a high alanine content to be most affected. These proteins 
are primarily ribosomal proteins and cell wall proteins (Table 5.1). In lieu of commercially 
available antibodies for yeast cell wall proteins, these genes could be endogenously tagged to 
facilitate immunostaining and determine whether expressing AARS1 alleles decreases their 
abundance. Alternately, the fitness of the cell wall could be evaluated using stains such as 
calcofluor white, which produces greater signal when there is cell wall stress, or aniline blue and 
FITC-ConA, which stain for 1,3-β-glucan and mannoproteins, respectively.447 Here, we would 
expect a recessive AARS1 allele and a dominant-negative AARS1 to decrease cell wall integrity, 
which could contribute to decreased cell viability. In the case of E337K, if it acts to decrease the 
amount of charged tRNAAla in the cell, we would also expect to see impaired cell wall integrity. 
However, if it triggers misfolding of specific proteins, or global protein misfolding, we would 
not necessarily expect this to impact on cell wall proteins. 
 




Table 5.1. Alanine-rich proteins in S. cerevisiae. 
Name % alanine 
CWP2 Cell wall protein* 26 
HOR7 Hypo-osmolarity responsive protein 24 
RLA3 60S acidic ribosomal protein P1-beta 23 
PAU7 Seripauperin-7* 22 
CCW12 Covalently-linked cell wall protein 12* 22 
TIR3 Cell wall protein TIR3* 22 
DDR2 Protein DDR2 21 
FIT3 Facilitator of iron transport 3* 21 
RLA4 60S acidic ribosomal protein P2-beta 21 
TIR1 Cold shock-induced protein TIR1* 21 
RLA2 60S acidic ribosomal protein P2-alpha 21 
TIP1 Temperature shock-inducible protein 1* 20 
TIR2 Cold shock-induced protein* 20 
TOM6 Mitochondrial import receptor subunit 20 
RLA1 60S acidic ribosomal protein P1-alpha 19 
HS150 Cell wall mannoprotein HSP150* 18 
PIR3 Cell wall mannoprotein PIR3* 18 
ATP5E ATP synthase subunit epsilon, mitochondrial 18 
PAU5 Seripauperin-5* 17 
DAN1 Cell wall protein DAN1* 17 
PAU17 Seripauperin-17* 17 
RL13B 60S ribosomal protein L13-B 17 
LSO2 Protein LSO2 16 
PAU16 Seripauperin-16* 16 
PAU19 Seripauperin-19* 16 
PAU3 Seripauperin-3* 16 
 




The humanized yeast assay to detect dominant-negative alleles should next be expanded to 
assess pathogenic alleles in other dominant ARS disease genes. Here, the initial focus should be 
on variants with strong genetic evidence of pathogenicity, such as G240R160,448 and G526R449 in  
GARS1, T132I174 and D364Y174 in HARS1, D314G265 and H257R264 in WARS1, and G41R and 
E196K in YARS1.379275 For studies of HARS1, WARS1, and YARS1, yeast strains with a 
doxycycline-repressible promoter driving HTS1, WRS1, and TYS1 are available commercially 
from the Hughes Collection.435 Although such a strain does not exist for GARS1 studies, another 
graduate student in the Antonellis group, Sheila Marte, is currently working to replace the 
endogenous GRS1 promoter with a doxycycline-repressible promoter.  
 
The above neuropathy-associated ARS variants are loss-of-function alleles in homodimeric 
enzymes; therefore, we expect them to act as dominant-negative alleles when co-expressed with 
the respective wild-type gene, similar to the dominant-negative variants in AARS1. Interestingly, 
there is some preliminary evidence to suggest that G41R and E196K YARS1 show properties of 
dominant-negatives alleles when tested in yeast. When each variant was modeled in the yeast 
ortholog TYS1 and over-expressed in yeast with wild-type TYS1, they repressed yeast growth.275 
Similarly, yeast expressing wild-type TYS1 and G41R YARS1 grew slower than yeast expressing 
wild-type TYS1 and wild-type YARS1, or yeast expressing TYS1 and E196K YARS1.275 This 
could indicate that G41R YARS1 may also repress the endogenous TYS1, acting similar to R329H 
AARS1 (as discussed in Chapter 4).  
 
To conclusively determine that dominant toxicity is a result of a dominant-negative effect, as 
opposed to some other gain of function, it is necessary to reduce the dimerization of the mutant 
allele and determine if this rescues the phenotype. In the cases of GARS1 and YARS1, dimer-
reducing alleles have already been identified. The T209K GARS1 variant was identified as a 
recessive allele in zebrafish gars, and was shown to significantly reduce the percentage of 
dimeric gars in native western blots. Additionally, P167T YARS1, which causes a severe 
multisystem disease in the homozygous state, was shown to reduce binding to wild-type YARS1 
in co-immunoprecipitation assays.273 Identifying dimer-reducing variants in HARS1 and WARS1 
may be more challenging. Here, the published crystal structures of human WARS160 and human 
HARS141 will be valuable resources for identifying residues to target that could disrupt 
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dimerization. In these structures, the dimer interface is internal, and does not lend itself to large 
domain deletions. Alanine scanning may be the best approach, followed by yeast 
complementation assays and immunoblotting to identify loss-of-function, stably expressed 
alleles. Once these alleles have been identified, they can be tested for reduced binding to the 
wild-type protein using the co-immunoprecipitation approach described in Chapter 4.  
 
If multiple pathogenic variants across multiple ARS genes are shown to act as dominant-negative 
alleles, this would provide strong evidence that this is a relevant disease mechanism.  
Importantly, benign polymorphisms selected from gnomAD should be included in assessments 
for each of these genes, to demonstrate the specificity of a dominant-negative effect. These data 
would indicate that reduced ARS function is likely a central component of disease pathology, 
which would support previous observations of impaired protein translation in neuronal models of 
dominant ARS disease.306,350 Alternately, yeast may be more sensitive to reduced function of 
some ARS than others, and it may be difficult to detect dominant-negative effects for all variants 
in all ARS genes. It is also possible that some pathogenic ARS variants may have an alternative 
mechanism of action; if any variants cause dominant toxicity that is not rescued by reducing 
dimerization, this could provide an opportunity to explore other gain-of-function hypotheses, 
such as interference with other components of the translation machinery.   
 
5.2.3 Defining a panel of dominant-negative GARS1 alleles  
One goal of the Antonellis group is to use high-throughput techniques to identify all loss-of-
function variants in pathogenic ARS genes. This will circumvent the need to individually test 
patient variants for loss-of-function effects in yeast, which is not a feasible approach to assess all 
possible variants of uncertain significance. In collaboration with Jacob Kitzman’s group, a 
postdoctoral fellow in the Antonellis laboratory, Megan Forrest, is performing saturation genome 
editing on GARS1 in vitro to identify all variants that do not support cell growth. This work will 
provide novel insights into GARS1 biology, as well as help separate out benign variants and 
deleterious variants. However, as discussed previously, we do not expect all loss-of-function 
variants to be dominantly toxic, and as such, it will be difficult to differentiate between 
candidates for recessive disease and candidates for dominant disease. 
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Here, the yeast dominant toxicity assay can play a significant role. Any loss-of-function variants 
identified in GARS1 saturation genome editing should first be assessed for an effect on protein 
stability, using a flow-sorting method such as VAMP-seq450 that is amenable to testing a large 
library of variants. Then, a smaller panel of variants that are loss-of-function but stably expressed 
can be tested in the yeast dominant toxicity assay. Although this assay is low-throughput, this 
assay does have the advantage of being relatively inexpensive and quick. If mutagenesis and 
cloning were performed in a high-throughput fashion, then over 100 variants could be tested in 
1-2 months. The benefits of overlapping a yeast dominant toxicity assay with the saturation 
mutagenesis efforts are two-fold: (1) GARS1 variants that are loss-of-function but dominantly 
toxic will be pre-emptively defined, providing support for pathogenicity if they are identified in 
patients with dominant peripheral neuropathy, and (2) distinguishing loss-of-function, non-
dominant variants from loss-of-function dominant variants will yield greater insight into the 
mechanism of GARS1 pathogenicity. If both types of variants are mapped onto the GARS1 
crystal structure, this could also provide insights into the structural features that play a role in 
disease. 
 
5.2.4 Predicting dominant-negative alleles in additional homodimeric, cytoplasmic ARS 
Once the yeast dominant-negative assay has been appropriately validated for a series of 
pathogenic alleles in ARS genes already implicated in dominant neuropathy, this assay can then 
be used to predict and assess variants in ARS genes that have not yet been implicated in 
dominant disease, particularly other the five remaining homodimeric, cytoplasmic ARS (TARS1, 
CARS1, KARS1, DARS1, and SARS1). This could produce preliminary evidence that they are 
candidate genes for dominant peripheral neuropathy. This assay could be incorporated into the 
model organism prediction pipeline described in Chapter 2, to help prioritize candidate mutations 
for testing in worm and mouse. 
 
The above efforts should begin with TARS1; the appropriate yeast strain is available from the 
Hughes Collection435 and the crystal structure of TARS1 is available56 to inform careful design 
of loss-of-function mutations, as well as mutations that could decrease dimerization (a critical 
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part of demonstrating a dominant-negative effect, as discussed above). Currently, another 
graduate student in the Antonellis group, Allison Cale, is developing these tools. After designing 
TARS1 variants at conserved residues and testing them for impaired function, it will be important 
to assess the variant’s effect on protein stability. Then, the yeast dominant-negative assay can be 
used to identify the best candidates to test further, which may improve the likelihood that the 
selected variant is dominantly toxic to neurons in a multicellular organism.  
 
All of the remaining homodimeric ARS enzymes should also be evaluated in this system. Here, it 
would be helpful to begin with the ARS loci that include peripheral neuropathy as part of a 
recessive pathology. This might indicate that peripheral nerves are sensitive to decreased 
function of that ARS. This applies to patients with bi-allelic variants in cysteinyl-tRNA 
synthetase (CARS1)126 and lysyl-tRNA synthetase (KARS1).195 The remaining cytoplasmic, 
homodimeric enzymes are aspartyl-tRNA synthetase (DARS1) and seryl-tRNA synthetase 
(SARS1), which could be targeted next. For CARS1, KARS1, DARS1, and SARS1, yeast strains 
with a doxycycline-repressible promoter driving the respective ARS ortholog are commercially 
available435; however, any other methods of repressing endogenous yeast ARS function while 
over-expressing both mutant and wild-type human ARS would also be valid approaches.  
 
5.2.5 Detecting ARS dominant toxicity in cultured mammalian cells  
As the dominant-negative assay expands to additional ARS, it would be valuable to develop an 
orthogonal approach in human cell lines. This would obviate the need for developing and 
validating numerous yeast strains. A cell line should be selected with a single copy of the wild-
type ARS gene. HAP1 cells would be the most feasible and applicable across different ARS 
genes. (Alternately CRISPR-Cas9 editing could be used to reduce the number of functional ARS 
copies in multi-ploidal cell lines, including neuroblastoma cell lines that can be differentiated to 
harbor neurite projections.) Then, wild-type or mutant ARS expressed by a doxycycline-
inducible promoter could be transfected into the cell population, with a drug resistance cassette 
or GFP marker to select for the transfected population. Application of doxycycline to the cells 
would induce expression of wild-type or mutant ARS, and dominant toxicity would be measured 
by determining cell viability. This approach should first be validated with known pathogenic 
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dominant-negative alleles like R329H AARS1, but then could be expanded as a predictive assay 
for novel ARS loci and alleles. Moreover, because cell lines are more amenable to high-
throughput analysis of ARS loci, many variants could be assessed simultaneously. In this 
scenario, comparing the frequency of alleles before and after doxycycline induction would allow 
identification of the alleles that were dominantly toxic and reduced cell viability. In combination 
with saturation genome editing, this approach could be a high-throughput assay to differentiate 
between loss-of-function, dominantly toxic alleles and loss-of-function, non-toxic alleles, as 
discussed above for GARS1.  
 
5.2.6 Defining the requirement for threonyl-tRNA synthetase in the mouse lung and hair follicle 
The experiments proposed above would significantly advance our understanding of the allelic 
spectrum of dominant ARS-mediated disease, as well as the mechanism of disease. We predict 
that mild to moderate impairment of protein synthesis, caused by reduction in any population of 
charged tRNA, specifically impacts the peripheral nervous system due to the long, terminally 
differentiated axons that perform local protein synthesis at synapses.439 This is in contrast to our 
proposed mechanism of ARS-mediated recessive disease, in which a greater reduction of ARS 
function causes severe impairment of protein synthesis, affecting numerous tissues across the 
body that have high protein translation demands. However, there are still outstanding questions 
as to why pathogenic variants in some ARS genes affect certain tissues more than others. For 
example, it is unclear why the lung is particularly sensitive to mutations in MARS1210, or why the 
liver is particularly sensitive to mutations in LARS.196 One hypothesis is that there are critical 
proteins in these tissues with a high requirement for a certain amino acid, and that such proteins 
are therefore particularly sensitive to reduced function of the corresponding ARS.   
 
The phenotypes of the TarsR433H/F538Kfs*4 mouse (Section 3.3.12) may provide some clues. One of 
the most striking phenotypes was premature death at P0. Histopathology of these mice showed 
that there was no air present in the alveoli, indicating that mice either died in utero or upon birth. 
There was also an absence of PAS+ club cells in the bronchioles, indicating a lack of 
glycoproteins and/or mucins. Intriguingly, these proteins are threonine-rich; the backbone of 
mucin proteins is composed of tandem proline, threonine, and/or serine repeats (PTS domains). 
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These PTS domains are densely O-glycosylated, which contribute to the structure and function of 
mucous membranes.412 We hypothesize that reduced TARS1 function preferentially impacts the 
production of these mucin proteins, impairing the formation or maintenance of the mucosal 
linings in the lungs.  
 
Initial research into hypothesis should include immunohistochemistry staining for a series of 
mucin proteins expressed in the lung, including mucin-4, mucin-20, and endomucin (see Table 
3.2). If there is reduced mucin protein expression, protein mass spectrometry of lung tissue 
should be performed and the threonine content of misregulated proteins should be analyzed. If 
there is a significant depletion of threonine-rich proteins, this would indicate an amino acid 
specific defect in protein synthesis. If there is no significant depletion for threonine-rich proteins, 
this may indicate a global impairment in protein synthesis that happens to include mucin 
proteins. In either case, this analysis may provide insight into the pathways dysregulated in the 
lung tissue of these mice. 
 
It will also be important to determine if the absent PAS+ stain reflects the absence of club cells, 
or merely a lack of PAS+ material within them. This could be done by performing 
immunohistochemistry for SCGB1A1, the primary product of club cells (which is only 7% 
threonine, and therefore unlikely to be targeted by a threonine-specific mechanism). Club cells 
are important in maintaining lung homeostasis and protection against infection. They are also 
stem cells.451 Club cells arise from the primary stem cell population, basal cells; then, club cells 
can differentiate into either ciliated cells or the mucin-producing goblet cells.451 If club cell 
abundance is reduced in TarsR433H/F538Kfs*4 mice, this could indicate an impairment in stem cell 
proliferation or differentiation. Indeed, stem cells may be particularly sensitive to reductions in 
ARS function—a recent investigation of the microcephaly phenotype in recessive NARS1-
mediated disease demonstrated that in brain organoids derived from patient cells, radial glial 
cells showed reduced viability and proliferation.221 More broadly, undifferentiated stem cells 
have been found to maintain a low basal rate of translation, which increases upon 
differentiation.452,453,454,455 For example, in quiescent skeletal muscle stem cells, eIF2α 
phosphorylation maintains stem cell state; loss of phosphorylation by replacing the 
phosphorylated eIF2α serine residue with alanine causes differentiation and activation of the 
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myogenic program.456 One explanation for a possible lack of club cells in TarsR433H/F538Kfs*4 mice 
is that the uncharged levels of tRNAThr in basal stem cells maintain a state of global translation 
repression through eIF2α phosphorylation, preventing differentiation into club cells. 
 
Another indication of impaired stem cell function in TarsR433H/F538Kfs*4 mice may be found in 
their hair phenotype.  71% of adult TarsR433H/F538Kfs*4 mice lose hair on their heads and upper 
back by 23 weeks of age (Figure 3.18); however, significant work is needed to further define this 
phenotype. One explanation is that the reservoir of hair stem cells is affected by impaired Tars 
function, and may be unable to differentiate and generate new hair follicles. A study of protein 
synthesis in mouse hair follicles found that translation was highly dynamic across the stages of 
the hair follicle life cycle.457 The authors used OP-puromycin incorporation to quantify the rate 
of nascent protein synthesis across bulge stem cells and differentiated cells. They found that 
protein synthesis increased in the transition from the quiescence stage (telogen) to growth stage 
(anagen), and was highest in differentiated cell populations in the growth stage. This data 
suggests there is a correlation between hair stem cell activation and increased protein translation 
rate. Here, as with basal cells in the lung, reduced Tars function may impair the ability of bulge 
stem cells to exit quiescence by preventing an increase in global protein translation needed to 
fully execute the differentiation program. In both cases, immunostaining of different cell 
populations in both the lung and the hair follicle may provide more information on whether there 
are increased populations of stem cells and/or decreased populations of differentiated cells. It 
would also be informative to measure OP-puromycin incorporation in differentiating lung or hair 
cells and determine if these cells show reduced global protein synthesis compared to their control 
littermates. 
 
5.3 Concluding Remarks 
 
The work presented in this dissertation addressed three aims: 1) expanding the allelic, locus, and 
phenotypic heterogeneity of ARS-mediated disorders, 2) predicting the pathogenicity of ARS 
loci that have not yet been implicated in disease, and 3) testing high-confidence pathogenic ARS 
alleles for a dominant-negative effect. Here, we have characterized newly identified patient 
alleles in GARS1, HARS1, MARS1, TARS1, and NARS1, and provided an assessment of their 
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pathogenicity. We have also developed a pipeline of model organism assays to predict the 
pathogenicity of dominant and recessive TARS1 alleles. Through these efforts, we have produced 
new models of TARS1-mediated recessive phenotypes that will be assets in investigating the 
effects of reduced TARS1 activity on cellular function. Finally, we have pioneered a yeast assay 
to assess human ARS alleles for a dominant-negative effect, and demonstrated that pathogenic 
AARS1 variants are dominant-negative alleles. This work strengthens the evidence for a 





Table A.1 Gateway cloning primers for yeast complementation constructs. Primers are 
listed 5’ to 3’. 
 
Primer Sequence 
MARS1 ORF GW F GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATAGAACCATGAGACTGTTCGTGAGTGATGG 
MARS1 ORF GW R GGGGACCACTTTGTACAAGAAAGCTGGGTCTTACTTTTTCTTCTTGCCTTTAGG 
HARS1 ORF GW F GGGGACAAGTTTGTACAAAAAAGCAGGCTCAATGGCAGAGCGTGCGGCGCTGG 
HARS1 ORF GW R GGGGACCACTTTGTACAAGAAAGCTGGGTTTCAGCAGATGCAGAGGGGCTGG 
NARS1 ORF GW F GGGGACAAGTTTGTACAAAAAAGCAGGCTCTATGGTGCTAGCAGAGCTGTACG 
NARS1 ORF GW R GGGGACCACTTTGTACAAGAAAGCTGGGTCTTATGGCGTGCAACGCTGGACA 
TARS1 ORF GW F GGGGACAAGTTTGTACAAAAAAGCAGGCTCAATGTTTGAGGAGAAGGCCAGC 
TARS1 ORF GW R GGGGACCACTTTGTACAAGAAAGCTGGGTTTTAAAATTCTTCTTCTGC 
scALA1 6xHis GW F GGAGAAGCTTTCCATTCATCATCACCATCACCATTAAGACCCAGCTTTCT 










G327R GARS1 Mut F GCTGCTGCCCAGATTAGAAATTCTTTTAGAA 
G327R GARS1 Mut R TTCTAAAAGAATTTCTAATCTGGGCAGCAGC 
V155G HARS1 Mut F ACCACATAGCAAAGGGATATCGGCGGGATAA 
V155G HARS1 Mut R TTATCCCGCCGATATCCCTTTGCTATGTGGT 
Y330C HARS1 Mut F CTCGAGGGCTGGATTGCTACACTGGGGTGAT 
Y330C HARS1 Mut R ATCACCCCAGTGTAGCAATCCAGCCCTCGAG 
S356N HARS1 Mut F CCCTGGGTGTGGGCAATGTGGCTGCTGGAG 
S356N HARS1 Mut R CTCCAGCAGCCACATTGCCCACACCCAGGG 
A397T MARS1 Mut F TGTGCTCGCTTCCTGACTGACCGCTTCGTGG 
A397T MARS1 Mut R CCACGAAGCGGTCAGTCAGGAAGCGAGCACA 
R618C MARS1 Mut F CCTGCTGACATCTGGTGCTTCTATCTGCTGT 
R618C MARS1 Mut R ACAGCAGATAGAAGCACCAGATGTCAGCAGG 
Y307C MARS1 Mut F AGTGGAACACCCTCTGTCTGTGTGGGACAGA 
Y307C MARS1 Mut R TCTGTCCCACACAGACAGAGGGTGTTCCACT 
S461F NARS1 Mut F CCCGTCTTACTGAATTTGTCGACGTGTTGAT 
S461F NARS1 Mut R ATCAACACGTCGACAAATTCAGTAAGACGGG 
C342Y NARS1 Mut F CACGTGGAAGCTGAGTATCCTTTCCTGACTTT 
C342Y NARS1 Mut R AAAGTCAGGAAAGGATACTCAGCTTCCACGTG 
∆M236 NARS1 Mut F CAACAACAGACACATGATCCGAGGAGAAAA 
∆M236 NARS1 Mut R TTTTCTCCTCGGATCATGTGTCTGTTGTTG 
R131H TARS1 Mut F TGTGGGACCTGGACCACCCTCTGGAAGAAGA 
R131H TARS1 Mut R TCTTCTTCCAGAGGGTGGTCCAGGTCCCACA 
V372I TARS1 Mut F AGAGGATTCCAGGAGATAGTCACCCCAAACA 
V372I TARS1 Mut R TGTTTGGGGTGACTATCTCCTGGAATCCTCT 
R619C TARS1 Mut F TTTTGGCTGTCCCCTTGCCAGGTAATGGTAG 
R619C TARS1 Mut R CTACCATTACCTGGCAAGGGGACAGCCAAAA 
Q639P TARS1 Mut F CCCAAAAGGTACGACCACAATTCCACGATGC 
Q639P TARS1 Mut R GCATCGTGGAATTGTGGTCGTACCTTTTGGG 
R663Q TARS1 Mut F TGAATAAAAAGATTCAAAATGCACAGTTAGC 
R663Q TARS1 Mut R GCTAACTGTGCATTTTGAATCTTTTTATTCA 
G541R TARS1 Mut F GATGGAGCTTTCTATCGCCCAAAGATTGACATAC 
G541R TARS1 Mut R GTATGTCAATCTTTGGGCGATAGAAAGCTCCATC 
R433H TARS1 Mut F CGAGAACTGCCTCTGCACCTAGCTGATTTTGGG 
R433H TARS1 Mut R CCCAAAATCAGCTAGGTGCAGAGGCAGTTCTCG 
N412Y TARS1 Mut F CCTGAAACCCATGTACTGCCCAGGACACTGC 
N412Y TARS1 Mut R GCAGTGTCCTGGGCAGTACATGGGTTTCAGG 
G757* AARS1 Mut F ATTGTGGCTGTCACATGACTGGTGCCGAGGCCCAG 
G757* AARS1 Mut R CTGGGCCTCGGCACCAGTCATGTGACAGCCACAAT 
R329H AARS1 Mut F TGAGACGGATTCTCCACCGAGCTGTCCGATA 
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R329H AARS1 Mut R TATCGGACAGCTCGGTGGAGAATCCGTCTCA 
G102R AARS1 Mut F TTCTTCGAGATGCTGCGCTCTTGGTCTTTTG 
G102R AARS1 Mut R CAAAAGACCAAGAGCGCAGCATCTCGAAGAA 
R326W AARS1 Mut F GGATATGTGTTGAGATGGATTCTCCGCCGAG 
R326W AARS1 Mut R CTCGGCGGAGAATCCATCTCAACACATATCC 
R329S AARS1 Mut F TTGAGACGGATTCTCAGCCGAGCTGTCCGAT 
R329S AARS1 Mut R ATCGGACAGCTCGGCTGAGAATCCGTCTCAA 
R329C AARS1 Mut F TTGAGACGGATTCTCTGCCGAGCTGTCCGAT 
R329C AARS1 Mut R ATCGGACAGCTCGGCAGAGAATCCGTCTCAA 
Q855* AARS1 Mut F GACAGCAACCCCAACTAGCCTCCTGTCATCC 
Q855* AARS1 Mut R GGATGACAGGAGGCTAGTTGGGGTTGCTGTC 
∆KNVGCLQ AARS1 Mut F GCACAGGCCACAGGCGAGGCGCTGCAGCTG 
∆KNVGCLQ AARS1 Mut R CAGCTGCAGCGCCTCGCCTGTGGCCTGTGC 
∆NVG AARS1 Mut F CAGGCCACAGGCAAGTGCCTGCAGGAGGCG 
∆NVG AARS1 Mut R CGCCTCCTGCAGGCACTTGCCTGTGGCCTG 
∆C947 AARS1 Mut F GGCAAGAACGTTGGCCTGCAGGAGGCGCTG 
∆C947 AARS1 Mut R CAGCGCCTCCTGCAGGCCAACGTTCTTGCC 
∆QE AARS1 Mut F AACGTTGGCTGCCTGGCGCTGCAGCTGGCC 




Table A.3 Gateway cloning primers for C. elegans expression constructs. Primers are listed 




c.e. tars-1 GW F GGGGACAAGTTTGTACAAAAAAGCAGGCTCAAAAAATGCGATTGAACTGTTTCC 
c.e. tars-1 GW R GGGGACCACTTTGTACAAGAAAGCTGGGTTTTATGCCCATTCCTCAGACTTTTCC 
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Table A.4 Mutagenesis primers for tars-1 cDNA. Primers are listed 5’ to 3’. 
 
Primer Sequence 
c.e. tars-1 G540R Mut F AGAAATGAAATGTCTAGAGCTTTGACTGGACTT 
c.e. tars-1 G540R Mut R AAGTCCAGTCAAAGCTCTAGACATTTCATTTCT 
c.e. tars-1 N411Y Mut F GGTTTGAAGCCGATGTACTGCCCGGGGCATT 
c.e. tars-1 N411Y Mut R AATGCCCCGGGCAGTACATCGGCTTCAAACC 
c.e. tars-1 R432H Mut F ATGAGCTTCCATTCCATTTCGCTGATTTTGGA 
c.e. tars-1 R432H Mut R TCCAAAATCAGCGAAATGGAATGGAAGCTCAT 
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G540R sgRNA  CCGGGAGATGGAGCATTCTACGG 





Table A.6 Single stranded oligonucleotide repair templates for C. elegans gene editing. 
















Table A.7 PCR primers for tars-1 G540R locus and tars-1 R432H locus (C. elegans). 
Primers are listed 5’ to 3’. 
 
Primer Sequence 
G540R tars-1 F CGTCAAGATCAAATTTCCGAGG 
G540R tars-1 R CGAGTCAGTCAGAGACTATGCA 
R432H tars-1 F ATCGGCGTTCTGGTATCC 
R432H tars-1 R CCAATGCGCTCAACGCTT 
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Table A.8 PCR primers for mouse Tars1 G540R and F538Kfs*4 locus, and Tars1 R432H 
locus. Primers are listed 5’ to 3’. 
 
Primer Sequence 
G540R and F538Kfs*4 Tars F GTGTCGAGTGAGGGAATGTTTTCTGTA 
G540R and F538Kfs*4 Tars R TTAAACCTGATGGGCAACTGAAA 
R432H Tars F CTTCTATTGCTCTGTGAGGC 
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